10000000000000000_1	Drug Research and Development Activities What are the key activities in the research and development phase of creating new drugs.	drug research develop activ key activ research develop phase creat new drug
19890110000000000_1	ANTI ANEMIA DRUG FINALLY GETS CLOSE TO CIRCULATION.	anti anemia drug final get close circul
19890110000000000_2	The magic potion is a clear liquid packed in vials and kept refrigerated in a Thousand Oaks warehouse while it sits waiting to be sold.	magic potion clear liquid pack vial kept refriger thou oak warehous sit wait sold
19890110000000000_3	It s the latest biotechnology drug called erythropoietin or EPO an anti anemia treatment that after seven years and 70 million in research and development will be the first commercial product of a company called Amgen.	latest biotechnolog drug call erythropoietin epo anti anemia treatment seven year million research develop first commerci product compani call amgen
19890110000000000_4	said Gordon Binder Amgen s chief executive.	said gordon binder amgen chief execut
19890110000000000_5	So Amgen s new manufacturing plant is up and running and has turned out a three month supply of EPO while Amgen is hiring salespeople and has lined up refrigerated warehouses around the country to keep the drug fresh.	amgen new manufactur plant run ha turn three month suppli epo amgen hire salespeopl ha line refriger warehous around countri keep drug fresh
19890110000000000_6	Everything is ready save one thing.	everi thing readi save one thing
19890110000000000_7	Food and Drug Administration approval to sell the drug.	food drug administr approv sell drug
19890110000000000_8	No one expects the FDA to reject Amgen s request to sell EPO a hormone that triggers production of red blood cells that in clinical tests successfully treated the chronic anemia suffered by patients with kidney disease.	one expect fda reject amgen request sell epo hormon trigger product red blood cell clinic test success fulli treat chronic anemia suffer patient kidney diseas
19890110000000000_9	EPO was discovered by scientists in 1906 but the body produces only microscopic amounts of the hormone and the challenge has been how to get enough of it.	epo wa discov scientist bodi produc onli microscop amount hormon challeng ha get enough
19890110000000000_10	Able to Make Drug But in biotechnology scientists are medical detectives who by resplicing genes which carry the blueprints of life can trigger production of rare hormones and proteins so they can be used as a therapeutic drug.	abl make drug biotechnolog scientist medic detect resplic gene carri blueprint life trigger product rare hormon protein use therapeut drug
19890110000000000_11	Amgen has submitted 40 000 pages of supporting documents and conducted extensive EPO tests on patients winning glowing reviews in the New England Journal of Medicine.	amgen ha submit page support document conduct extens epo test patient win glow review new england journal medicin
19890110000000000_12	Amgen s executives had hoped that the FDA would complete its elaborate review and approve EPO for sale by late 1988.	amgen execut hope fda would complet elabor review approv epo sale late
19890110000000000_13	Now the company is "very optimistic" that the drug will be approved for sale by March Binder said.	compani veri optimist drug approv sale march binder said
19890110000000000_14	During the wait Amgen s stock has bounced up and down on each scrap of news about the FDA s approval process.	dure wait amgen stock ha bounc scrap news fda approv process
19890110000000000_15	Financial analysts still expect Amgen to be the first company to win approval to sell EPO because it applied to the FDA more than a year ahead of any other company.	financi analyst still expect amgen first compani win approv sell epo becaus appli fda year ahead ani compani
19890110000000000_16	What is unnerving though is that no one seems certain how plentiful those riches will be.	unnerv though one seem certain plenti rich
19890110000000000_17	In November Amgen s stock spurted when an analyst with Shearson Lehman Hutton predicted worldwide sales for EPO of 3.	novemb amgen stock spurt analyst shearson lehman hutton predict worldwid sale epo
19890110000000000_18	Excited About Amgen Last week Montgomery Securities analyst Denise Gilbert made her own projection that EPO would sell no more than 450 million in the United States by 1993 and the stock dipped.	excit amgen last week mont gomeri secur analyst denis gilbert made project epo would sell million unit state stock dip
19890110000000000_19	The trouble is that the stock market has lost much of its confidence in biotechnology and fears that only a few companies out of the hundreds will actually produce drugs that are big winners.	troubl stock market ha lost much confid biotechnolog fear onli compani hundr actual produc drug big winner
19890110000000000_20	The company has five other drugs undergoing tests in humans but EPO has secured the little company s reputation and boosted the value of Amgen s stock to 550 million even though until now it essentially has been without a product to sell.	compani ha five drug undergo test human epo ha secur littl compani reput boost valu amgen stock million even though essenti ha without product sell
19890110000000000_21	The sales are primarily advances from the company s research and development partners while the "profits" are from investments.	sale primarili advanc compani research develop partner profit invest
19890110000000000_22	The stock market is also pessimistic about biotechnology because of the many misadventures of Genentech the San Francisco biotech company whose reputation took a terrible beating last year.	stock market also pessimist biotechnolog becaus mani misadventur genentech san francisco biotech compani whose reput took terribl beat last year
19890110000000000_23	A year ago Genentech s stock was trading at 47 per share and there was no end to the enthusiasm for its latest drug TPA an anti blood clotting agent that could save heart attack victims.	year ago genentech stock wa trade per share wa end enthusiasm latest drug tpa anti blood clot agent could save heart attack victim
19890110000000000_24	The drug would sell 400 million in its first year analysts boasted and Genentech s executives did nothing to discourage those expectations.	drug would sell million first year analyst boast genentech execut noth discourag expect
19890110000000000_25	Genentech ended up selling about 175 million worth of TPA in 1988 still a record for first year sales of a new drug but the stock collapsed and now languishes at 17.	genentech end sell million worth tpa still record first year sale new drug stock collaps languish
19890110000000000_26	The drug was expensive at 2 200 a dose TPA is 10 times the price of older heart attack drugs and various studies were inconclusive about TPA s advantages over other drugs.	drug wa expens dose tpa time price older heart attack drug variou studi inconclus tpa advantag drug
19890110000000000_27	Only last month Genentech wrote off 25 million worth of TPA inventory because the drug is perishable and sales were far slower than the company s optimistic projections.	onli last month genentech wrote million worth tpa inventori becaus drug perish sale far slower compani optimist project
19890110000000000_28	Gilbert recently trimmed her 1990 profit estimates for Amgen after the company s executives told her what they would need to spend to get EPO into the market.	gilbert recent trim profit estim amgen compani execut told would need spend get epo market
19890110000000000_29	Still most analysts figure Amgen has a big winner in EPO.	still analyst figur amgen ha big winner epo
19890110000000000_30	The biggest use will be to help treat patients who undergo kidney dialysis to cleanse impurities from their blood.	biggest use help treat patient undergo kidney dialysi cleans impur blood
19890110000000000_31	Those patients cannot produce enough red blood cells and many of them need transfusions of up to four quarts of blood a month.	patient cannot produc enough red blood cell mani need transfus four quart blood month
19890110000000000_32	But patients injected with EPO didn t need the transfusions and were able go about their lives more normally.	patient inject epo need transfus abl go live normal
19890110000000000_33	To encourage companies to come up with drugs to treat relatively rare diseases Congress awards so called "orphan drug status " a seven year exclusive franchise to the first manufacturer of such drugs.	encourag compani come drug treat rel rare diseas congress award call orphan drug statu seven year exclus franchis first manufactur drug
19890110000000000_34	EPO qualifies as an orphan drug and Amgen has shrewdly kept the rights to sell EPO to kidney dialysis patients.	epo qualifi orphan drug amgen ha shrewdli kept right sell epo kidney dialysi patient
19890110000000000_35	Jim McCamant editor of the Medical Technology Stock Letter says that is likely to be a 200 million a year market in this country.	jim mccamant editor medic technolog stock letter say like million year market thi countri
19890110000000000_36	Other Possible Uses EPO may also work in treating other kinds of anemia including chemotherapy and leukemia patients.	possibl use epo may also work treat kind anemia includ chemotherapi leukemia patient
19890110000000000_37	EPO is also being tested with AZT an AIDS treatment drug that produces anemia as a side effect.	epo also test zt aid treatment drug produc anemia side effect
19890110000000000_38	Sales of EPO to patients other than those with kidney disease would be open to other companies with their own versions of EPO but analysts can t agree on how big that market will be.	sale epo patient kidney diseas would open compani version epo analyst agre big market
19890110000000000_39	Johnson Johnson will sell Amgen s version of EPO for other disparate uses in this country while paying Amgen a royalty estimated by analysts at 8 of gross sales.	johnson johnson sell amgen version epo dispar use thi countri pay amgen royalti estim analyst gross sale
19890110000000000_40	By Gilbert s reckoning Amgen s profits will grow like a weed from 15 million for the March 1990 fiscal year to 83 million in 1993.	gilbert reckon amgen profit grow like weed million march fiscal year million
19890110000000000_41	By then she figures Amgen s second drug G CSF which produces white blood cells will strike gold as well.	figur amgen second drug g csf produc white blood cell strike gold well
19890110000000000_42	Even if Amgen wins the EPO race from the laboratory to the marketplace it must still win a battle of wits in the courtroom to ensure its profits.	even amgen win epo race laboratori marketplac must still win battl wit courtroom ensur profit
19890110000000000_43	Amgen is now locked in four patent infringement lawsuits with its chief rival Genetics Institute a biotech company which with Chugai Pharmaceutical of Tokyo is racing to get its own version of EPO approved for sale in the United States.	amgen lock four patent infring lawsuit chief rival genet institut biotech compani chugai pharmaceut tokyo race get version epo approv sale unit state
19890110000000000_44	Most analysts figure that Genetics Institute with headquarters in Cambridge Mass.	analyst figur genet institut headquart cambridg mass
19890110000000000_45	Both Amgen and Genetics Institute have separate seemingly conflicting patents relating to EPO and it could take years for the cases to go all the way through to the U.	amgen genet institut separ seemingli conflict patent relat epo could take year case go way u
19890110000000000_46	Until the cases are resolved both companies should be free to sell the new drug but whichever company wins in court figures to take home the biggest share of profits.	case resolv compani free sell new drug whichev compani win court figur take home biggest share profit
19890110000000000_47	Genetics Institute has been willing to discuss an out of court settlement with Amgen presumably for some sort of cross licensing deal in which both could sell the drug but Amgen s executives have refused.	genet institut ha discuss court settlement amgen presum sort cross licens deal could sell drug amgen execut refus
19890530000000000_1	ISIS FOUNDER HAD NO TROUBLE LURING BACKERS TO AN UNEXPLORED FRONTIER OF BIOTECHNOLOGY.	isi founder troubl l ure backer unexplor frontier biotechnolog
19890530000000000_2	As ISIS Pharmaceuticals President Stanley Crooke walked through his company s newly leased Carlsbad facility he took pains to point out that despite the mostly vacant office and laboratory space his new biotechnology firm is hard at work developing products at a temporary lab in Sorrento Valley.	isi pharmaceut presid stanley crook walk hi compani newli leas carlsbad facil took pain point despit mostli vacant offic laboratori space hi new biotechnolog firm hard work develop product temporari lab sorrento valley
19890530000000000_3	But the nearly empty building in the Carlsbad Research Center symbolizes Crooke s formidable task of building a company from scratch of being a pioneer in an unexplored frontier of biotechnology and of having to translate the as yet undeveloped technology into marketable products.	nearli empti build carlsbad research center symbol crook formid task build compani scratch pioneer unexplor frontier biotechnolog translat yet undevelop technolog market product
19890530000000000_4	Crooke 44 formed ISIS two months ago after an illustrious career heading up product research operations at two major pharmaceutical firms SmithKline Beckman and Bristol Myers.	crook form isi two month ago illustri career head product research oper two jor pharmaceut firm smith kline beckman bristol myer
19890530000000000_5	Crooke who holds a medical degree as well as a doctorate in pharmacology oversaw the introduction of 17 new drugs during his 14 years at the two firms.	crook hold medic degre well doctor pharmacolog oversaw introduct new drug dure hi year two firm
19890530000000000_6	Cheaper Than Boston He selected San Diego County for ISIS headquarters so it could be near the growing biotechnology community clustered around UC San Diego and Scripps Clinic and Research Foundation.	cheaper boston select san diego counti isi headquart could near grow biotechnolog commun cluster around uc san diego scripp clinic research foundat
19890530000000000_7	Although housing is expensive in San Diego Crooke said it s cheaper than in Boston and the San Francisco Bay area two other headquarters sites he considered.	although hous expens san diego crook said cheaper boston san francisco bay area two headquart site consid
19890530000000000_8	Carlsbad was chosen over other county locations because of favorable lease rates he said.	carlsbad wa chosen counti locat becaus favor leas rate said
19890530000000000_9	said Christopher Gabrieli general partner of Bessemer Venture Partners a Menlo Park based venture capital firm with investments in eight biotechnology companies including ISIS.	said christoph gabri gener partner bessem ventur partner menlo park base ventur capit firm invest eight biotechnolog compani includ isi
19890530000000000_10	He described drug development as an enormously complex drawn out and expensive process.	describ drug develop enorm complex drawn expens process
19890530000000000_11	Before resigning last summer Crooke was vice president in charge of SmithKline s research and development operation where he had a 300 million budget.	befor resign last summer crook wa vice presid charg smith kline research develop oper million budget
19890530000000000_12	At Bristol Myers which he left in 1980 to join SmithKline Crooke helped develop an array of chemotherapy drugs for cancer patients that put Bristol at the forefront of cancer treatment.	bristol myer left join smith kline crook help develop array chemotherapi drug cancer patient put bristol forefront cancer treatment
19890530000000000_13	Trading on his visibility in the pharmaceutical industry Crooke has moved fast since starting up ISIS in March.	trade hi visibl pharmaceut industri crook ha move fast sinc start isi march
19890530000000000_14	2 million in venture capital and hired 20 employees many of them research "stars" with strong track records in pharmaceuticals and academia.	million ventur capit hire employe mani research star strong track record pharmaceut academia
19890530000000000_15	Crooke was able to raise the money from five venture capital firms including Bessemer plus obtain commitments for up to 10 million next year even though ISIS may be years away from successful technology much less U.	crook wa abl rais money five ventur capit firm includ bessem plu obtain commit million next year even though isi may year away success ful technolog much less u
19890530000000000_16	The company s payroll will grow from 20 to 30 employees by year s end and to as many as 90 in 1990 he said.	compani payrol grow employe year end mani said
19890530000000000_17	said Ray Dittamore managing partner of Arthur Young Co.	said ray dittamor manag partner arthur young co
19890530000000000_18	a firm whose clients include more than a quarter of San Diego s 70 biotechnology companies including ISIS.	firm whose client includ quarter san diego biotechnolog compani includ isi
19890530000000000_19	Apart from Crooke the venture capitalists interest revolves around the technology ISIS is trying to develop called anti sense oligonucleotides.	apart crook ventur capitalist interest revolv around technolog isi tri develop call anti sens oligonucleotid
19890530000000000_20	The "oligos" are bits of DNA that bind to "messenger molecules" sent out by DNA that cause the production of disease bearing proteins.	oligo bit dna bind messeng molecul sent dna caus product diseas bear protein
19890530000000000_21	By binding to disease messengers which are called messenger RNA the oligos theoretically prevent the disease "message" from being passed on and thus from ever being produced Crooke said.	bind diseas messeng call messeng rna oligo theoret prevent diseas messag pass thu ever produc crook said
19890530000000000_22	said Ignacio Tinoco a professor of chemistry at University of California Berkeley who is on ISIS scientific advisory board.	said ignacio tinoco professor chemistri univers california berkeley isi scientif advisori board
19890530000000000_23	Crooke said the potential for anti sense drugs is enormous because they could be manufactured as therapeutic agents for virtually any disease since virtually all diseases start as aberrant proteins set in motion by messenger RNA molecules.	crook said potenti anti sens drug enorm becaus could manufactur therapeut agent virtual ani diseas sinc virtual diseas start aberr protein set motion messeng rna molecul
19890530000000000_24	ISIS plans to develop its anti sense drugs using so called "rational drug design " or the computer aided process of designing drugs "by force of thought " Crooke said.	isi plan develop anti sens drug use call ration drug design comput aid process design drug forc thought crook said
19890530000000000_25	2 Billion Market Citing competitive concerns Crooke refused to disclose which diseases ISIS has targeted for its first set of products.	billion market cite competit concern crook refus disclos diseas isi ha target first set product
19890530000000000_26	He did say however that the company is pursuing He declined to say whether AIDS is one of the diseases targeted.	say howev compani pursu declin say whether aid one diseas target
19890530000000000_27	ISIS competition so far includes San Diego based Genta a company that was spun off recently by Gen Probe a publicly held manufacturer of DNA probe diagnostic products.	isi competit far includ san diego base genta compani wa spun recent gen probe publicli held manufactur dna probe diagnost product
19890530000000000_28	(Genta President Thomas Adams was unavailable for comment Friday.	genta presid thoma adam wa unavail comment friday
19890530000000000_29	) Crooke said he expects major pharmaceutical firms to join the field in coming years as well.	crook said expect jor pharmaceut firm join field come year well
19890530000000000_30	Although Crooke had studied anti sense oligonucleotides for the better part of two decades he said he became convinced they could be used as therapeutic drugs three years ago.	although crook studi anti sens oligonucleotid better part two decad said becam convinc could use therapeut drug three year ago
19890530000000000_31	That conviction sprang from advances in molecular biology research that have enabled scientists to clone or synthesize DNA molecules.	convict sprang advanc molecular biolog research enabl scientist clone synthes dna molecul
19890530000000000_32	Crooke was also encouraged by scientists increasing ability to modify or manipulate those molecules through a process called hybridization or the binding of one molecule to another.	crook wa also encourag scientist increas abil modifi manipul molecul process call hybrid bind one molecul anoth
19890530000000000_33	It s that binding process by which ISIS anti sense nucleotides will someday "kill" the disease causing RNA molecules he said.	bind process isi anti sens nucleotid someday kill diseas caus rna molecul said
19890530000000000_34	But Crooke said he was unable to generate much enthusiasm among his SmithKline colleagues for pursuing the technology perhaps because the approach was so revolutionary.	crook said wa unabl gener much enthusiasm among hi smith kline colleagu pursu technolog perhap becaus approach wa revolutionari
19890530000000000_35	That combined with SmithKline s financial problems last year and the resulting impact on the 3 000 scientist research program in Upper Merion Pa.	combin smith kline financi problem last year result impact scientist research program upper merion pa
19890530000000000_36	Return to Academia At first Crooke s plan after leaving the drug company was to return to academia specifically to Baylor College of Medicine in Houston where he has been a faculty member on and off for the past 15 years.	return academia first crook plan leav drug compani wa return academia specif baylor colleg medicin houston ha faculti member past year
19890530000000000_37	But Crooke soon realized that he was too enamored of the high stakes game of producing new drugs and the social benefits that successful drugs represent.	crook soon realiz wa enamor high stake game produc new drug social benefit success ful drug repres
19890530000000000_38	A turning point in his medical career came when as a young doctor in Houston he watched a 24 year old man die of testicular cancer a disease that is now largely curable with drugs developed at Bristol Myers during Crooke s tenure there.	turn point hi medic career came young doctor houston watch year old man die testicular cancer diseas larg curabl drug develop bristol myer dure crook tenur
19890530000000000_39	In March ISIS signed an agreement with Applied Biosystems a publicly held biotech company in Foster City that is a leading manufacturer of instruments that produce DNA.	march isi sign agreement appli biosystem publicli held biotech compani foster citi lead manufactur instrument produc dna
19890530000000000_40	The deal calls for the two companies to share rights to products developed.	deal call two compani share right product develop
19890530000000000_41	ISIS expects Applied Biosystems to help it surmount a formidable problem.	isi expect appli biosystem help surmount formid problem
19890530000000000_42	how to produce anti sense drugs in adequate quantities.	produc anti sens drug adequ quantiti
19890530000000000_43	Producing DNA and its derivatives is exceedingly difficult in anything but trace amounts he said.	produc dna deriv exceedingli difficult anyth trace amount said
19890530000000000_44	said Timothy Geiser senior scientist at Applied Biosystems.	said timothi geiser senior scientist appli biosystem
19890530000000000_45	Because of the difficulty the products that will be developed by ISIS and Applied Biosystems instead will be derived from substitutes called DNA analogs.	becaus difficulti product develop isi appli biosystem instead deriv substitut call dna analog
19890530000000000_46	Geiser said his company expects to sign similar agreements with other anti sense manufacturers.	geiser said hi compani expect sign similar agreement anti sens manufactur
19890602000000000_1	GENE SPLICED ANEMIA DRUG OKD FOR SALE.	gene splice anemia drug okd sale
19890602000000000_2	A genetically engineered drug expected to relieve the chronic anemia suffered by thousands of people with kidney disease was approved for sale Thursday by the U.	genet engin drug expect reliev chronic anemia suffer thou peopl kidney diseas wa approv sale thursday u
19890602000000000_3	The drug also has shown promise in treating anemia in AIDS and cancer patients but it was not yet approved for those uses by the government.	drug also ha shown promis treat anemia aid cancer patient wa yet approv use govern
19890602000000000_4	The announcement capped an eight year effort by Amgen Inc.	announc cap eight year effort amgen inc
19890602000000000_5	of Thousand Oaks to bring to market what is expected to be one of biotechnology s first blockbuster drugs.	thou oak bring market expect one biotechnolog first blockbust drug
19890602000000000_6	Amgen s costly drug known as erythropoietin or EPO is a gene spliced version of a naturally occurring protein in the kidney that triggers production of red blood cells which in turn transport oxygen throughout the body.	amgen costli drug known erythropoietin epo gene splice version natur occur protein kidney trigger product red blood cell turn transport oxygen throughout bodi
19890602000000000_7	Patients suffering from kidney disease do not produce enough red blood cells and often have very little energy and many of them must endure frequent blood transfusions.	patient suffer kidney diseas produc enough red blood cell often veri littl energi mani must endur frequent blood transfus
19890602000000000_8	There are about 100 000 kidney dialysis patients in this country and the 25 000 or so who need frequent transfusions are ideal candidates for EPO experts say.	kidney dialysi patient thi countri need frequent transfus ideal candid epo expert say
19890602000000000_9	In clinical tests most patients given injections of EPO no longer needed blood transfusions and found that much of their old energy returned.	clinic test patient given inject epo longer need blood transfus found much old energi return
19890602000000000_10	EPO is being tested with the AIDS drug AZT in hopes of minimizing anemia and is being reviewed for treating the types of anemia suffered by patients with cancer rheumatoid arthritis and other diseases.	epo test aid drug zt hope minim anemia review treat type anemia suffer patient cancer rheumatoid arthriti diseas
19890602000000000_11	said David Weber a securities analyst with the brokerage firm of Alex.	said david weber secur analyst brokerag firm alex
19890602000000000_12	The FDA approved EPO which will be sold under the brand name Epogen only for anemia caused by kidney disease.	fda approv epo sold brand name epogen onli anemia caus kidney diseas
19890602000000000_13	However once it is on the market doctors may prescribe it for anemia due to other causes although that practice has note been endorsed by the FDA.	howev onc market doctor may prescrib anemia due caus although practic ha note endors fda
19890602000000000_14	It could become one of the most expensive drugs ever reimbursed by the federal government eventually costing perhaps 200 million to 500 million a year overall for all kidney dialysis patients.	could becom one expens drug ever reimburs feder govern eventu cost perhap million million year overal kidney dialysi patient
19890602000000000_15	Government s Costs The average patient suffering from kidney disease would need 4 000 to 8 000 worth of the drug every year but Gordon Binder Amgen s chief executive said he expects the federal government to cover most of that expense.	govern cost averag patient suffer kidney diseas would need worth drug everi year gordon binder amgen chief execut said expect feder govern cover expens
19890602000000000_16	Until EPO is approved for other uses however it will not be determined how much of the cost would be picked up in those cases.	epo approv use howev determin much cost would pick case
19890602000000000_17	Pete Stark (D Oakland) who is chairman of the health subcommittee of the House Ways and Means Committee said he is concerned about the hundreds of millions of dollars that the use of EPO could cost the federal government.	pete stark oakland chairman health subcommitte hous way mean committe said concern hundr million dollar use epo could cost feder govern
19890602000000000_18	Some of that concern may stem from the fact that members of Stark s staff using data released in a court battle between Amgen and another manufacturer calculated that it would cost only only 140 to manufacture a year s supply of the drug for an average patient.	concern may stem fact member stark staff use data releas court battl amgen anoth manufactur calcul would cost onli onli manufactur year suppli drug averag patient
19890602000000000_19	Amgen officials said the high price being charged for the drug would help the company recoup the cost of developing EPO estimated at 100 million and would provide money to develop other new products.	amgen offici said high price charg drug would help compani recoup cost develop epo estim million would provid money develop new product
19890602000000000_20	Besides Amgen the winners from the FDA approval are the patients who have been waiting to get the drug.	besid amgen winner fda approv patient wait get drug
19890602000000000_21	Amgen expected to start selling EPO last winter but when things were delayed some frustrated kidney dialysis patients began buying EPO by mail order from Europe.	amgen expect start sell epo last winter thing delay frustrat kidney dialysi patient began buy epo mail order europ
19890602000000000_22	Patients such as Valerie Buhler of Pasadena were taking advantage of an obscure FDA policy that allows for personal importation of most drugs that are legally available overseas as long as they are purchased in small amounts and for personal use.	patient valeri buhler pasadena take advantag obscur fda polici allow person import drug legal avail oversea long purchas small amount person use
19890602000000000_23	Since March Buhler 65 has been spending 650 a month out of her own pocket to buy EPO from a pharmacy in West Germany.	sinc march buhler ha spend month pocket buy epo pharmaci west germani
19890602000000000_24	Before she began her twice a week treatments she said.	befor began twice week treatment said
19890602000000000_25	Since then She added The FDA s approval she said was "fantastic " and timely as well.	sinc ad fda approv said wa fantast time well
19890602000000000_26	Kidney disease patients who lack the natural protein would take regular injections of the drug for life to prevent the anemia.	kidney diseas patient lack natur protein would take regular inject drug life prevent anemia
19890602000000000_27	Keating director of Northern Ohio Red Cross Blood Services and chairman of the FDA advisory committee that recommended the drug s approval.	keat director northern ohio red cross blood servic chairman fda advisori committe recommend drug approv
19890602000000000_28	As the first company to win approval to sell EPO Amgen is expected to win a big chunk of the market for kidney dialysis patients which is expected to be at least 250 million a year by the early 1990s.	first compani win approv sell epo amgen expect win big chunk market kidney dialysi patient expect least million year earli
19890602000000000_29	For now there is no alternative to EPO a fact that has excited the financial community.	altern epo fact ha excit financi commun
19890602000000000_30	The drug Amgen s first commercial product for the company said Denise Gilbert a biotechnology analyst with Montgomery Securities.	drug amgen first commerci product compani said denis gilbert biotechnolog analyst mont gomeri secur
19890602000000000_31	Binder said the first shipments of the drug marketed under the trade name Epogen will arrive next week in doctors offices.	binder said first shipment drug market trade name epogen arriv next week doctor offic
19890602000000000_32	By the end of the year Binder expects Amgen to be selling EPO at a rate of 100 million a year.	end year binder expect amgen sell epo rate million year
19890602000000000_33	Amgen s stock traded over the counter closed Thursday at 41 a share up 87.	amgen stock trade counter close thursday share
19890602000000000_34	Amgen has kept the rights to sell EPO to the kidney dialysis market but it has licensed all other uses of the drug in this country to Johnson Johnson.	amgen ha kept right sell epo kidney dialysi market ha licens use drug thi countri johnson johnson
19890602000000000_35	How much business Amgen will enjoy is unclear because the company is locked in a major patent infringement lawsuit over EPO with biotech rival Genetics Institute of Cambridge Mass.	much busi amgen enjoy unclear becaus compani lock jor patent infring lawsuit epo biotech rival genet institut cambridg mass
19890602000000000_36	Amgen and Genetics Institute hold different patents related to EPO and a patent infringement trial is scheduled to begin Aug.	amgen genet institut hold differ patent relat epo patent infring trial schedul begin aug
19890602000000000_37	Patent and Trademark Office will begin hearings this summer to decide which of the two rival companies EPO claims have priority.	patent trademark offic begin hear thi summer decid two rival compani epo claim prioriti
19890602000000000_38	In the past Amgen officials have refused to consider an out of court cross licensing agreement with Genetics Institute a tactic some analysts say is risky.	past amgen offici refus consid court cross licens agreement genet institut tactic analyst say riski
19890602000000000_39	Binder said Thursday however that an out of court agreement "is always a possibility.	binder said thursday howev court agreement alway possibl
19890602000000000_40	" Possible Settlement Bruce Eisen chief patent counsel with Genetics Institute also said that an out of court pact is possible before the patent trial begins.	possibl settlement bruce eisen chief patent counsel genet institut also said court pact possibl befor patent trial begin
19890602000000000_41	The FDA awarded so called orphan drug status to Amgen s EPO which ordinarily would give the company a seven year exclusive right to sell the drug to kidney dialysis patients.	fda award call orphan drug statu amgen epo ordinarili would give compani seven year exclus right sell drug kidney dialysi patient
19890602000000000_42	Orphan drug status covers drugs that treat patients suffering from relatively rare diseases those with fewer than 200 000 cases.	orphan drug statu cover drug treat patient suffer rel rare diseas fewer case
19890602000000000_43	But the FDA also said it might also award orphan drug status to another version of EPO that has been developed by Chugai Upjohn using technology licensed by Genetics Institute.	fda also said might also award orphan drug statu anoth version epo ha develop chugai upjohn use technolog licens genet institut
19890602000000000_44	Joseph Sobota chief operating officer at Chugai Upjohn said his company hopes to win FDA approval within six months and expects to be "a vigorous competitor" despite Amgen s head start.	joseph sobota chief oper offic chugai upjohn said hi compani hope win fda approv within six month expect vigor competitor despit amgen head start
19890602000000000_45	Amgen s Binder said Spending heavily to prepare for the launch of the drug Amgen lost 8 million in its fiscal year ended March 31.	amgen binder said spend heavili prepar launch drug amgen lost million fiscal year end march
19890602000000000_46	However analyst Gilbert expects Amgen to have pre tax earnings of 70 million from EPO sales by 1993.	howev analyst gilbert expect amgen pre tax earn million epo sale
19920131000000000_1	FT 31 JAN 92 Survey of World Industrial Review (9).	ft jan survey world industri review
19920131000000000_2	THE PATHS followed over the last year by the world s chemical and pharmaceutical industries have diverged markedly in spite of their common scientific base.	path follow last year world chemic pharmaceut industri diverg markedli spite common scientif base
19920131000000000_3	Buoyed by ageing populations and increasingly expensive and sophisticated drugs pharmaceutical groups have proved inoculated against the insidious slowdown of the world economy.	buoy age popul increasingli expens sophist drug pharmaceut group prove inocul insidi slow world economi
19920131000000000_4	In contrast the chemicals sector has confirmed its lamentable reputation for being the most cyclical of industries.	contrast chemic sector ha confirm lament reput cyclic industri
19920131000000000_5	The industry is making too little money as it makes too much pollution.	industri make littl money make much pollut
19920131000000000_6	The recession and the Gulf war have battered demand for basic chemicals.	recess gulf war batter demand basic chemic
19920131000000000_7	At the same time capacity ordered in the boom times of the late 1980s when even the least efficient plants were profitable continues to come on stream increasing competition still further.	time capac order boom time late even least effici plant profit continu come stream increas competit still
19920131000000000_8	The consequent squeeze on margins has been further exacerbated by the increased capital costs required by ever tougher environmental legislation.	consequ squeez margin ha exacerb increas capit cost requir ever tougher environment legisl
19920131000000000_9	Complying with environmental legislation is cutting deeply into ordinary capital expenditure.	compli environment legisl cut deepli ordinari capit expenditur
19920131000000000_10	Increasing public and legislative demands for more environmental protection appear unlikely to slacken in coming years.	increas public legisl demand environment protect appear unlik slacken come year
19920131000000000_11	At the end of last year German chemical companies complained that new taxes on emissions would stretch the industry to its limits making Germany too expensive for manufacturing certain types of products.	end last year german chemic compani complain new tax emiss would stretch industri limit make germani expens manufactur certain type product
19920131000000000_12	The UK s Chemical Industry Association estimates capital expenditure on the environment will double between 1990 and 1992 from Pounds 200m a year to Pounds 400m.	uk chemic industri associ estim capit expenditur environ doubl pound year pound
19920131000000000_13	With costs and capacity rising while demand falls the descent from profits to loss has been precipitous.	cost capac rise demand fall descent profit loss ha precipit
19920131000000000_14	Even the German giants hitherto protected by German reunification are suffering a slowdown.	even german giant hitherto protect german reunif suffer slow
19920131000000000_15	Mr Wolfgang Hilger president of the German Chemical Industry Association warned this month that the German domestic market was likely to stagnate this year and there was no sign of upturn in export markets.	mr wolfgang hilger presid german chemic industri associ warn thi month german domest market wa like stagnat thi year wa sign upturn export market
19920131000000000_16	Only in the Far East has demand held up but capacity there particularly in the petrochemical sector looks set to grow rapidly over the next few years as investments by newly industrialised nations come on stream.	onli far east ha demand held capac particularli petrochem sector look set grow rapidli next year invest newli industrialis nation come stream
19920131000000000_17	Drugs have proved a panacea for those companies trying to escape the roller coaster ride of the cyclical commodity chemicals business.	drug prove panacea compani tri escap roller coaster ride cyclic commod chemic busi
19920131000000000_18	ICI and Rhone Poulenc two groups traditionally involved with basic chemicals reported profits last year heavily dependent upon the success of their pharmaceuticals business.	ici rhone poulenc two group tradit involv basic chemic report profit last year heavili depend upon success pharmaceut busi
19920131000000000_19	For the pure pharmaceuticals companies 1991 was a heady year.	pure pharmaceut compani wa headi year
19920131000000000_20	Most European pharmaceuticals groups proved the ultimate counter cyclical stocks with the sector reporting sales growth averaging 13 per cent over the past 12 months.	european pharmaceut group prove ultim counter cyclic stock sector report sale grow th averag per cent past month
19920131000000000_21	But although the pharmaceuticals market remains buoyant the horizon is not without its clouds.	although pharmaceut market remain buoyant horizon without cloud
19920131000000000_22	Research and development costs are rising inexorably at the same time as governments are beginning to balk at the ever increasing cost of drugs.	research develop cost rise inexor time govern begin balk ever increas cost drug
19920131000000000_23	Western governments are grappling with ever increasing healthcare budgets.	western govern grappl ever increas health care budget
19920131000000000_24	In Germany for example health costs more than 13 per cent of GNP.	germani exampl health cost per cent gnp
19920131000000000_25	Drugs form a significant proportion of such costs and have been designated as easy targets for recession battered governments.	drug form signific proport cost design easi target recess batter govern
19920131000000000_26	In Germany pharmaceutical spending represents nearly 16 per cent of healthcare costs while in Italy and Portugal it represents more than 30 per cent.	germani pharmaceut spend repres nearli per cent health care cost itali portug repres per cent
19920131000000000_27	Prices are likely to come under increasing pressure in coming years.	price like come increas pressur come year
19920131000000000_28	And the sparkling performance of the pharmaceuticals groups over the last 12 months has not helped their position.	sparkl perform pharmaceut group last month ha help posit
19920131000000000_29	In the US the world s largest drug market Senator Edward Kennedy has conducted a vocal campaign to restrain price increases for drugs sold to public health service funded institutions.	us world largest drug market senat edward kennedi ha conduct vocal campaign restrain price increas drug sold public health servic fund institut
19920131000000000_30	A wave of pricing legislation is presently sweeping through Congress questioning the sector s pricing structure.	wave price legisl present sweep congress question sector price structur
19920131000000000_31	A debate also opened up last year on whether uncontrolled healthcare costs had not become a full blown contagion one that was sapping the nation s competitiveness and standard of living.	debat also open last year whether uncontrol health care cost becom full blown contagion one wa sap nation competit standard live
19920131000000000_32	It is far from clear whether the pharmaceutical industry s traditional defences the need to reinvest profits in research and development and the requirement for a return for the significant risks involved in drug development will withstand the current political tide.	far clear whether pharmaceut industri tradit defenc need reinvest profit research develop requir return signific risk involv drug develop stand current polit tide
19920131000000000_33	Outside the US governments are already attempting to limit drugs expenditure through.	outsid us govern al readi attempt limit drug expenditur
19920131000000000_34	Lists of products which doctors are forbidden to prescribe or for which patients receive only partial reimbursement.	list product doctor forbidden prescrib patient receiv onli partial reimburs
19920131000000000_35	Profit controls which insist on a limited return on capital employed.	profit control insist limit return capit employ
19920131000000000_36	Encouraging generic non patented cheaper products.	encourag gener non patent cheaper product
19920131000000000_37	At the same time the pharmaceutical groups continue to struggle with the inexorable rise in research and development costs.	time pharmaceut group continu struggl inexor rise research develop cost
19920131000000000_38	Such growth in costs is partly explained by the increasing complexity of new drugs.	grow th cost partli explain increas complex new drug
19920131000000000_39	But it has also been caused by the growth in regulation to test the safety quality and efficacy of drugs.	ha also caus grow th regul test safeti qualiti efficaci drug
19920131000000000_40	Meanwhile recessionary storms appear to have set in for the duration over the the basic chemicals industry.	mean recessionari storm appear set durat basic chemic industri
19920131000000000_41	Dark clouds may also be gathering for the pharmaceuticals sector.	dark cloud may also gather pharmaceut sector
19920221000000000_1	The market was too quick to interpret yesterday s half year figures from Glaxo as evidence that Zantac is faltering.	market wa quick interpret yesterday half year figur glax evid zantac falter
19920221000000000_2	Underlying growth of the ulcer drug was certainly down on the most recent 12 month period but a buyers strike in Italy and an obligatory Medicaid refund in the US exaggerated the trend.	underli grow th ulcer drug wa certainli recent month period buyer strike itali obligatori medicaid refund us exagger trend
19920221000000000_3	Even with these disappointments Glaxo s overall sales at constant exchange rates increased by an impressive 18 per cent in the six months against just 16 per cent for the financial year 1991 as a whole.	even disappoint glax overal sale constant exchang rate increas impress per cent six month per cent financi year whole
19920221000000000_4	Prospects for the new generation of Glaxo drugs are little clearer.	prospect new gener glax drug littl clearer
19920221000000000_5	The anti emetic product Zofran looks like hitting Pounds 250m of sales for the full year but the question remains whether it can be sold to treat other illnesses.	anti emet product zofran look like hit pound sale full year question remain whether sold treat ill
19920221000000000_6	The jury remains out on Imigran which looks set to receive US approval this summer and on scare affected Serevent.	juri remain migran look set receiv us approv thi summer scare affect serev
19920221000000000_7	Investors will take more encouragement from news that marketing expenses should fall as a proportion of sales and that increases in R D spending will in future mirror sales growth.	investor take encourag news market expens fall proport sale increas r spend futur mirror sale grow th
19920221000000000_8	With perhaps one third of the equity now in US hands the key to the next share price move almost certainly lies on Wall Street.	perhap one third equiti us hand key next share price move almost certainli lie wall street
19920221000000000_9	Comparisons may be pertinent with 1983 a year when the world economy was coming out of recession and Zantac won approval in the US.	comparison may pertin year world economi wa come recess zantac approv us
19920221000000000_10	The first half then saw continued outperformance though on the back of the sort of heavy US demand which nine years later may have run out of steam.	first half saw continu outperform though back sort heavi us demand nine year later may run steam
19920221000000000_11	The second half of 1983 saw a sharp underperformance more than wiping out the relative gains of the first six months.	second half saw sharp underperform wipe rel gain first six month
19920227000000000_1	FT 27 FEB 92 Denmark asks EC to look at Glaxo pricing.	ft feb denmark ask ec look glax price
19920227000000000_2	GLAXO the UK pharmaceuticals group is being challenged over its European drug pricing strategy.	glaxo uk pharmaceut group challeng european drug price strategi
19920227000000000_3	The Danish office of fair trading has asked the European Commission to investigate whether the company is abusing a dominant market position by charging excessively high prices for its drugs.	danish offic fair trade ha ask european commiss investig whether compani abus domin market posit charg excess high price drug
19920227000000000_4	Glaxo s strategy of commanding premium prices for innovative products could be severely undermined if the Danish move is successful.	glax strategi command premium price innov product could sever undermin danish move success ful
19920227000000000_5	The group needs to generate substantial revenues from new pharmaceutical products over the next few years if it is to compensate for an expected fall in sales of Zantac its best selling ulcer drug.	group need gener substanti revenu new pharmaceut product next year compens expect fall sale zantac best sell ulcer drug
19920227000000000_6	The Danish authorities have complained about the price of three recently introduced products.	danish author complain price three recent introduc product
19920227000000000_7	All three drugs have been described by analysts as possible blockbusters with potential sales of more than Dollars 1bn (Pounds 500m) a year.	three drug describ analyst possibl blockbust potenti sale dollar bn pound year
19920227000000000_8	Analysts forecast Imigran will generate revenues of more than Dollars 2bn a year by 1997.	analyst fore cast migran gener revenu dollar bn year
19920227000000000_9	In order to prove that Glaxo is abusing a dominant position the Commission will have to show that it charges excessive prices by conducting an analysis of the cost of producing the drug.	order prove glax abus domin posit commiss show charg excess price conduct analysi cost produc drug
19920227000000000_10	The European Court of Justice has ruled in the past that prices are excessive when they have no reasonable relation to the economic value of the product.	european court justic ha rule past price excess reason relat econom valu product
19920227000000000_11	Glaxo said last night it was studying the Danish complaint.	glax said last night wa studi danish complaint
19920227000000000_12	The company said its drug prices reflected the benefit of each product to society and the patient as well as the cost of research and development.	compani said drug price reflect benefit product societi patient well cost research develop
19920227000000000_13	It expects to spend Pounds 600m on R D this year.	expect spend pound r thi year
19920227000000000_14	Mr Robin Gilbert an analyst at James Capel said the Danish move was unprecedented.	mr robin gilbert analyst jame capel said danish move wa unpreced
19920227000000000_15	He said the complaint was unlikely to have much effect on sales in the short term but that it could be significant in the long term if it made other governments question Glaxo s pricing policy.	said complaint wa unlik much effect sale short term could signific long term made govern question glax price polici
19920227000000000_16	This is an unpleasant straw in the wind he added.	thi unplea ant straw wind ad
19920227000000000_17	The Danish announcement just before the London stock market closed led to a 10p fall in Glaxo s price.	danish announc befor london stock market close led p fall glax price
19920303000000000_1	Wellcome s increasing presence in the international pharmaceuticals market.	well come increas presenc intern pharmaceut market
19920303000000000_2	The company he founded in 1880 to make compressed medicines or tablets has become one of the world s fastest growing pharmaceuticals businesses.	compani found make compress medicin tablet ha becom one world fastest grow pharmaceut busi
19920303000000000_3	Now with the proposed sale by the medical charity Wellcome Trust of much of its controlling stake the company will fully enter the commercial world.	propos sale medic chariti well come trust much control stake compani fulli enter commerci world
19920303000000000_4	It will have to satisfy the more rigorous demands of institutional shareholders but will have greater management freedom to run its business.	sati fy rigor demand institut sharehold greater manag freedom run busi
19920303000000000_5	Since 25 per cent of Wellcome s shares were floated on the stock market in 1986 it has become one of the largest public companies in the UK.	sinc per cent well come share float stock market ha becom one largest public compani uk
19920303000000000_6	The Trust to which Sir Henry bequeathed the company has seen the value of its shareholding grow to a point where it feels it must reduce its 73.	trust sir henri bequeath compani ha seen valu sharehold grow point feel must reduc
19920303000000000_7	At the time of the flotation Sir Alfred Shepperd the chairman and chief executive who retired in 1990 insisted that the group was a commercial business run to make profits.	time flotat sir alfr shepperd chairman chief execut retir insist group wa commerci busi run make profit
19920303000000000_8	Since then the company has become a much stronger competitor in the world drugs industry.	sinc compani ha becom much stronger competitor world drug industri
19920303000000000_9	Research scientists could enjoy working at Wellcome as though it were an academic institution.	research scientist could enjoy work well come though academ institut
19920303000000000_10	The company would pursue the scientifically fascinating rather than the commercially promising.	compani would pursu scientif fascin rather commerci promis
19920303000000000_11	Mr John Robb chief executive of Wellcome has been pursuing a restructuring programme aimed at sharpening the business and increasing profit margins.	mr john robb chief execut well come ha pursu restructur programm aim sharpen busi increas profit margin
19920303000000000_12	The strategy is nearing completion and he now supports the Trust s plans to sell a large part of its stake.	strategi near complet support trust plan sell larg part stake
19920303000000000_13	Previously he had feared such a large sale would have been disruptive.	previous fear larg sale would di ruptiv
19920303000000000_14	As part of this programme several tough decisions have been taken.	part thi programm sever tough decis taken
19920303000000000_15	The group gave up work on TPA a blood clot dissolving drug.	group gave work tpa blood clot dissolv drug
19920303000000000_16	That was hard Mr Robb says after more than Pounds 40m had been spent on it.	wa hard mr robb say pound spent
19920303000000000_17	But Wellcome realised it would be difficult to make a commercial success of the product.	well come realis would difficult make commerci success product
19920303000000000_18	Other measures have included the sale of peripheral activities where margins were low.	measur includ sale peripher activ margin low
19920303000000000_19	These included businesses such as vaccines to which Wellcome had a strong sentimental attachment.	includ busi vaccin well come strong sentiment attach
19920303000000000_20	There have been cuts in overheads including about 10 per cent of the 400 jobs at its London head office.	cut head includ per cent job london head offic
19920303000000000_21	Wellcome has also made a much more determined effort to market its drugs.	well come ha also made much determin effort market drug
19920303000000000_22	As a result the company s fast profit growth which had slowed in the 1989 90 financial year has resumed.	result compani fast profit grow th slow financi year ha resum
19920303000000000_23	This year pre tax profits are forecast to top Pounds 500m a rise from Pounds 402.	thi year pre tax profit fore cast top pound rise pound
19920303000000000_24	And the balance sheet is strong with net cash of about Pounds 200m at the end of August last year.	balanc sheet strong net cash pound end august last year
19920303000000000_25	The story of Wellcome s stock market career has been dominated by Retrovir its high profile Aids drug.	stori well come stock market career ha domin retrovir high profil aid drug
19920303000000000_26	Launched in 1987 it is still the only widely used treatment for the condition.	launch still onli wide use treatment condit
19920303000000000_27	The company s share price has fallen and more often risen with the ebb and flow of news about Retrovir.	compani share price ha fallen often risen eb b flow news retrovir
19920303000000000_28	It has arguably the best record of any UK drug company for turning research and development into new products.	ha arguabl best record ani uk drug compani turn research develop new product
19920303000000000_29	It has accelerated the rate at which it launches new drugs developing a product almost every year for the past decade.	ha acceler rate launch new drug develop product almost everi year past decad
19920303000000000_30	Wellcome s strength in research and its dominance of the anti viral market have been the basis of its growth.	well come strength research domin anti viral market basi grow th
19920303000000000_31	Its best selling drug Zovirax used to treat herpes shingles and now chicken pox was launched in 1981.	best sell drug zovirax use treat herp shingl chicken pox wa launch
19920303000000000_32	Only now as its patents are approaching the end of their lives is it realising its full sales potential of about Pounds 500m a year.	onli patent approach end live realis full sale potenti pound year
19920303000000000_33	Since Mr Robb joined the company in March 1989 as deputy chief executive co marketing deals and higher prices for Zovirax have improved profit margins.	sinc mr robb join compani march deputi chief execut co market deal higher price zovirax improv profit margin
19920303000000000_34	Both Retrovir and Zovirax faced the problem of being launched into a new market although the publicity surrounding Aids has meant a greater public awareness of Retrovir.	retrovir zovirax face problem launch new market although public surround aid ha meant greater public awar retrovir
19920303000000000_35	Its sales growth since its launch has outstripped that of Zovirax in the initial years.	sale grow th sinc launch ha outstrip zovirax initi year
19920303000000000_36	Retrovir too was not as well marketed as it might have been says Mr Jonathan de Pass an industry analyst at Barclays de Zoete Wedd.	retrovir wa well market might say mr jonathan de pass industri analyst barclay de zoet wedd
19920303000000000_37	The possibility that Wellcome is failing to maximise drugs sales and therefore profits is also reflected in the company s 25 per cent gross profit margin lower than that of its competitors in the drugs business ICI Glaxo or Fisons.	possibl well come fail maximis drug sale therefor profit also reflect compani per cent gross profit margin lower competitor drug busi ici glax fison
19920303000000000_38	Wellcome s newfound marketing priority is important too in its non prescription drugs business.	well come new found market prioriti import non prescript drug busi
19920303000000000_39	It is noted for its cough and cold remedies Actifed and Sudafed and for other over the counter (OTC) products that can be bought without a prescription such as Calpol a pain reliever for infants.	note cough cold remedi actif sudaf counter otc product bought without prescript calpol pain reliev infant
19920303000000000_40	Aggressive marketing is also preparing the ground for the sale of Zovirax as a treatment for cold sores without a prescription.	aggress market also prepar ground sale zovirax treatment cold sore without prescript
19920303000000000_41	Mr Robb denies that the business of selling low technology OTC cures is out of place in a research driven company.	mr robb deni busi sell low technolog otc cure place research driven compani
19920303000000000_42	A significant position in OTC will become increasingly important as pressure on prices of prescription drugs increases.	signific posit otc becom increasingli import pressur price prescript drug increas
19920303000000000_43	As margins are squeezed on prescription drugs Wellcome can turn to OTC drugs as a stable source of income.	margin squeez prescript drug well come turn otc drug stabl sourc incom
19920303000000000_44	While Glaxo for example disposed of its OTC drugs several years ago Mr Robb sees OTC as a means of extending the profit earning life of a drug.	glax exampl dispos otc drug sever year ago mr robb see otc mean extend profit earn life drug
19920303000000000_45	When a prescription drug loses its patent rivals can produce the same drug cheaply.	prescript drug lose patent rival produc drug cheapli
19920303000000000_46	But the hope is by turning a prescription drug into a branded consumer product premium prices can be maintained.	hope turn prescript drug brand consum product premium price maintain
19920303000000000_47	Already Zovirax is being sold over the counter in New Zealand.	al readi zovirax sold counter new zealand
19920303000000000_48	SmithKline Beecham has a similar philosophy.	smith kline beecham ha similar philosophi
19920303000000000_49	It has earmarked its ulcer treatment Tagamet once the world s best selling drug for OTC sales to treat upset stomachs.	ha earmark ulcer treatment tagamet onc world best sell drug otc sale treat upset stomach
19920303000000000_50	Wellcome is seeking a partner to expand its international OTC business.	well come seek partner expand intern otc busi
19920303000000000_51	Wellcome s need for marketing partners is not confined to OTC drugs.	well come need market partner confin otc drug
19920303000000000_52	While it is strong in selling anti viral drugs its new products essential for the group s profits growth are in areas where it has little experience.	strong sell anti viral drug new product essenti group profit grow th area ha littl experi
19920303000000000_53	These include epilepsy muscle relaxants (for operations) hepatitis B and eventually the potentially big market of migraine treatments.	includ epilepsi muscl relax oper hepat b eventu potenti big market migrain treatment
19920303000000000_54	These new drugs will need to compensate for the eventual decline of Zovirax.	new drug need compens eventu declin zovirax
19920303000000000_55	Investors considering whether to buy the shares released by the Trust will have to decide whether the promise of products in the pipeline will enable Wellcome to continue its strong stock market performance.	investor consid whether buy share releas trust decid whether promis product pipelin enabl well come continu strong stock market perform
19920303000000000_56	A FREER HAND Key products for the 1990s Drug Treatment 1991 Estimated sales sales by 1995 Pounds Pounds Zovirax Anti virus 471m 870m Retrpvor Anti Aids 177m 300m Exosurf Lung treatment for premature babies 22m 100m Wellferon Hepatitis B 12m 80m Lamictal Epilepsy New launch 100m BW256U Replace BW882C Zovirax 1995 97 launch Source.	freer hand key product drug treatment estim sale sale pound pound zovirax anti viru retrpvor anti aid exosurf lung treatment prematur babi wellferon hepat b lamict epilepsi new launch bw u replac bw c zovirax launch sourc
19920303000000000_57	Wellcome BZW Lehman Brothers TOP 10 UK TRUSTS Grants Assets Pounds m Pounds m Wellcome Trust 58.	well come bz w lehman brother top uk trust grant asset pound pound well come trust
19920402000000000_1	FT 02 APR 92 Glaxo s head of French operations leaves company.	ft apr glax head french oper leav compani
19920402000000000_2	GLAXO S president of French operations Mr Edwin Nathan has left the company following a breakdown in relations between the British group and the French government over the pricing of Imigran its new migraine drug.	glaxo presid french oper mr edwin nathan ha left compani follow break relat british group french govern price migran new migrain drug
19920402000000000_3	Glaxo refused to give reasons for his move.	glax refus give reason hi move
19920402000000000_4	He was in charge of negotiations with the French government for Imigran.	wa charg negoti french govern migran
19920402000000000_5	Last month he told a French newspaper that in exchange for a high price for Imigran Glaxo would construct a FFr1bn (Pounds 100m) factory in France set up a research and development centre or co market the drug with Sanofi the French pharmaceuticals group.	last month told french new spaper exchang high price migran glax would construct f fr bn pound factori franc set research develop centr co market drug sanofi french pharmaceut group
19920402000000000_6	Such deals are common in France though are not normally referred to in public.	deal common franc though normal refer public
19920402000000000_7	He told Les Echos the French financial daily.	told le echo french financi daili
19920402000000000_8	The different ministers are dragging out the negotiations perhaps in order not to take risks before the next elections.	differ minist drag negoti perhap order take risk befor next elect
19920402000000000_9	He pointed out France was one of the last European countries to license Imigran.	point franc wa one last european countri licens migran
19920402000000000_10	Two weeks later the French government ordered an investigation into the ethical legal and medical acceptability of methods used by Glaxo to market Imigran.	two week later french govern order investig ethic legal medic accept method use glax market migran
19920402000000000_11	It set up a commission to decide whether to ask the European Commission to investigate possible abuse of market position.	set commiss decid whether k european commiss investig possibl abus market posit
19920402000000000_12	French officials said they were concerned that Glaxo was generating public pressure on the government to license the drug.	french offici said concern glax wa gener public pressur govern licens drug
19920402000000000_13	In particular they were irritated by the number of articles about Imigran in consumer magazines.	particular irrit number articl migran consum magazin
19920402000000000_14	France traditionally has low pharmaceuticals prices but has among the largest per capita consumption of drugs in Europe.	franc tradit ha low pharmaceut price ha among largest per capita consumpt drug europ
19920402000000000_15	7 per cent of its GNP last year on healthcare the second highest spending in Europe after Germany.	per cent gnp last year health care second highest spend europ germani
19920402000000000_16	Glaxo has a strategy of charging high prices for innovative products.	glax ha strategi charg high price innov product
19920402000000000_17	The group like other pharmaceuticals companies is finding it hard to maintain prices for existing products in Japan and Europe.	group like pharmaceut compani find hard maintain price exist product japan europ
19920402000000000_18	In the US many have been forced by political pressure to introduce voluntary price freezes or promises not to increase prices above the rate of inflation.	us mani forc polit pressur introduc voluntari price freez promis increas price abov rate inflat
19920402000000000_19	Mr Nathan is to be replaced by Mr Christopher Adam Glaxo s commercial director.	mr nathan replac mr christoph adam glax commerci director
19920421000000000_1	GLAXO the pharmaceuticals group and the UK s biggest company by market capitalisation has won its fifth award for technology with its antibiotic Zinnat.	glaxo pharmaceut group uk biggest compani market capitalis ha fifth award technolog antibiot zinnat
19920421000000000_2	Zinnat was developed because other drugs in its class needed to be injected and were therefore of little use outside the hospital environment.	zinnat wa develop becaus drug class need inject therefor littl use outsid hospit environ
19920421000000000_3	In addition bacteria were building up resistance to existing antibiotics such as penicillin which were proving increasingly less effective.	addit bacteria build resist exist antibiot penicillin prove increasingli less effect
19920421000000000_4	The challenge for Glaxo was to develop a drug that was.	challeng glax wa develop drug wa
19920421000000000_5	The active ingredient within Zinnat Cefuroxime Axetil had an extremely unpleasant taste.	activ ingredi within zinnat cefuroxim axetil extrem unplea ant tast
19920421000000000_6	stable in water so that it retained its potency within the stomach and gut.	stabl water retain potenc within stomach gut
19920421000000000_7	resistant to the enzymes in the gut but which could be ingested effectively into the body.	resist enzym gut could ingest effect bodi
19920421000000000_8	quick acting once it had been taken into the blood stream.	quick act onc taken blood stream
19920421000000000_9	without any toxic by products and therefore without serious side effects.	without ani toxic product therefor without seriou side effect
19920421000000000_10	able to resist Beta lactamase a substance excreted by bacteria which prevents some antibiotics working effectively.	abl resist beta lactamas substanc excret bacteria prevent antibiot work effect
19920421000000000_11	Glaxo believes it tested as many as 10 000 different formulations at its Greenford research centre in north west London over a period of about six years before it discovered the right drug.	glax believ test mani differ formul greenford research centr north west london period six year befor discov right drug
19920421000000000_12	Its pharmacists also invented a new process to manufacture a wax coating around the drug.	pharmacist also invent new process manufactur wax coat around drug
19920421000000000_13	The coating was not unpleasant to taste but dissolved when required in the gut to release the active ingredients.	coat wa unplea ant tast dissolv requir gut releas activ ingredi
19920421000000000_14	Since it was launched in 1987 more than 25m people have been treated with the drug.	sinc wa launch peopl treat drug
19920421000000000_15	Zinnat is used for a large number of infections ranging from upper respiratory infections such as tonsilitis and sinusitis to urinary tract infections and gonorrhoea.	zinnat use larg number infect rang upper respiratori infect tonsil sinus urinari tract infect gonorrhoea
19920421000000000_16	Clinical trials showed that cure or improvement is achieved in more than 88 per cent of patients with lower respiratory infections and more than 90 per cent of patients with gonorrhoea.	clinic trial show cure improv achiev per cent patient lower respiratori infect per cent patient gonorrhoea
19920421000000000_17	Zinnat also has a low incidence of side effects.	zinnat also ha low incid side effect
19920421000000000_18	More than Pounds 500m of sales have been generated by the drug since its launch which according to Glaxo makes its the second best selling antibiotic in its class.	pound sale gener drug sinc launch accord glax make second best sell antibiot class
19920421000000000_19	Previous awards for technology were for Ventolin and Becotide the asthma drugs Zantac an ulcer treatment which is the world s best selling medicine and Fortum another antibiotic.	previou award technolog ventolin becotid asthm drug zantac ulcer treatment world best sell medicin fortum anoth antibiot
19920421000000000_20	Glaxo has spent nearly Dollars 4bn on research and development over the last 10 years.	glax ha spent nearli dollar bn research develop last year
19920421000000000_21	In the last fiscal year alone Glaxo spent Dollars 880m on research and development and is expected by analysts to spend more than Dollars 1bn more than any other company.	last fiscal year alon glax spent dollar research develop expect analyst spend dollar bn ani compani
19920601000000000_1	FT 01 JUN 92 A marketing prescription for Wellcome John Robb talks about prospects for the drugs group.	ft jun market prescript well come john robb talk prospect drug group
19920601000000000_2	WELLCOME S chief executive Mr John Robb prides himself on his market orientated approach to business.	wellcom chief execut mr john robb pride hi market orient approach busi
19920601000000000_3	The 56 year old Scot and former consumer products executive at Beecham has proved determined to make the group more market driven since he was appointed by chairman Sir Alistair Frame in July 1990.	year old scot former consum product execut beecham ha prove determin make group market driven sinc wa appoint chairman sir alistair frame juli
19920601000000000_4	But Mr Robb is now faced with the biggest marketing challenge of his life the sale of up to 50 per cent of the group in the largest ever issue by a privately owned British company.	mr robb face biggest market challeng hi life sale per cent group largest ever issu privat british compani
19920601000000000_5	The offer scheduled for mid July could raise as much as Pounds 4bn.	offer schedul mid juli could rais much pound bn
19920601000000000_6	The company is the fastest growing among the world s 20 largest pharmaceutical companies.	compani fastest grow among world largest pharmaceut compani
19920601000000000_7	On a five year average Wellcome has enjoyed the highest earnings per share growth rate of any pharmaceutical stock some 30.	five year averag well come ha enjoy highest earn per share grow th rate ani pharmaceut stock
19920601000000000_8	In addition the company has a dominant position about 80 per cent in the fast growing anti viral market.	addit compani ha domin posit per cent fast grow anti viral market
19920601000000000_9	Sales of Zovirax its herpes treatment are expected to grow by about 20 per cent during the next two years reaching Pounds 820m by 1994.	sale zovirax herp treatment expect grow per cent dure next two year reach pound
19920601000000000_10	Retrovir the anti Aids drug also known as AZT could reach annual sales of Pounds 340m in 1994 according to a recent note by SG Warburg the company s brokers.	retrovir anti aid drug also known zt could reach annual sale pound accord recent note sg warburg compani broker
19920601000000000_11	But although Wellcome s short term future looks bright Mr Robb s task is complicated by two doubts on its long term growth.	although well come short term futur look bright mr robb task complic two doubt long term grow th
19920601000000000_12	First the beneficial effects of the group s wide ranging disposal programme run out next year.	first benefici effect group wide rang dispos programm run next year
19920601000000000_13	Since he took over the helm operating margins have improved from 21.	sinc took helm oper margin improv
19920601000000000_14	During the first half of this year they rose 2.	dure first half thi year rose
19920601000000000_15	However more than half of that improvement came from a programme of disposals which is now coming to an end.	howev half improv came programm dispos come end
19920601000000000_16	During the first half of 1992 sales increased 26 per cent.	dure first half sale increas per cent
19920601000000000_17	Commentators believe as much as 40 per cent of Wellcome s revenue growth could come from this product next year.	comment believ much per cent well come revenu grow th could come thi product next year
19920601000000000_18	Its main patents expire in Germany next year the UK in 1995 and the US and Japan in 1997.	main patent expir germani next year uk us japan
19920601000000000_19	Sales are still growing remarkably fast given that it was launched Mr Robb says he recognises the threat to Zovirax and has developed a twin strategy to deal with the problem.	sale still grow remark fast given wa launch mr robb say recognis threat zovirax ha develop twin strategi deal problem
19920601000000000_20	The first element consists of two new compounds known as 256U and 882C which should eventually replace Zovirax.	first element consist two new compound known u c eventu replac zovirax
19920601000000000_21	The two drugs should be launched in 1995 and 1996 although both are still in clinical trials.	two drug launch although still clinic trial
19920601000000000_22	SmithKline Beecham which Mr Robb acknowledges has an excellent marketing track record is scheduled to launch a competitor drug Famciclovir in 1995.	smith kline beecham mr robb acknowledg ha excel market track record schedul launch competitor drug famciclovir
19920601000000000_23	The other element of Mr Robb s defence strategy is to sell Zovirax without a doctor s prescription in chemists.	element mr robb defenc strategi sell zovirax without doctor prescript chemist
19920601000000000_24	We don t have the marketing clout to exploit Zovirax in the OTC (over the counter) market on our own admits Mr Robb.	market clout exploit zovirax otc counter market admit mr robb
19920601000000000_25	He plays down another possible threat that to Retrovir Wellcome s anti Aids drug.	play anoth possibl threat retrovir well come anti aid drug
19920601000000000_26	He argues analysts at one stage became fixated by Retrovir seeing the group merely in relation to Aids although the drug represented only 11 per cent of group turnover last year.	argu analyst one stage becam fixat retrovir see group mere relat aid although drug repres onli per cent group turnov last year
19920601000000000_27	Competition to Retrovir from new drugs is unlikely to make much impact in the medium term reckons Mr Robb.	competit retrovir new drug unlik make much impact medium term reckon mr robb
19920601000000000_28	Our view is that Aids will continue to be treated with Retrovir in combination with other therapies at least for the next five years.	view aid continu treat retrovir combin therapi least next five year
19920601000000000_29	The market is growing and the competition is more noise than anything else at the moment.	market grow competit nois anyth els moment
19920601000000000_30	Concern does exist about a challenge to Retrovir s US patent however.	concern doe exist challeng retrovir us patent howev
19920601000000000_31	The patent s validity is being challenged by Barr Laboratories a US group.	patent valid challeng barr laboratori us group
19920601000000000_32	The outcome of the case is unclear since it will be decided next year by a jury in North Carolina.	come case unclear sinc decid next year juri north carolina
19920601000000000_33	If Wellcome loses it plans to appeal but Barr would probably be able to market a generic version of the drug in the meanwhile.	well come lose plan appeal barr would probabl abl market gener version drug mean
19920601000000000_34	In spite of the problems facing the group Mr Robb is confident he can deliver the targets he has promised.	spite problem face group mr robb confid deliv target ha promis
19920601000000000_35	These include underlying sales growth in excess of 10 per cent an operating margin of 30 per cent by 1996 and earning per share growth of more than 15 per cent a year.	includ underli sale grow th excess per cent oper margin per cent earn per share grow th per cent year
19920601000000000_36	The group s research and development has become much more focused he says.	group research develop ha becom much focus say
19920601000000000_37	The company remains committed to outstanding research but has adopted the project management approach perfected by Glaxo in the 1980s which involves dropping compounds which fail to reach development targets on time.	compani remain commit stand research ha adopt project manag approach perfect glax involv drop compound fail reach develop target time
19920601000000000_38	Since September 1989 the number of compounds in development has fallen from 78 to 34.	sinc septemb number compound develop ha fallen
19920601000000000_39	Those drugs that are fully developed will be launched in all possible markets to justify the money invested in them it costs up to Dollars 230m (Pounds 127m) to bring a drug to market.	drug fulli develop launch possibl market justifi money invest cost dollar pound bring drug market
19920601000000000_40	We have a great reputation in research and development but not a comparable reputation in marketing he says.	great reput research develop compar reput market say
19920601000000000_41	We used to think if we got the research and development right the products would sell themselves.	use think got research develop right product would sell themselv
19920601000000000_42	He plans to improve marketing by expanding Wellcome s sales force.	plan improv market expand well come sale forc
19920601000000000_43	He has also hired new sales managers for the US and Japan.	ha also hire new sale manag us japan
19920601000000000_44	Elsewhere he will continue his strategy of co marketing with other companies.	els continu hi strategi co market compani
19920601000000000_45	It s incredibly important to raise our marketing skills to the same level as our research and development skills says Mr Robb.	incred import rais market skill level research develop skill say mr robb
19920601000000000_46	As he launches a world wide marketing campaign on Thursday his most immediate challenge is to make sure the flotation itself does not run into trouble.	launch world wide market campaign thursday hi immedi challeng make sure flotat doe run troubl
19920601000000000_47	With as much as Pounds 4bn at stake his much vaunted marketing skills will be in demand.	much pound bn stake hi much vaunt market skill demand
19920602000000000_1	Cornerstone of economic development in the 1990s Pharmaceuticals thrives in Montreal.	cornerston econom develop pharmaceut thrive montreal
19920602000000000_2	THE WESTERN suburbs of Montreal illustrate the turnround in the Quebec pharmaceuticals industry from decline in the early 1980s to a cornerstone of economic development in the 1990s.	western suburb montreal illustr turnround quebec pharmaceut industri declin earli cornerston econom develop
19920602000000000_3	Hoffman La Roche Canadian arm of the Swiss multinational built extensive new research and manufacturing space in pastoral Vaudreuil.	hoffman la roch canadian arm swiss multin built extens new research manufactur space pastor vaudreuil
19920602000000000_4	The multi storey tower and five storey building alongside were designed for the 21st century.	multi storey tower five storey build alongsid design st centuri
19920602000000000_5	But in 1969 the federal government introduced compulsory licensing for imported products and reduced basic patent protection for brand name medicines to four years.	feder govern introduc compulsori licens import product reduc basic patent protect brand name medicin four year
19920602000000000_6	The company never moved into its space age facilities.	compani never move space age facil
19920602000000000_7	Nor did an American based concern which had built a new research lab in the same area.	american base concern built new research lab area
19920602000000000_8	Hoffman La Roche moved its Canadian head office to Ontario and its Canadian research facilities to the US.	hoffman la roch move canadian head offic ontario canadian research facil us
19920602000000000_9	It waited several years to sell its Vaudreuil venture.	wait sever year sell vaudreuil ventur
19920602000000000_10	The brand name companies maintained that patent protection had been reduced to the clear advantage of generic producers in the name of lower drug prices.	brand name compani maintain patent protect reduc clear advantag gener produc name lower drug price
19920602000000000_11	They warned that the compulsory licensing system would not work for Canada or Quebec.	warn compulsori licens system would work canada quebec
19920602000000000_12	By the early 1980s Ayerst McKenna Harrison closed its Montreal laboratory merging it into the parent s US research operations.	earli ayerst mckenna harrison close montreal laboratori merg parent us research oper
19920602000000000_13	With Canadian financial backing one group founded a new company specialising in products for treating diseases of the immune system and cancer and viral diseases.	canadian financi back one group found new compani specialis product treat diseas immun system cancer viral diseas
19920602000000000_14	Six year old BioChem Pharma has yet to show an operating profit but it boasts a market valuation of CDollars 1bn.	six year old b chem pharma ha yet show oper profit boast market valuat cdollar bn
19920602000000000_15	It is Glaxo s Canadian partner in developing anti Aids drugs.	glax canadian partner develop anti aid drug
19920602000000000_16	A big change came in 1987 when Ottawa bowed to pressure from the multinationals and agreed to extend patent protection to seven years in return for promises of sizeable investment in Canada.	big chang came ottaw bow pressur multin agre extend patent protect seven year return promis sizeabl invest canada
19920602000000000_17	The same western suburbs of Montreal now display the results of the investment spree that followed.	western suburb montreal display result invest spree follow
19920602000000000_18	Nearly Dollars 500m has been invested by brand name international and domestic companies in new research laboratories and production plants in Quebec since then.	nearli dollar ha invest brand name intern domest compani new research laboratori product plant quebec sinc
19920602000000000_19	Montreal has become the undisputed centre of Canada s pharmaceutical industry.	montreal ha becom undisput centr canada pharmaceut industri
19920602000000000_20	Merck Frosst Canada Burroughs Wellcome Bristol Myers Squibb Pharmaceutical Group and BioChem Pharma are among those which led the way.	merck frosst canada burrough well come bristol myer squibb pharmaceut group b chem pharma among led way
19920602000000000_21	Now the Federal Government plans to extend patent protection further in line with international practice and end compulsory licensing.	feder govern plan extend patent protect line intern practic end compulsori licens
19920602000000000_22	We want the government to adopt legislation placing Canada on a level playing field with the major industrial nations for protection of pharmaceutical products says Mr Michael Carnow president of Merck Frosst Canada.	want govern adopt legisl place canada level play field jor industri nation protect pharmaceut product say mr michael carnow presid merck frosst canada
19920602000000000_23	This will enable Canada and Quebec to compete for investment.	thi enabl canada quebec compet invest
19920602000000000_24	He said Gatt deadlines for agreement on patent protection have slipped and Canada should move unilaterally to ensure Canadian based companies can compete.	said gatt deadlin agreement patent protect slip canada move unilater ensur canadian base compani compet
19920602000000000_25	Merck Frosst has begun engineering work on a big manufacturing expansion in Montreal.	merck frosst ha begun engin work big manufactur expans montreal
19920602000000000_26	The new plant will be geared to specific products for international markets.	new plant gear specif product intern market
19920602000000000_27	The company s Canadian research budget is CDollars 270m for 1991 95 including a new Dollars 70m research centre opened last September.	compani canadian research budget cdollar includ new dollar research centr open last septemb
19920602000000000_28	Colin Mallet president of Sandoz Canada says the investment spree should continue.	colin mallet presid sandoz canada say invest spree continu
19920602000000000_29	He predicts that hundreds of new research and production jobs will be created in Quebec and Canada this decade if conditions are favourable.	predict hundr new research product job creat quebec canada thi decad condit favour
19920602000000000_30	The Quebec government is likely to work hard to ensure that the bulk of the new investment comes to the province.	quebec govern like work hard ensur bulk new invest come provinc
19920602000000000_31	Pharmaceuticals represent one of Quebec s three most important competitive industrial clusters employing more than 2 000 researchers and planning investment of up to Dollars 1.	pharmaceut repres one quebec three import competit industri cluster employ research plan invest dollar
19920602000000000_32	Almost half the total Canadian pharmaceutical industry and more than half its annual Dollars 300m research effort are now located in Quebec.	almost half total canadian pharmaceut industri half annual dollar research effort locat quebec
19920602000000000_33	The province has four university faculties of medicine two pharmacology faculties an array of specialised bodies such as the Montreal Clinical Research Biotechnology Research and the Heart and Cancer Institutes.	provinc ha four univers faculti medicin two pharmacolog faculti array specialis bodi montreal clinic research biotechnolog research heart cancer institut
19920602000000000_34	Research is also carried out at Laval University in Quebec City.	research also carri laval univers quebec citi
19920602000000000_35	The Quebec industry s activities range from basic applied and clinical research to biotech engineering.	quebec industri activ rang basic appli clinic research biotech engin
19920602000000000_36	Production includes fine chemicals pharmaceutic and therapeutic products vaccines biological and diagnostic products.	product includ fine chemic pharmaceut therapeut product vaccin biolog diagnost product
19920602000000000_37	In 1990 the Quebec industry invested Dollars 126m in research up 28 per cent from 1989 and the 1991 total was higher.	quebec industri invest dollar research per cent total wa higher
19920602000000000_38	It also includes some generic producers though these have congregated mainly in Ontario.	also includ gener produc though congreg mainli ontario
19920602000000000_39	The federal government is now considering extending the patent protection period to 20 years after application or equivalent to about 10 years in the market place.	feder govern consid extend patent protect period year applic equival year market place
19920602000000000_40	With the population ageing the industry will play a more crucial role in the economy says Mr Mallet.	popul age industri play crucial role economi say mr mallet
19920602000000000_41	We re all moving towards longer protection partly because testing lasts longer and is more complex.	move toward longer protect partli becaus test last longer complex
19920602000000000_42	We must provide an environment fostering competition with other industrial countries in scientific expertise and patent protection.	must provid environ foster competit industri countri scientif expertis patent protect
19920602000000000_43	The dice are still loaded against Canada now because its local market is lost to generic manufacturers after only seven years.	dice still load canada becaus local market lost gener manufactur onli seven year
19920602000000000_44	Canadian firms and researchers must be given a fighting chance.	canadian firm research must given fight chanc
19920602000000000_45	Generic producers have reacted strongly to suggestions that patent protection will be extended significantly.	gener produc react strongli suggest patent protect extend significantli
19920602000000000_46	Mr Barry Sherman president of Apotex Toronto one of Canada s two biggest generic drug makers said the government has capitulated to US pressure.	mr barri sherman presid apotex toronto one canada two biggest gener drug maker said govern ha capitul us pressur
19920602000000000_47	Apotex is not going ahead with plans for a Dollars 50m extension to its Winnipeg plant.	apotex go ahead plan dollar extens winnipeg plant
19920602000000000_48	MR GERALD TREMBLAY Quebec s industry minister stands behind his desk energetically spreading a sheaf of brightly coloured charts in front of him like a croupier dealing baccarat cards These are the road maps he explains to Quebec s latest initiative to draw government business labour and academia together in a concerted industrial strategy.	mr gerald tremblay quebec industri minist stand behind hi desk energet spread af brightli colour chart front like croupier deal baccarat card road map explain quebec latest initi draw govern busi labour academia togeth concert industri strategi
19920602000000000_49	Mr Tremblay who has an MBA from Harvard University asks rhetorically.	mr tremblay ha mba harvard univers ask rhetor
19920602000000000_50	Each diagram with a complex pattern of lilac orange and pink boxes (some of the boxes are multi coloured) represents one of 13 industrial clusters.	diagram complex pattern lilac orang pink box box multi colour repres one industri cluster
19920602000000000_51	These are the sectors which Quebec believes have the best chance of being competitive in world markets.	sector quebec believ best chanc competit world market
19920602000000000_52	The aim is to encourage manufacturers in these industries to co operate closely with suppliers government trade unions university researchers and with each other to create efficient and technologically advanced industries.	aim encourag manufactur industri co oper close supplier govern trade union univers research creat effici technolog advanc industri
19920602000000000_53	Corporatism has been a cornerstone of Quebec economic policy for the past 30 years.	corporat ha cornerston quebec econom polici past year
19920602000000000_54	Contracts for Hydro Quebec s big James Bay power projects put muscle into the Quebec engineering and construction industries.	contract hydro quebec big jame bay power project put muscl quebec engin construct industri
19920602000000000_55	Government direction and financial support have helped attract pharmaceutical and aerospace companies to the province.	govern direct financi support help attract pharmaceut aerospac compani provinc
19920602000000000_56	Getting everyone to pull in the same direction has been relatively easy in a province with a tightly knit homogeneous population.	get everyon pull direct ha rel easi provinc tightli knit homogen popul
19920602000000000_57	There is far more job hopping between the senior ranks of business and government in Quebec than in other parts of Canada.	far job hop senior rank busi govern quebec part canada
19920602000000000_58	However implementing a far reaching industrial strategy is less simple than it used to be.	howev implement far reach industri strategi less simpl use
19920602000000000_59	The ability of the government to use financial support as a tool of its industrial policy is constrained by its CDollars 4bn budget deficit.	abil govern use financi support tool industri polici constrain cdollar bn budget deficit
19920602000000000_60	Furthermore Hydro Quebec s construction programme will slow down sharply in the second half of the decade forcing many local companies to look elsewhere for contracts.	furthermor hydro quebec construct programm slow sharpli second half decad forc mani local compani look el se contract
19920602000000000_61	Mr Pierre Fournier research director at Levesque Beaubien Geoffrion Quebec s leading securities firm predicts the government will be able to give little more than moral support to the new industrial cluster concept.	mr pierr fournier research director leve que beaubien geoffrion quebec lead secur firm predict govern abl give littl moral support new industri cluster concept
19920602000000000_62	I like it but it s going to take a long time Mr Fournier says.	like go take long time mr fournier say
19920602000000000_63	Five sectors aerospace pharmaceuticals information technology products power generating equipment and metal processing are well established both in domestic and international markets.	five sector aerospac pharmaceut inform technolog product power gener equip metal process well establish domest intern market
19920602000000000_64	According to Mr Paul Lussier director of investment services in the ministry of industry and commerce Quebec has reached a point where no major pharmaceutical company does anything in North America without considering Quebec as an option.	accord mr paul lussier director invest servic ministri industri commerc quebec ha reach point jor pharmaceut compani doe anyth north america without consid quebec option
19920602000000000_65	If we could do that in five or six sectors we d be in great shape.	could five six sector great shape
19920602000000000_66	The second group includes transport equipment petrochemicals agri business textiles and clothing forestry housing environmental products and cultural industries.	second group includ transport equip petrochem agri busi textil cloth forestri hous environment product cultur industri
19920602000000000_67	Several of these sectors have faced severe competitive pressures in recent years and will need a shake up if they are to fulfil the hopes being placed in them.	sever sector face sever competit pressur recent year need shake fulfil hope place
19920602000000000_68	Their inclusion as clusters is partly a recognition of the province s natural resources and of these sectors vital importance to regional development.	inclus cluster partli recognit provinc natur resourc sector vital import region develop
19920602000000000_69	Each group of industries has set up a task force to identify its strengths and weaknesses.	group industri ha set task forc identifi strength weak
19920602000000000_70	In addition the province s 16 regions have been asked to submit a cluster wish list within the next few months.	addit provinc region ask submit cluster wish list within next month
19920602000000000_71	Mr Tremblay sees the government s role as a catalyst.	mr tremblay see govern role catalyst
19920602000000000_72	It s a big puzzle and we put all the pieces together he says.	big puzzl put piec togeth say
19920602000000000_73	For example vigorous arm twisting by Quebec has persuaded the federal government to locate a new Canadian space agency in Montreal.	exampl vigor arm twist quebec ha persuad feder govern locat new canadian space agenc montreal
19920602000000000_74	A forestry technology centre has moved from Ottawa to Quebec City.	forestri technolog centr ha move ottaw quebec citi
19920602000000000_75	Among the products of collaboration with business taking shape is an institute for pharmaceutical research in Montreal.	among product collabor busi take shape institut pharmaceut research montreal
19920602000000000_76	Twenty one brand name and generic drug makers have each contributed CDollars 100 000.	twenti one brand name gener drug maker contribut cdollar
19920602000000000_77	The federal and provincial governments have chipped in another CDollars 6m between them.	feder provinci govern chip anoth cdollar
19920602000000000_78	In spite of budget constraints some government money is available for individual companies too.	spite budget constraint govern money avail individu compani
19920602000000000_79	Since 1987 the government has provided over 1 000 businesses with CDollars 519m in loans.	sinc govern ha provid busi cdollar loan
19920602000000000_80	Principal repayments on a modernisation loan for example normally start only in the seventh year.	princip repay modernis loan exampl normal start onli seventh year
19920602000000000_81	Research and development expenses enjoy tax credits of up to 40 per cent.	research develop expens enjoy tax credit per cent
19920602000000000_82	But in an effort to nudge academics towards practical research the credits are doubled for R D undertaken in partnership with a university.	effort nudg academ toward practic research credit doubl r undertaken partnership univers
19920602000000000_83	Foreign investment is an important part of Quebec s industrial strategy.	foreign invest import part quebec industri strategi
19920602000000000_84	US European and Asian companies have large stakes in many of the 13 clusters as well as other parts of the economy.	us european asian compani larg stake mani cluster well part economi
19920602000000000_85	Two of South Korea s biggest North American investments are in Quebec in the form of a Hyundai car plant in the eastern townships and a Sami Steel factory in Montreal.	two south korea biggest north american invest quebec form hyundai car plant eastern township sami steel factori montreal
19920602000000000_86	Much of the emphasis in the years ahead will be on attracting more Asian capital.	much emphasi year ahead attract asian capit
19920602000000000_87	The government has just opened a trade and investment office in Vancouver with a mandate to try and divert to Quebec some of the money flowing into Canada s western provinces from Hong Kong Taiwan and Singapore.	govern ha open trade invest offic vancouv mandat tri divert quebec money flow canada western provinc hong kong taiwan singapor
19920603000000000_1	BRITISH Biotechnology Group yesterday published the pathfinder prospectus for its international share offer planned for July.	british biotechnolog group yesterday publish path finder prospectu intern share offer plan juli
19920603000000000_2	The Oxford based pharmaceutical company says it aims to raise some Pounds 30m by selling about 20 per cent of its equity through a share issue in London and New York.	oxford base pharmaceut compani say aim rais pound sell per cent equiti share issu london new york
19920603000000000_3	The issue is expected to be priced at between 400p and 450p valuing the company at about Pounds 150m.	issu expect price p p valu compani pound
19920603000000000_4	British Biotechnology will use the proceeds of the flotation primarily to fund its research and development programme which covers four medical areas.	british biotechnolog use proce flotat primarili fund research develop programm cover four medic area
19920603000000000_5	It has two drugs undergoing in early clinical trials and a third due to begin clinical testing in August.	ha two drug undergo earli clinic trial third due begin clinic test august
19920603000000000_6	But the group does not expect to market or generate revenues from the commercialisation of its pharmaceutical products until at least the latter half of the 1990s.	group doe expect market gener revenu commercialis pharmaceut product least latter half
19920618000000000_1	Japanese drug makers slow off the mark Pharmaceutical groups are under pressure to expand and innovate.	japanes drug maker slow mark pharmaceut group pressur expand innov
19920618000000000_2	A RUSH to invest overseas by Japanese pharmaceutical companies in the late 1980s appeared to signal their entrance on to the world stage.	rush invest oversea japanes pharmaceut compani late appear signal entranc world stage
19920618000000000_3	However it has since become clear that Japanese pharmaceutical groups are far from becoming the Toyotas or Matsushitas of the global drugs market.	howev ha sinc becom clear japanes pharmaceut group far becom toyota matsushita global drug market
19920618000000000_4	Despite strong efforts by some Japanese groups the country s pharmaceutical industry has been unable to develop the world beating innovatory products needed to break into overseas markets.	despit strong effort japanes group countri pharmaceut industri ha unabl develop world beat innovatori product need break oversea market
19920618000000000_5	Yamanouchi Pharmaceutical with annual sales of Y226bn (Dollars 1.	yamanouchi pharmaceut annual sale bn dollar
19920618000000000_6	8bn) and one of the drugs companies to expand most aggressively internationally hopes to be a truly global company within the next 10 years.	bn one drug compani expand aggress intern hope truli global compani within next year
19920618000000000_7	Fujisawa Pharmaceutical Japan s third largest with sales of Y227bn says.	fujisawa pharmaceut japan third largest sale bn say
19920618000000000_8	It s essential for Japanese companies to globalise since domestic market conditions are going to be increasingly difficult.	essenti japanes compani globalis sinc domest market condit go increasingli difficult
19920618000000000_9	Mr Thomas Hofstatter executive managing director of Hoechst Japan says most Japanese drugs companies are going to take time to grow into leading global operations unless a real breakthrough product is discovered.	mr thoma hofstatt execut manag director hoechst japan say japanes drug compani go take time grow lead global oper unless real breakthrough product discov
19920618000000000_10	In the 1980s most Japanese drugs companies started their overseas expansion with simple licensing agreements and established clinical trial offices.	japanes drug compani start oversea expans simpl licens agreement establish clinic trial offic
19920618000000000_11	The more ambitious however set up joint ventures or acquired distributors in the US and Europe.	ambiti howev set joint ventur acquir distributor us europ
19920618000000000_12	Fujisawa acquired Lyphomed a small drugs company in the US and Yamanouchi built a manufacturing plant in Ireland a research centre in Oxford and last year acquired the pharmaceutical division of Gist Brocades a Dutch chemical company.	fujisawa acquir lyphom small drug compani us yamanouchi built manufactur plant ireland research centr oxford last year acquir pharmaceut divis gist brocad dutch chemic compani
19920618000000000_13	Japanese drugs makers are now trying to build comprehensive independent operations in research and development production and marketing.	japanes drug maker tri build comprehens independ oper research develop product market
19920618000000000_14	Fujisawa is increasing production and marketing capacity in the US and Europe ahead of the launch of FK 506 an immune system suppressor used to prevent transplant patients rejecting their new organs.	fujisawa increas product market capac us europ ahead launch fk immun system suppressor use prevent transplant patient reject new organ
19920618000000000_15	However compared with the multi billion dollar mergers and acquisitions of US and European companies the Japanese operations and acquisitions have been modest in size.	howev compar multi billion dollar merger acquisit us european compani japanes oper acquisit modest size
19920618000000000_16	Total overseas sales by Japanese pharmaceutical companies remain around 5 per cent of their turnover compared with 30 to 50 per cent of leading US companies and 70 to 90 per cent of leading European companies.	total oversea sale japanes pharmaceut compani remain around per cent turnov compar per cent lead us compani per cent lead european compani
19920618000000000_17	The main barrier for the Japanese companies has been their lack of marketable products as most have lagged in the development of important new drugs.	main barrier japanes compani ha lack market product lag develop import new drug
19920618000000000_18	This was due to their reliance on small step innovations of existing drugs mainly lower value antibiotics and vitamins.	thi wa due relianc small step innov exist drug mainli lower valu antibiot vitamin
19920618000000000_19	Mr Muneyuki Sakai pharmaceutical analyst at County NatWest in Tokyo says an overseas subsidiary needs at least four or five original mainline products.	mr muneyuki sakai pharmaceut analyst counti natwest tokyo say oversea subsidiari need least four five origin mainlin product
19920618000000000_20	Exceptions to this pattern include Sankyo with its anti cholesterol product Mevalotin.	except thi pattern includ sank yo anti cholesterol product mevalotin
19920618000000000_21	Yamanouchi is known for its anti ulcer agent Gastar which had Y90bn overseas sales last year.	yamanouchi known anti ulcer agent gastar bn oversea sale last year
19920618000000000_22	Japanese drug companies have traditionally been complacent about R D because of the government s pricing policy on drugs.	japanes drug compani tradit complac r becaus govern price polici drug
19920618000000000_23	The Health Ministry used to award all new drugs premium prices whether they were improvements or not and failed to give drug companies an incentive to develop innovative drugs.	health ministri use award new drug premium price whether improv fail give drug compani incent develop innov drug
19920618000000000_24	Rather than take the risk of spending high sums on product development many of the larger companies chose to only make small improvements of existing drugs and distribute drugs supplied by foreign companies under licence for the Japanese market only.	rather take risk spend high sum product develop mani larger compani chose onli make small improv exist drug distribut drug suppli foreign compani licenc japanes market onli
19920618000000000_25	Development programmes have also been hurt by cumulative price cuts by the Health Ministry which started in 1981.	develop programm also hurt cumul price cut health ministri start
19920618000000000_26	It forced 10 to 15 per cent price reductions every two years.	forc per cent price reduct everi two year
19920618000000000_27	This pressured cash flow at the Japanese drug companies which are considerably smaller than their western counterparts.	thi pressur cash flow japanes drug compani consider smaller western counterpart
19920618000000000_28	However attitudes towards R D are changing rapidly as innovation has become the key to profits.	howev attitud toward r chang rapidli innov ha becom key profit
19920618000000000_29	The ministry is pushing for innovative drugs through a change in its pricing rules.	ministri push innov drug chang price rule
19920618000000000_30	From this fiscal year the only drugs to be allowed premium prices will be those which represent a new concept are more effective than existing drugs and which make a noticeable contribution to treatment.	thi fiscal year onli drug allow premium price repres new concept effect exist drug make notic contribut treatment
19920618000000000_31	At the same time foreign drug companies have started to end distribution tie ups as they establish their own networks in Japan reducing commissions at the former Japanese partners.	time foreign drug compani start end distribut tie establish network japan reduc commiss former japanes partner
19920618000000000_32	Ultimately companies will need to establish a worldwide presence in order to recoup mounting R D costs.	ultim compani need establish worldwid presenc order recoup mount r cost
19920618000000000_33	Fujisawa needs to globalise because its market share in Japan has hit a ceiling and profits have reached their upward limit.	fujisawa need globalis becaus market share japan ha hit ceil profit reach upward limit
19920618000000000_34	Companies which do not succeed internationally will see a pressure on profits.	compani succeed intern see pressur profit
19920618000000000_35	In the long run Japanese companies are expected to become more innovative.	long run japanes compani expect becom innov
19920618000000000_36	However for companies whose development policies are aimed at marginal improvements changing direction will not be easy.	howev compani whose develop polici aim margin improv chang direct easi
19920618000000000_37	Mr John Wilson analyst at James Capel says.	mr john wilson analyst jame capel say
19920618000000000_38	Companies are under pressure with sales of the industry growing at 5 per cent and costs of R D increasing by 10 per cent.	compani pressur sale industri grow per cent cost r increas per cent
19920618000000000_39	Since a typical drug takes 10 years and Y10bn to develop only those companies large enough to absorb the costs will be able to survive.	sinc typic drug take year bn develop onli compani larg enough absorb cost abl surviv
19920618000000000_40	Mr Sakai at County NatWest believes that about 10 companies led by Sankyo Fujisawa and Yamanouchi will be able to establish a position in the international pharmaceutical market.	mr sakai counti natwest believ compani led sank yo fujisawa yamanouchi abl establish posit intern pharmaceut market
19920618000000000_41	In the near future companies predict a wave of mergers and acquisitions especially rescues of smaller companies lacking new products.	near futur compani predict wave merger acquisit especi rescu smaller compani lack new product
19920618000000000_42	Mergers and acquisitions by foreign companies in line with Merck and Banyu in 1983 and more recently Bohringer Ingelheim and Yamaguchi Seiyaku in 1990 are also expected to increase as Japanese companies are now cheaper following the slump in Japanese share prices.	merger acquisit foreign compani line merck banyu recent bohring ingel im yamaguchi seiyaku also expect increas japanes compani cheaper follow slump japanes share price
19920626000000000_1	Wellcome sale could raise about Pounds 3bn.	well come sale could rais pound bn
19920626000000000_2	WELLCOME Trust the medical charity indicated yesterday it would sell 330m shares in Wellcome the drug company in next month s international tender offer.	wellcom trust medic chariti indic yesterday would sell share well come drug compani next month intern tender offer
19920626000000000_3	At yesterday s closing share price of 914p up 1p the offer would be worth Pounds 3bn.	yesterday close share price p p offer would worth pound bn
19920626000000000_4	The prospectus published yesterday said the group expected pre tax profits and earnings per share for the year to August 31 to be significantly higher than in the 1991 financial year.	prospectu publish yesterday said group expect pre tax profit earn per share year august significantli higher financi year
19920626000000000_5	Analysts are forecasting profits of Pounds 500m to Pounds 510m and earnings of about 36p per share.	analyst fore cast profit pound pound earn p per share
19920626000000000_6	Mr Lawrence Banks head of corporate finance at Robert Fleming the merchant bank co ordinating the global offer said the 330m figure was conservative and he was very confident there would be excess demand.	mr lawrenc bank head corpor financ robert fleme merchant bank co ordin global offer said figur wa conserv wa veri confid would excess demand
19920626000000000_7	Mr Roger Gibbs chairman of the trust said strong interest had been shown.	mr roger gibb chairman trust said strong interest shown
19920626000000000_8	The provisional allocation gives 165m to the UK market 80m to the US 25m to Japan and the remainder to be spread around the rest of the world.	provision alloc give uk market us japan remaind spread around rest world
19920626000000000_9	Within the UK portion Pounds 180m worth of shares is being earmarked for the public offer.	within uk portion pound worth share earmark public offer
19920626000000000_10	The company today starts presentations to investors in 29 cities.	compani today start present investor citi
19920626000000000_11	The official tender process starts on July 6 and is expected to close on July 24.	offici tender process start juli expect close juli
19920626000000000_12	The tender price and basis of allocations should be announced on July 27 with dealings suspended for the first 1 1 2 hours of that trading day.	tender price basi alloc announc juli deal suspend first hour trade day
19920626000000000_13	Mr John Robb chief executive of Wellcome said yesterday he would emphasise five of the drug group s strengths to potential buyers.	mr john robb chief execut well come said yesterday would emphasis five drug group strength potenti buyer
19920626000000000_14	These included the group s dominance of the growing anti viral drug market its promising research and development pipeline and its emphasis on sales and marketing.	includ group domin grow anti viral drug market promis research develop pipelin emphasi sale market
19920626000000000_15	He also pointed to Wellcome s strong volume growth in sales limiting the effect of pricing pressures on drugs and the ability to increase margins.	also point well come strong volum grow th sale limit effect price pressur drug abil increas margin
19920626000000000_16	Mr Banks said that retail demand was hard to estimate.	mr bank said retail demand wa hard estim
19920626000000000_17	So far more than 250 000 people had rung the Wellcome share information office.	far peopl rung well come share inform offic
19920626000000000_18	Wellcome has about 23 000 individuals on its shareholder register of which 10 000 are employees.	well come ha individu sharehold regist employe
19920626000000000_19	More than 80 regional stockbrokers are prepared to apply on behalf of private investors who can also participate via application forms.	region stockbrok prepar appli behalf privat investor also particip via applic form
19920626000000000_20	Existing Wellcome shareholders with addresses in the UK will receive a special application form giving them priority for up to Pounds 5 000 worth of shares.	exist well come sharehold address uk receiv special applic form give prioriti pound worth share
19920626000000000_21	Retail investors have to offer to buy shares at the tender price being fixed through the international book building process.	retail investor offer buy share tender price fix intern book build process
19920626000000000_22	However as the tender price will not be announced until a few days after the public offer closes applicants must specify the value of shares they wish to buy with a minimum of Pounds 1 000.	howev tender price announc day public offer close applic must specifi valu share wish buy minimum pound
19920626000000000_23	The sale of 330m shares would reduce the trust s stake from 73.	sale share would reduc trust stake
19920626000000000_24	The trust can increase the issue and Fleming has the option to sell a further 15 per cent of the final size.	trust increas issu fleme ha option sell per cent final size
19920626000000000_25	If the maximum 417m were sold the trust would be left with 25 per cent which it says it would retain as a long term investment.	maximum sold trust would left per cent say would retain long term invest
19920626000000000_26	The trust will be paying total commissions of between 3 1 2 and 3 3 4 per cent of the value of the shares sold.	trust pay total commiss per cent valu share sold
19920626000000000_27	Paul Abrahams examines the issue of shares in the UK pharmaceuticals group.	paul abraham examin issu share uk pharmaceut group
19920626000000000_28	Mr John Robb chief executive of Wellcome the pharmaceuticals company will pack his bags today and head for his native Scotland.	mr john robb chief execut well come pharmaceut compani pack hi bag today head hi nativ scotland
19920626000000000_29	Edinburgh will be his first stop on a round the world road show taking in more than 16 cities from San Francisco to Osaka.	edinburgh hi first stop round world road show take citi san francisco osaka
19920626000000000_30	On his travels he aims to promote the sale of at least 330m shares worth about Pounds 3bn.	hi travel aim promot sale least share worth pound bn
19920626000000000_31	Mr Lawrence Banks head of corporate finance at Robert Fleming the adviser to Wellcome Trust the charity which currently holds 73.	mr lawrenc bank head corpor financ robert fleme advis well come trust chariti current hold
19920626000000000_32	5 per cent of Wellcome was optimistic about the offer yesterday.	per cent well come wa optimist offer yesterday
19920626000000000_33	We have been pleased with the level of interest both in the UK and internationally in this first rate pharmaceuticals company he said.	pleas level interest uk intern thi first rate pharmaceut compani said
19920626000000000_34	In spite of Mr Banks s rhetoric the issue s success hangs in the balance.	spite mr bank rhetor issu success hang balanc
19920626000000000_35	Following last week s aborted flotation of GPA the aircraft leasing group the outlook for new issues has clouded over.	follow last week abort flotat gpa aircraft leas group look new issu ha cloud
19920626000000000_36	Between 1985 and 1990 the world drugs market grew on average by 13 per cent a year.	world drug market grew averag per cent year
19920626000000000_37	industry forecasts put the 1990 95 figure at 9 per cent.	industri fore cast put figur per cent
19920626000000000_38	the five years after that could see as little as 5 per cent average growth.	five year could see littl per cent averag grow th
19920626000000000_39	Last autumn when preparations for Wellcome s offer began Mr Robb s sales task appeared easier.	last autumn prepar well come offer began mr robb sale task appear easier
19920626000000000_40	Pharmaceuticals shares were star performers on global markets.	pharmaceut share star perform global market
19920626000000000_41	Between January 1990 and December 1991 British healthcare stocks driven by American buying outperformed the UK market by 65 per cent.	januari decemb british health care stock driven american buy outperform uk market per cent
19920626000000000_42	Over the same period American drugs stocks outstripped the US market by 55 per cent.	period american drug stock outstrip us market per cent
19920626000000000_43	Ageing populations in developed countries ensured that demand for drugs continued to grow even during recession.	age popul develop countri ensur demand drug continu grow even dure recess
19920626000000000_44	That guaranteed earnings growth far in excess of that experienced by other sectors.	guarante earn grow th far excess experienc sector
19920626000000000_45	Since January US pharmaceuticals shares have underperformed the market by nearly 20 per cent.	sinc januari us pharmaceut share underperform market nearli per cent
19920626000000000_46	American investors noting the apparent upturn in the US economy have switched from recession proof stocks into those that perform better during recovery.	american investor note appar upturn us economi switch recess proof stock perform better dure recoveri
19920626000000000_47	Wellcome has seen a similar shift in the UK.	well come ha seen similar shift uk
19920626000000000_48	26 before the issue was announced on March 2 to 914p yesterday.	befor issu wa announc march p yesterday
19920626000000000_49	Investors enthusiasm has also been dampened by the increasingly hostile environment for drugs companies.	investor enthusiasm ha also dampen increasingli hostil environ drug compani
19920626000000000_50	Costs associated with the research development and marketing of drugs are rising fast because drugs must go through expensive licensing procedures in individual countries at the same time.	cost associ research develop market drug rise fast becaus drug must go expens licens procedur individu countri time
19920626000000000_51	Meanwhile revenues are threatened by worldwide downward pressure on drugs prices as governments struggle to contain ever growing health expenditure.	mean revenu threaten worldwid downward pressur drug price govern struggl contain ever grow health expenditur
19920626000000000_52	Some US groups had disappointing first quarter results this year.	us group disappoint first quarter result thi year
19920626000000000_53	Shares in Bristol Myers Squibb the world s third largest drugs company fell 10 per cent on June 2 after it warned that sales growth for the second quarter would be less than 5 per cent.	share bristol myer squibb world third largest drug compani fell per cent june warn sale grow th second quarter would less per cent
19920626000000000_54	Against this difficult background Mr Robb must set out his case.	thi difficult background mr robb must set hi case
19920626000000000_55	First he must convince doubting audiences that he has adopted the right strategy for Wellcome to escape the twin pressures of rising costs and falling prices.	first must convinc doubt audienc ha adopt right strategi well come escap twin pressur rise cost fall price
19920626000000000_56	and he must answer misgivings about any perceived company weaknesses.	must answer misgiv ani perceiv compani weak
19920626000000000_57	The most crucial part of his tour will start next Friday when Mr Robb starts his US campaign.	crucial part hi tour start next friday mr robb start hi us campaign
19920626000000000_58	Morgan Stanley the US investment bank advising Wellcome will be charged with the successful selling of such a large volume.	morgan stanley us invest bank advis well come charg success ful sell larg volum
19920626000000000_59	Although the issue is only half of the US s largest public stock offer last month when General Motors raised Dollars 2.	although issu onli half us largest public stock offer last month gener motor rais dollar
19920626000000000_60	14bn the British company is not widely known in north America.	bn british compani wide known north america
19920626000000000_61	Only 2 per cent of its stock is owned in the US compared with about 26 per cent of Glaxo the UK pharmaceuticals group and about 32 per cent of SmithKline Beecham the Anglo American company.	onli per cent stock us compar per cent glax uk pharmaceut group per cent smith kline beecham anglo american compani
19920626000000000_62	Another problem for Mr Robb s US campaign is that Wellcome s price earnings ratio is slightly higher than that of Merck the world s largest drug company and last year one of US investors favourite stocks.	anoth problem mr robb us campaign well come price earn ratio slightli higher merck world largest drug compani last year one us investor favourit stock
19920626000000000_63	Mr Steve Plag pharmaceuticals analyst at County Natwest the only important UK broker not directly involved in the issue explained.	mr steve plag pharmaceut analyst counti natwest onli import uk broker directli involv issu explain
19920626000000000_64	On my calculations Wellcome is on a prospective price earnings ratio of 22 whereas Merck is on 20 and Glaxo is on 18.	calcul well come prospect price earn ratio wherea merck glax
19920626000000000_65	The question is whether US investors will be willing to buy a stock on a higher ratio than Merck.	question whether us investor buy stock higher ratio merck
19920626000000000_66	Nevertheless Mr Robb can point to several factors in his company s favour.	nevertheless mr robb point sever factor hi compani favour
19920626000000000_67	Wellcome is the fastest growing of the world s 20 largest pharmaceutical companies.	well come fastest grow world largest pharmaceut compani
19920626000000000_68	Over the past five years it has enjoyed the highest average annual earnings per share growth rate of any big pharmaceutical company some 30.	past five year ha enjoy highest averag annual earn per share grow th rate ani big pharmaceut compani
19920626000000000_69	In the short term in spite of difficult conditions Wellcome s earnings growth looks assured.	short term spite difficult condit well come earn grow th look assur
19920626000000000_70	S G Warburg the company s broker forecast in its most recent circular that sales from continuing operations are set to grow at 16 per cent a year over the next three years.	g warburg compani broker fore cast recent circular sale continu oper set grow per cent year next three year
19920626000000000_71	Meanwhile operating profit margins over the same period should increase from 24.	mean oper profit margin period increas
19920626000000000_72	The strongest card in Mr Robb s hand is the company s ability to withstand pricing pressures.	strongest card mr robb hand compani abil stand price pressur
19920626000000000_73	During the past six months sales increased 21 per cent over the same period of 1991.	dure past six month sale increas per cent period
19920626000000000_74	But only 3 percentage points came from price increases.	onli percentag point came price increas
19920626000000000_75	The rest was generated by volume growth.	rest wa gener volum grow th
19920626000000000_76	There s little disagreement that Robb and his new management team have done an excellent job and that earnings growth looks strong for the next two years said Mr Plag.	littl disagr robb hi new manag team done excel job earn grow th look strong next two year said mr plag
19920626000000000_77	There is a significant risk that earnings growth may start to decelerate.	signific risk earn grow th may start deceler
19920626000000000_78	Mr Plag claimed that the two main motors for earnings growth the company s sales of less profitable subsidiaries and Zovirax the anti viral treatment will start running out of steam soon.	mr plag claim two main motor earn grow th compani sale less profit subsidiari zovirax anti viral treatment start run steam soon
19920626000000000_79	Unusually for such an 11 year old product Zovirax s sales are still growing fast.	unusu year old product zovirax sale still grow fast
19920626000000000_80	But growth is likely to slow in the mid 1990s despite Wellcome s acquisition of licences around the world for Zovirax to treat diseases such as chicken pox and shingles.	grow th like slow mid despit well come acquisit licenc around world zovirax treat diseas chicken pox shingl
19920626000000000_81	The drug s patents expire in Germany in 1993 followed by the UK in 1995 and the US where 39 per cent of sales are made in 1997.	drug patent expir germani follow uk us per cent sale made
19920626000000000_82	The patent expiries could be significant because much of Wellcome s growth derives from Zovirax.	patent expiri could signific becaus much well come grow th deriv zovirax
19920626000000000_83	Mr Plag estimates the product could account for more than 40 per cent of sales growth next year.	mr plag estim product could account per cent sale grow th next year
19920626000000000_84	For long term prosperity Wellcome is dependent upon the development of new products to replace existing earners.	long term prosper well come depend upon develop new product replac exist earner
19920626000000000_85	The company s strong research base is clearly crucial and Mr Robb says R D investment will remain at about 14 per cent of sales for the foreseeable future.	compani strong research base clearli crucial mr robb say r invest remain per cent sale forese futur
19920626000000000_86	Since joining the company from Beecham where he was consumer products executive in 1989 Mr Robb has tried to integrate R D more closely into the marketing effort.	sinc join compani beecham wa consum product execut mr robb ha tri integr r close market effort
19920626000000000_87	Symbolically the group marketing operations have been moved to the Beckenham R D site providing far closer co operation between the two divisions.	symbol group market oper move beckenham r site provid far closer co oper two divis
19920626000000000_88	We used to think if we got the research and development right the products would sell themselves.	use think got research develop right product would sell themselv
19920626000000000_89	Rather than building up expensive marketing networks however the group is turning to co marketing agreements with other companies.	rather build expens market network howev group turn co market agreement compani
19920626000000000_90	It has initialled deals with Hoechst in Germany Sigma Tau in Italy and Sumitomo in Japan to help market Zovirax.	ha initial deal hoechst germani sigma tau itali sumitomo japan help market zovirax
19920626000000000_91	Last spring the company conducted the most thorough review of its R D projects it had undertaken.	last spring compani conduct thorough review r project undertaken
19920626000000000_92	Its aim was to avoid research on scientifically interesting but commercially fruitless compounds.	aim wa avoid research scientif interest commerci fruitless compound
19920626000000000_93	As a result numerous products were dropped leaving resources for fewer but potentially more lucrative drugs such as Atovaquone Wellcome s medicine for Aids related pneumonia.	result numer product drop leav resourc fewer potenti lucr drug tovaquon well come medicin aid relat pneumonia
19920626000000000_94	Mr Robb has also moved to set up clinical trials simultaneously in Japan Europe and the US for Wellcome s new herpes treatment known as 256.	mr robb ha also move set clinic trial simultan japan europ us well come new herp treatment known
19920626000000000_95	Previously such trials were carried out consecutively leading to long gaps between approval in each market.	previous trial carri consecut lead long gap approv market
19920626000000000_96	Project teams have been established to anticipate potential delays with the regulatory authorities.	project team establish anticip potenti delay regulatori author
19920626000000000_97	Mr Robb s hope is that 256 could be rolled out into the world s three largest market s the US Japan and Europe within 72 months.	mr robb hope could roll world three largest market us japan europ within month
19920626000000000_98	In spite of Mr Robb s efforts weaknesses remain.	spite mr robb effort weak remain
19920626000000000_99	Wellcome s corporate tax rate for example is relatively high because it has not moved parts of its manufacturing base to countries such as Singapore and Puerto Rico which have liberal tax regimes.	well come corpor tax rate exampl rel high becaus ha move part manufactur base countri singapor puerto rico liber tax regim
19920626000000000_100	5 per cent of its profits in tax in contrast to Glaxo s 28 per cent and Merck s 26 per cent.	per cent profit tax contrast glax per cent merck per cent
19920626000000000_101	S G Warburg said in its circular that it expects Wellcome s tax burden to increase by 1 percentage point this year.	g warburg said circular expect well come tax burden increas percentag point thi year
19920626000000000_102	Another concern is Retrovir Wellcome s anti HIV drug.	anoth concern retrovir well come anti hiv drug
19920626000000000_103	Its patent is being challenged by Barr Laboratories a US generics group which is seeking to market its own version of the drug.	patent challeng barr laboratori us gener group seek market version drug
19920626000000000_104	Wellcome s case is technically strong but the case will be decided by a North Carolina jury next year said Mr Plag at County Natwest.	well come case technic strong case decid north carolina juri next year said mr plag counti natwest
19920626000000000_105	Both Retrovir and Aids are emotive issues and the outcome is by no means certain.	retrovir aid emot issu come mean certain
19920626000000000_106	If Wellcome loses the group s earnings growth could fall significantly after 1994.	well come lose group earn grow th could fall significantli
19920626000000000_107	Although the drug has a high name recognition it represents only 14 per cent of group sales.	although drug ha high name recognit repres onli per cent group sale
19920626000000000_108	Robert Fleming s Mr Banks will have to wait until July 24 when the offer closes to see whether his optimism is justified.	robert fleme mr bank wait juli offer close see whether hi optim justifi
19920626000000000_109	As Mr Robb jets round the world his marketing skills are likely to be much in demand.	mr robb jet round world hi market skill like much demand
19920626000000000_110	Despite the questions surrounding Wellcome s long term growth they are likely to ensure the issue succeeds.	despit question surround well come long term grow th like ensur issu succe
19920626000000000_111	New era looks to mind drugs In the second article of a series on drug research Clive Cookson outlines treatments for mental conditions from anxiety to memory loss.	new era look mind drug second articl seri drug research clive cookson line treatment mental condit anxieti memori loss
19920626000000000_112	The pharmaceutical industry has an abysmal record in treating disorders of the brain and nervous system.	pharmaceut industri ha abysm record treat disord brain nervou system
19920626000000000_113	While new drugs have transformed the outlook for people suffering from infectious illnesses heart disease and gastro intestinal problems most psychiatric patients depend on medicines discovered several decades ago.	new drug transform look peopl suffer infecti ill heart diseas gastro intestin problem psychiatr patient depend medicin discov sever decad ago
19920626000000000_114	Current treatments for mental conditions from mild anxiety to severe psychosis emerged during the black box era of drug discovery.	current treatment mental condit mild anxieti sever psychosi emerg dure black box era drug discoveri
19920626000000000_115	Doctors observed that they relieved symptoms often poorly and unpredictably but pharmacologists had no idea how they worked.	doctor observ reliev symptom often poorli unpredict pharmacologist idea work
19920626000000000_116	For the most serious problems degenerative brain diseases such as Alzheimer s there is still nothing that really works.	seriou problem degen brain diseas alzheim still noth realli work
19920626000000000_117	The outlook however is much brighter as scientific discoveries about the chemistry and biology of the brain find their way into new drugs.	look howev much brighter scientif discoveri chemistri biolog brain find way new drug
19920626000000000_118	The ones being introduced during the 1990s are based on an understanding of neurotransmitters (chemical messengers which send signals between cells) and receptors (protein molecules on the cell which receive the signals and initiate specific biological responses).	one introduc dure base understand neurotransmitt chemic messeng send signal cell receptor protein molecul cell receiv signal initi specif biolog respons
19920626000000000_119	After the year 2000 there is the prospect of far superior treatments based on the genetic processes involved in mental disorders.	year prospect far superior treatment base genet process involv mental disord
19920626000000000_120	The best known neurotransmitter is 5 HT also called 5 hyroxytryptamine or serotonin which is active not only in the brain but also in other parts of the body.	best known neurotransmitt ht also call hyroxytryptamin serotonin activ onli brain also part bodi
19920626000000000_121	It is associated with several types of receptor each giving a different biological response.	associ sever type receptor give differ biolog respons
19920626000000000_122	The pharmaceutical industry is developing drugs to interact with each specific type as an agonist to stimulate the receptor or as an antagonist to block it.	pharmaceut industri develop drug interact specif type agonist stimul receptor antagonist block
19920626000000000_123	Glaxo of the UK has been investigating 5 HT systems for almost 20 years and expects a spectacular payback from two drugs.	glax uk ha investig ht system almost year expect spectacular payback two drug
19920626000000000_124	Sumatriptan (trade name Imigran) is the first effective treatment for migraine the intense recurrent headache suffered by at least one adult in 12.	sumatriptan trade name migran first effect treatment migrain intens recurr headach suffer least one adult
19920626000000000_125	It was launched last year as an injection and is being introduced in the UK this month in more convenient form as pills.	wa launch last year inject introduc uk thi month conveni form pill
19920626000000000_126	With sumatriptan ahead of competition its potential sales are huge more than Pounds 1bn a year if it can overcome doctors fear of side effects.	sumatriptan ahead competit potenti sale huge pound bn year overcom doctor fear side effect
19920626000000000_127	Sumatriptan is an agonist for the 5 HT1 category of receptor stimulating the uptake of 5 HT in the cranial blood vessels.	sumatriptan agonist ht categori receptor stimul uptak ht cranial blood vessel
19920626000000000_128	Glaxo had hoped sumatriptan would have no effect elsewhere in the body but experience shows that some patients feel tightness in the chest after injections.	glax hope sumatriptan would effect el se bodi experi show patient feel tight chest inject
19920626000000000_129	That is presumably because blood vessels elsewhere in the body contain a few of the same 5 HT1 receptors.	presum becaus blood vessel el se bodi contain ht receptor
19920626000000000_130	Glaxo says sumatriptan s side effects are insignificant for healthy people but they show how difficult it is to make a selective receptor based drug.	glax say sumatriptan side effect insignific healthi peopl show difficult make select receptor base drug
19920626000000000_131	Ondansetron (Zofran) is an antagonist for a different receptor type the 5 HT3.	ondansetron zofran antagonist differ receptor type ht
19920626000000000_132	It was launched two years ago as an anti emetic to prevent nausea and vomiting induced by cancer therapy but Glaxo is now carrying out clinical trials with ondansetron for a range of psychiatric conditions including anxiety schizophrenia addiction and age associated memory impairment.	wa launch two year ago anti emet prevent nausea vomit induc cancer therapi glax carri clinic trial ondansetron rang psychiatr condit includ anxieti schizophrenia addict age associ memori impair
19920626000000000_133	Glaxo researchers are understandably cautious about proclaiming ondansetron to be a psychiatric wonder drug.	glax research understand cautiou proclaim ondansetron psychiatr wonder drug
19920626000000000_134	They blanch when outsiders talk of it as a potential smart drug which could improve everyone s memory.	blanch outsid talk potenti smart drug could improv everyon memori
19920626000000000_135	Mike Tyers pharmacology director for Glaxo Group Research says the 5 HT3 receptors on neurones (nerve cells in the brain) seem to be there to control things when they go wrong.	mike tyer pharmacolog director glax group research say ht receptor neuron nerv cell brain seem control thing go wrong
19920626000000000_136	When everything is working properly they are fairly silent.	everi thing work properli fairli silent
19920626000000000_137	If so a 5 HT3 antagonist such as ondansetron may help to restore the balance in several disorders without side effects.	ht antagonist ondansetron may help restor balanc sever disord without side effect
19920626000000000_138	Another group of new drugs based on the 5 HT system is leading to improved treatments for depression.	anoth group new drug base ht system lead improv treatment depress
19920626000000000_139	The specific serotonin re uptake inhibitors (SSRIs) as they are known increase the low 5 HT levels in the brain which are associated with many forms of depression.	specif serotonin uptak inhibitor ssri known increas low ht level brain associ mani form depress
19920626000000000_140	Eli Lilley of the US is already selling more than Dollars 1bn a year of its pioneering SSRI fluoxetine (Prozac) launched in 1988.	eli lilley us al readi sell dollar bn year pioneer ssri fluoxetin prozac launch
19920626000000000_141	In hot pursuit is a second generation of SSRIs led by paroxetine (Seroxat) which was developed jointly by Novo Nordisk of Denmark and SmithKline Beecham the Anglo American group.	hot pursuit second gener ssri led paroxetin seroxat wa develop jointli novo nordisk denmark smith kline beecham anglo american group
19920626000000000_142	SSRIs have fewer side effects than the tricyclic drugs which have dominated antidepressant treatment for 30 years.	ssri fewer side effect tricycl drug domin antidepress treatment year
19920626000000000_143	Yet SSRIs still leave much to be desired.	yet ssri still leav much desir
19920626000000000_144	they take at least two weeks to relieve depression and they fail to work in about one third of patients.	take least two week reliev depress fail work one third patient
19920626000000000_145	That may reflect partly the poor quality of clinical diagnosis in depression and other non acute mental disorders.	may reflect partli poor qualiti clinic diagnosi depress non acut mental disord
19920626000000000_146	Some scientists believe that all forms of depression ultimately work through a common biochemical pathway.	scientist believ form depress ultim work common biochem pathway
19920626000000000_147	If they are right and not everyone agrees with the theory it may eventually be possible to find a fast acting drug that will help anyone who is clinically depressed.	right everyon agre theori may eventu possibl find fast act drug help anyon clinic depress
19920626000000000_148	The greatest neurological challenge for pharmaceutical research is to find a cure for the degenerative brain diseases which lead inexorably to dementia and death.	greatest neurolog challeng pharmaceut research find cure degen brain diseas lead inexor dementia death
19920626000000000_149	The most prevalent is Alzheimer s which affects as many as 20 per cent of people over 70.	preval alzheim affect mani per cent peopl
19920626000000000_150	The search for an Alzheimer s treatment has led to a new class of drugs the nootropics developed to enhance memory and other cognitive functions.	search alzheim treatment ha led new class drug nootrop develop enhanc memori cognit function
19920626000000000_151	The first generation of nootropics aims to increase the amount of acetylcholine in the brain.	first gener nootrop aim increas amount acetylcholin brain
19920626000000000_152	Alzheimer s patients have a marked deficit of this neurotransmitter.	alzheim patient mark deficit thi neurotransmitt
19920626000000000_153	Most of the Alzheimer s drugs developed recently work indirectly by inhibiting an enzyme called cholinesterase which breaks down acetylcholine.	alzheim drug develop recent work indirectli inhibit enzym call cholinesteras break acetylcholin
19920626000000000_154	Although they have shown promise in clinical trials the manufacturers have not yet produced evidence strong enough to convince the US Food and Administration to licence any of the drugs.	although shown promis clinic trial manufactur yet produc evid strong enough convinc us food administr licenc ani drug
19920626000000000_155	Du Pont Merck the pharmaceutical joint venture between Du Pont and Merck of the US has a promising anti dementia drug now in late clinical trials which works in a different way.	du pont merck pharmaceut joint ventur du pont merck us ha promis anti dementia drug late clinic trial work differ way
19920626000000000_156	It acts directly to stimulate the release of acetylcholine and other neurotransmitters in the brain.	act directli stimul releas acetylcholin neurotransmitt brain
19920626000000000_157	The drug (chemical name linopirdine) is noteworthy too for its unusually vivid and appealing trade name Aviva.	drug chemic name linopirdin noteworthi unusu vivid appeal trade name aviva
19920626000000000_158	However none of these memory enhancing drugs even Aviva can do more than temporarily reverse or slow down the mental degeneration that is characteristic of Alzheimer s disease.	howev none memori enhanc drug even aviva temporarili revers slow mental degener characterist alzheim diseas
19920626000000000_159	None prevents the build up of tangled plaques of amyloid protein which progressively destroy patients brains.	none prevent build tangl plaqu amyloid protein progress destroy patient brain
19920626000000000_160	The best long term hope for curing progressive dementias is to identify the genetic mechanism responsible and then develop drugs to block its effect.	best long term hope cure progress dementia identifi genet mechan respons develop drug block effect
19920626000000000_161	In the case of Alzheimer s a fault in a gene coding for amyloid precursor protein (APP) seems to be responsible.	case alzheim fault gene code amyloid precursor protein app seem respons
19920626000000000_162	In a few families this is inherited but it is more often caused by environmental factors.	famili thi inherit often caus environment factor
19920626000000000_163	Many pharmaceutical researchers are now working on long range projects to block APP though they are hampered by the fact that there is not yet a good animal model for Alzheimer s.	mani pharmaceut research work long rang project block app though hamper fact yet good anim model alzheim
19920626000000000_164	Athena Neurosciences of California is one of the biotechnology companies furthest advanced in this area.	athena neurosci california one biotechnolog compani furthest advanc thi area
19920626000000000_165	More futuristic still are ideas for repairing brain damage by growing new nerve cells.	futurist still idea repair brain damag grow new nerv cell
19920626000000000_166	That does not normally occur in an adult brain but scientists are accumulating evidence that selective regeneration could be achieved by removing some of the genetic factors that inhibit the process.	doe normal occur adult brain scientist accumul evid select regener could achiev remov genet factor inhibit process
19920626000000000_167	The series will continue next month by looking at asthma drugs.	seri continu next month look asthm drug
19920629000000000_1	FT 29 JUN 92 Cancer charity in pioneer drug deal.	ft jun cancer chariti pioneer drug deal
19920629000000000_2	CANCER Research Campaign the UK charity has signed a deal with a US pharmaceuticals company to develop a pioneering cancer treatment which could earn the charity as much as Pounds 20m a year.	cancer research campaign uk chariti ha sign deal us pharmaceut compani develop pioneer cancer treatment could earn chariti much pound year
19920629000000000_3	The drug called Temozolomide is the first effective treatment for glioma a form of brain tumour.	drug call temozolomid first effect treatment glioma form brain tumour
19920629000000000_4	Cancer Research funded research and development of the drug which was originally discovered by Aston University in Birmingham.	cancer research fund research develop drug wa origin discov aston univers birmingham
19920629000000000_5	Further clinical trials to establish the drug s effectiveness on other forms of cancer are being set up.	clinic trial establish drug effect form cancer set
19920629000000000_6	Professor Edward Newlands the head of cancer medicine at Charing Cross and Westminster Medical School and director of the drug s clinical trials said it may prove effective against bone marrow cancer.	professor edward newland head cancer medicin chare cross westminst medic school director drug clinic trial said may prove effect bone marrow cancer
19920629000000000_7	The agreement with Schering Plough the largest ever concluded by the charity s wholly owned technology transfer company is worth an immediate Dollars 1.	agreement schere plough largest ever conclud chariti wholli technolog transfer compani worth immedi dollar
19920629000000000_8	Once the drug is launched the charity will receive royalty payments.	onc drug launch chariti receiv royalti payment
19920629000000000_9	These could be worth up to Pounds 20m a year according to Dr Sue Foden managing director of Cancer Research Campaign Technology the charity s technology transfer subsidiary.	could worth pound year accord dr sue foden manag director cancer research campaign technolog chariti technolog transfer subsidiari
19920629000000000_10	Last year the charity s income raised mainly through voluntary contributions was Pounds 40.	last year chariti incom rais mainli voluntari contribut wa pound
19920629000000000_11	Under the agreement the charity will receive about 40 per cent of royalties which are worth between 2 per cent and 8 per cent of sales depending on volume.	agreement chariti receiv per cent royalti worth per cent per cent sale depend volum
19920629000000000_12	The remaining 60 per cent of royalties will be paid to Rhone Poulenc Rorer the Franco American company that helped with initial research Aston University which discovered the molecule and Charing Cross and Westminster Medical School which developed it.	remain per cent royalti paid rhone poulenc rorer franco american compani help initi research aston univers discov molecul chare cross westminst medic school develop
19920629000000000_13	Professor Newlands explained that half of glioma patients using the drug had shown clinical benefit and as many as 40 per cent had demonstrated an improvement when examined with brain scans.	professor newland explain half glioma patient use drug shown clinic benefit mani per cent demonstr improv examin brain scan
19920629000000000_14	Patients with skin cancer had also shown some improvement.	patient skin cancer also shown improv
19920629000000000_15	He said this was the first time a drug had had a repeatable noteworthy effect on brain tumours.	said thi wa first time drug repeat noteworthi effect brain tumour
19920629000000000_16	The charity said that it hoped Schering Plough would be able to use the US Food and Drug Administration s accelerated licensing programme so that the medicine would be on the American market within five years.	chariti said hope schere plough would abl use us food drug administr acceler licens programm medicin would american market within five year
19920629000000000_17	The potential market for Temozolomide was difficult to predict because it depended whether it worked against other cancers Professor Newlands said.	potenti market temozolomid wa difficult predict becaus depend whether work cancer professor newland said
19920702000000000_1	Healthy market for pharmaceuticals The growing accessibility of Japan s drugs sector.	healthi market pharmaceut grow access japan drug sector
19920702000000000_2	AFTER years of sitting in the back seat the world s leading pharmaceutical companies operating in Japan have started to gain presence in what used to be one of the most introverted sectors in the country.	year sit back seat world lead pharmaceut compani oper japan start gain presenc use one introvert sector countri
19920702000000000_3	Until recently Japanese drug companies had the market virtually to themselves with imports accounting for less than 10 per cent of total sales.	recent japanes drug compani market virtual themselv import account less per cent total sale
19920702000000000_4	However recent falls in asset values along with industry restructuring have created chances for international drug companies to expand their Japanese operations.	howev recent fall asset valu along industri restructur creat chanc intern drug compani expand japanes oper
19920702000000000_5	The country s drugs market the second largest in the world after the US with annual sales of Y6 000bn (Dollars 47bn) holds substantial potential for further growth as the population ages rapidly and Japanese consumers become increasingly health conscious.	countri drug market second largest world us annual sale bn dollar bn hold substanti potenti grow th popul age rapidli japanes consum becom increasingli health consciou
19920702000000000_6	Mr Thomas Hofstaetter executive managing director at Hoechst Japan says.	mr thoma hofstaett execut manag director hoechst japan say
19920702000000000_7	For a pharmaceutical company to be truly global it must maintain presence in US Europe and Japan.	pharmaceut compani truli global must maintain presenc us europ japan
19920702000000000_8	However until recently most foreign companies lacking distribution networks were forced to rely on tie ups with Japanese companies.	howev recent foreign compani lack distribut network forc reli tie japanes compani
19920702000000000_9	Although acquisitions by leading foreign companies date back as far as 1983 when Merck of the US purchased 55 per cent of Banyu Pharmaceutical a medium sized listed company such cases were rare.	although acquisit lead foreign compani date back far merck us purchas per cent banyu pharmaceut medium size list compani case rare
19920702000000000_10	The recent fall in the stock and real estate markets have triggered activity among foreign drugs companies.	recent fall stock real estat market trigger activ among foreign drug compani
19920702000000000_11	Earlier this year Pfizer the US drugs and chemicals group announced plans to buy Koshin Medical a privately owned medical equipment distributor for an estimated Y3bn.	earlier thi year pfizer us drug chemic group announc plan buy koshin medic privat medic equip distributor estim bn
19920702000000000_12	Last year Monsanto of the US acquired 12 per cent of Hokuriku Pharmaceuticals for Y14.	last year monsanto us acquir per cent hokuriku pharmaceut
19920702000000000_13	5bn and Roussel Medica merged with Morishita Pharmaceuticals.	bn roussel medica merg morishita pharmaceut
19920702000000000_14	Other leading European drug groups have also shown interest in purchasing Japanese companies.	lead european drug group also shown interest purchas japanes compani
19920702000000000_15	Bankers point out that some smaller Japanese drug makers and wholesalers are welcoming foreign drug companies which have comparative advantages over their Japanese counterparts.	banker point smaller japanes drug maker wholesal welcom foreign drug compani compar advantag japanes counterpart
19920702000000000_16	The price cuts by the Ministry of Health and Welfare implemented every two years from 1981 and averaging from 10 to 15 per cent have squeezed profits at drug manufacturers.	price cut ministri health welfar implement everi two year averag per cent squeez profit drug manufactur
19920702000000000_17	The small and medium sized companies which lack new innovative drugs face increasing difficulties.	small medium size compani lack new innov drug face increas difficulti
19920702000000000_18	Japanese drug wholesalers have also been forced to change their business strategies because of to the price cuts.	japanes drug wholesal also forc chang busi strategi becaus price cut
19920702000000000_19	In the past the manufacturer and wholesaler had special keiretsu corporate grouping type relationships.	past manufactur wholesal special keiretsu corpor group type relationship
19920702000000000_20	However the price cuts are continually depressing profit margins and wholesalers now need to distribute a wide range of products rather than those of just one manufacturer.	howev price cut continu depress profit margin wholesal need distribut wide rang product rather one manufactur
19920702000000000_21	Last April Japan s Fair Trade Commission banned manufacturers and distributors from manipulating drug prices and that has also broken their cozy relationship.	last april japan fair trade commiss ban manufactur distributor manipul drug price ha also broken cozi relationship
19920702000000000_22	Mr Kenji Wakamatsu at Sandoz Pharmaceuticals says.	mr kenji wakamatsu sandoz pharmaceut say
19920702000000000_23	Since wholesalers have more freedom it s much easier for foreign companies to establish ties.	sinc wholesal freedom much easier foreign compani establish tie
19920702000000000_24	Foreign companies that entered the Japanese market early have started to set up their own sales and marketing operations.	foreign compani enter japanes market earli start set sale market oper
19920702000000000_25	Sandoz which entered the market in the 1960s through a distribution tie up with Sankyo the second largest Japanese drugs maker set up its own distribution network in 1990.	sandoz enter market distribut tie sank yo second largest japanes drug maker set distribut network
19920702000000000_26	Bayer also ended its sales tie up with Takeda the industry leader in 1990.	bayer also end sale tie takeda industri leader
19920702000000000_27	Mr Hofstaetter at Hoechst says the key to success is to have a number of strong products.	mr hofstaett hoechst say key success number strong product
19920702000000000_28	Bayer s Adalaat a calcium antagonist posted sales of over Y50bn last year becoming the second best selling drug in Japan.	bayer adalaat calcium antagonist post sale bn last year becom second best sell drug japan
19920702000000000_29	Nippon Roche s Furtulon an anti cancer agent is also seeing brisk sales.	nippon roch furtulon anti cancer agent also see brisk sale
19920702000000000_30	Mr John Wilson pharmaceutical analyst at James Capel in Tokyo says.	mr john wilson pharmaceut analyst jame capel tokyo say
19920702000000000_31	Japan is a profitable market for foreign companies since they already have effective drugs and do not need to spend a fortune on research and development.	japan profit market foreign compani sinc al readi effect drug need spend fortun research develop
19920702000000000_32	Many foreign companies are in final stages of setting up full operations with production sales and research and development.	mani foreign compani final stage set full oper product sale research develop
19920702000000000_33	Bayer is investing Y20bn in its new research centre while Sandoz expanded its production plant north of Tokyo and expects its new Y15bn research laboratory to be completed next year.	bayer invest bn new research centr sandoz expand product plant north tokyo expect new research laboratori complet next year
19920702000000000_34	In contrast to foreign car and electronics makers foreign drug companies which hold about 20 per cent of the market say they are treated equally with the Japanese.	contrast foreign car electron maker foreign drug compani hold per cent market say treat equal japanes
19920702000000000_35	One problem which remains is clinical testing for new drugs where foreign companies must present data from clinical trials in Japan.	one problem remain clinic test new drug foreign compani must present data clinic trial japan
19920702000000000_36	However the Ministry of Health and Welfare is loosening its grip as more Japanese companies venture abroad and with some drugs overseas data from pre clinical tests are accepted.	howev ministri health welfar loosen grip japanes compani ventur abroad drug oversea data pre clinic test accept
19920702000000000_37	TOP TEN FOREIGN DRUG COMPANIES IN JAPAN 1991 sales change (Ybn) on year Banyu (Merck) 105.	top ten foreign drug compani japan sale chang ybn year banyu merck
19920702000000000_38	7 Figures are as of Dec 91 except Banyu (Mar 92) and Glaxo (June 91).	figur dec except banyu mar glax june
19920721000000000_1	Fresh water in the gene pool Exploring the role which genetic drugs will play in curing diseases at their source.	fresh water gene pool explor role genet drug play cure diseas sourc
19920721000000000_2	An entirely new generation of drugs that acts directly on human genes is likely to transform the pharmaceutical industry over the next two decades.	entir new gener drug act directli human gene like transform pharmaceut industri next two decad
19920721000000000_3	Genetic drug sales could be worth tens of billions of dollars a year within 20 years.	genet drug sale could worth ten billion dollar year within year
19920721000000000_4	Almost every drug today acts on proteins the chemicals that do the work in all living creatures from viruses to people.	almost everi drug today act protein chemic work live creatur virus peopl
19920721000000000_5	But the rapid expansion of genetic knowledge has made it possible to target drugs at the original cause of trouble the genes that tell cells exactly which proteins to make.	rapid expans genet knowledg ha made possibl target drug origin caus troubl gene tell cell exactli protein make
19920721000000000_6	Already scientists know the sequence and function of thousands of genes in humans and other animals plants and micro organisms and they expect within 15 years to have discovered all of the estimated 100 000 genes which provide the blueprint for every human being.	al readi scientist know sequenc function thou gene human anim plant micro organ expect within year discov estim gene provid blueprint everi human
19920721000000000_7	Genetic drugs can be aimed either at defective genes in the patient s own cells or at infectious organisms such as viruses.	genet drug aim either defect gene patient cell infecti organ virus
19920721000000000_8	They promise cures for diseases that are hard to treat with existing medicines.	promis cure diseas hard treat exist medicin
19920721000000000_9	And their exquisite specificity to use a favourite phrase of biotechnologists will avoid the side effects of today s protein based drugs.	exquisit specif use favourit phrase biotechnologist avoid side effect today protein base drug
19920721000000000_10	There are two broad categories of genetic drug both just beginning clinical trials.	two broad categori genet drug begin clinic trial
19920721000000000_11	Gene therapy involves inserting new genes into cells to produce therapeutic proteins in the body.	gene therapi involv insert new gene cell produc therapeut protein bodi
19920721000000000_12	Anti sense therapy or code blocking is the opposite process switching off genes so that they stop making harmful proteins.	anti sens therapi code block opposit process switch gene stop make harm protein
19920721000000000_13	A common view in the biotechnology industry last year was that anti sense had more commercial potential than gene therapy at least for the medium term because it is in principle a simpler process.	common view biotechnolog industri last year wa anti sens commerci potenti gene therapi least medium term becaus principl simpler process
19920721000000000_14	A specific gene can be switched off by a molecule small enough to be made by orthodox chemical synthesis.	specif gene switch molecul small enough made orthodox chemic synthesi
19920721000000000_15	Gene therapy on the other hand requires a whole new gene thousands of times larger than an anti sense drug which has to be made by biotechnology.	gene therapi hand requir whole new gene thou time larger anti sens drug ha made biotechnolog
19920721000000000_16	There also appeared to be immense problems in delivering new genes to the cells where they are needed and getting them to work there.	also appear immens problem deliv new gene cell need get work
19920721000000000_17	Over the last few months anti sense research has continued to make progress.	last month anti sens research ha continu make progress
19920721000000000_18	Isis Pharmaceuticals of California has started clinical trials of an anti sense drug to treat human papilloma virus (which causes genital warts and cervical cancer) and several other US companies specialising in anti sense technology including Genta Gilead Hybridon and TargeTech are developing drugs aimed at a wide variety of diseases.	isi pharmaceut california ha start clinic trial anti sens drug treat human papilloma viru caus genit wart cervic cancer sever us compani specialis anti sens technolog includ genta gilead hybridon targetech develop drug aim wide varieti diseas
19920721000000000_19	viral infections such as hepatitis B Aids and herpes.	viral infect hepat b aid herp
19920721000000000_20	But gene therapy is moving forward even faster on both the scientific and the commercial fronts and the view emerging in the pharmaceutical industry is that it will eventually be more important than anti sense technology.	gene therapi move forward even faster scientif commerci front view emerg pharmaceut industri eventu import anti sens technolog
19920721000000000_21	Researchers at the US National Institutes of Health (NIH) carried out the first human gene therapy trial in September 1990 on a four year old girl who had to be kept apart from other children because one defective gene in her immune system meant that she had no natural protection against infection.	research us nation institut health nih carri first human gene therapi trial septemb four year old girl kept apart children becaus one defect gene immun system meant natur protect infect
19920721000000000_22	Every month since then she has received a transfusion of about a billion of her own blood cells to which copies of the correct gene had been added (the treatment has to be repeated because the genetically engineered cells gradually die).	everi month sinc ha receiv transfus billion blood cell copi correct gene ad treatment ha repeat becaus genet engin cell gradual die
19920721000000000_23	Her immune defences are now strong enough for her to attend school normally.	immun defenc strong enough attend school normal
19920721000000000_24	That success had led to a flood of proposals for gene therapy experiments in the US where the clinical development of genetic medicine is well ahead of Europe and Japan.	success led flood propos gene therapi experi us clinic develop genet medicin well ahead europ japan
19920721000000000_25	The American regulators have already approved about 20 clinical trials and as with anti sense start up companies are rushing to exploit the technology.	american regul al readi approv clinic trial anti sens start compani ru hing exploit technolog
19920721000000000_26	Therapy Inc (GTI) based in Maryland near NIH and enjoying a close relationship with the pioneering gene therapy researchers there.	therapi inc gti base maryland near nih enjoy close relationship pioneer gene therapi research
19920721000000000_27	Others include Somatix Therapy Viagene Targeted Genetics Trans karyotic Therapies and Vical.	includ somatix therapi viagen target genet tran karyot therapi vical
19920721000000000_28	The range of treatments proposed for gene therapy is even wider than for anti sense.	rang treatment propos gene therapi even wider anti sens
19920721000000000_29	Candidates for treatment in the near future include inherited single gene disorders such as cystic fibrosis and haemophilia.	candid treatment near futur includ inherit singl gene disord cystic fibrosi haemophilia
19920721000000000_30	Eventually it may be possible to treat combinations of genetic faults with heart disease and degenerative brain disease the most valuable targets.	eventu may possibl treat combin genet fault heart diseas degen brain diseas valuabl target
19920721000000000_31	Giving the patient s own cells the ability to produce a therapeutic protein that is not normally present in the body.	give patient cell abil produc therapeut protein normal present bodi
19920721000000000_32	This has potential for treating many forms of cancer.	thi ha potenti treat mani form cancer
19920721000000000_33	Even after the rapid progress of the last few years however researchers still have to overcome several technical problems if gene therapy and anti sense are to become mass market treatments.	even rapid progress last year howev research still overcom sever technic problem gene therapi anti sens becom mass market treatment
19920721000000000_34	Most important of all is to develop better ways of enabling the genetic therapeutics to reach the cells where they are needed.	import develop better way enabl genet therapeut reach cell need
19920721000000000_35	The first generation of anti sense drugs is not designed to reach difficult sites inside the body.	first gener anti sens drug design reach difficult site insid bodi
19920721000000000_36	Genta is applying them to bone marrow cells removed temporarily from the body (to switch off a cancer causing gene in leukaemia) and Isis is targeting viral genes in herpes or papilloma infections on or near the skin.	genta appli bone marrow cell remov temporarili bodi switch cancer caus gene leukaemia isi target viral gene herp papilloma infect near skin
19920721000000000_37	All the early gene therapy trials use genetically engineered viruses to insert new genes into the patient s cells.	earli gene therapi trial use genet engin virus insert new gene patient cell
19920721000000000_38	Although the virus is disabled to prevent it causing any harm researchers cannot rule out the slight risk that it might stimulate a latent infection or even trigger cancer.	although viru disabl prevent caus ani harm research cannot rule slight risk might stimul latent infect even trigger cancer
19920721000000000_39	But new delivery systems are in prospect for both categories of genetic treatment.	new deliveri system prospect categori genet treatment
19920721000000000_40	Anti sense drugs are being linked to other chemicals which make them permeate cells more effectively and non viral vectors are being developed for gene therapy.	anti sens drug link chemic make permeat cell effect non viral vector develop gene therapi
19920721000000000_41	Until recently the established pharmaceutical giants had left gene based medicine to academic scientists and biotechnology start ups.	recent establish pharmaceut giant left gene base medicin academ scientist biotechnolog start
19920721000000000_42	They are now scrambling to catch up by starting research in house and forming alliances with the specialist biotech companies.	scrambl catch start research hous form allianc specialist biotech compani
19920721000000000_43	Isis for example has partnerships with Ciba Geigy of Switzerland Eisai of Japan and Rhone Poulenc of France.	isi exampl ha partnership ciba geigi switzerland eisai japan rhone poulenc franc
19920721000000000_44	Gilead its competitor has a collaborative research agreement with Glaxo of the UK.	gilead competitor ha collabor research agreement glax uk
19920721000000000_45	GTI is working with Sandoz of Switzerland which has shown more interest in gene therapy than any other large pharmaceutical company.	gti work sandoz switzerland ha shown interest gene therapi ani larg pharmaceut compani
19920721000000000_46	Researchers talk of total sales of genetic drugs running into tens of billion of dollars within 20 years though such estimates are highly speculative.	research talk total sale genet drug run ten billion dollar within year though estim highli specul
19920721000000000_47	Robertson Stephens Co Californian investment analysts say the US gene therapy market for just three cancers (renal ovarian and melanoma) is potentially worth Dollars 1.	robertson stephen co californian invest analyst say us gene therapi market three cancer renal ovarian melanoma potenti worth dollar
19920721000000000_48	2bn a year based on a cost of Dollars 15 000 per patient.	bn year base cost dollar per patient
19920721000000000_49	That seems expensive but it may be an acceptable price for a treatment which saves not only the patient s life but also tens of thousands of dollars in hospital fees.	seem expens may accept price treatment save onli patient life also ten thou dollar hospit fee
19920723000000000_1	Companies focus on new drugs and more research Japan s drugs industry.	compani focu new drug research japan drug industri
19920723000000000_2	MOUNTING worries over international expansion by Japan s pharmaceutical industry following their counterparts in the vehicle and electronics industries have been calmed by slower than expected results by the overseas operations of the drugs groups.	mount worri intern expans japan pharmaceut industri follow counterpart vehicl electron industri calm slower expect result oversea oper drug group
19920723000000000_3	However the Japanese pharmaceuticals industry is at a turning point as companies are shifting focus towards production of new and effective drugs and boosting research and development.	howev japanes pharmaceut industri turn point compani shift focu toward product new effect drug boost research develop
19920723000000000_4	Compared to their western counterparts Japanese drugs companies have operated on a smaller scale focusing on the domestic market the second largest in the world with annual sales of Y6 000bn.	compar western counterpart japanes drug compani oper smaller scale focus domest market second largest world annual sale bn
19920723000000000_5	The companies traditionally relied on small step innovations of existing drugs mainly lower value antibiotics and vitamins.	compani tradit reli small step innov exist drug mainli lower valu antibiot vitamin
19920723000000000_6	However a decline in profitability of domestic operations brought about by recent reforms by the Ministry of Health and Welfare has forced companies to shift emphasis on R D in order to create world beating innovatory products.	howev declin profit domest oper brought recent reform ministri health welfar ha forc compani shift emphasi r order creat world beat innovatori product
19920723000000000_7	Until recently Japanese drug companies have been complacent about R D because of the government s drug pricing policy where all new drugs were awarded premium prices whether or not they were dramatic improvements.	recent japanes drug compani complac r becaus govern drug price polici new drug award premium price whether dramat improv
19920723000000000_8	Companies lacking the incentive to develop innovative drugs chose only to make small changes to existing drugs rather than spend big sums on product development.	compani lack incent develop innov drug chose onli make small chang exist drug rather spend big sum product develop
19920723000000000_9	Companies also relied on profit margins from the distribution of drugs supplied by foreign companies under licence for the Japanese market.	compani also reli profit margin distribut drug suppli foreign compani licenc japanes market
19920723000000000_10	The push by the government for new and effective drugs has been prompted by a change in pricing rules.	push govern new effect drug ha prompt chang price rule
19920723000000000_11	From this fiscal year the only drugs to be allowed premium prices will be those which represent a new concept are more effective than existing drugs and which make a noticeable contribution to treatment.	thi fiscal year onli drug allow premium price repres new concept effect exist drug make notic contribut treatment
19920723000000000_12	Profits at companies lacking new products have been squeezed by the government s official price cuts implemented every two years from 1981 and averaging from 10 to 15 per cent.	profit compani lack new product squeez govern offici price cut implement everi two year averag per cent
19920723000000000_13	The cuts are applying pressure on companies to produce new drugs because the impact on the profit margins of new drugs is less severe.	cut appli pressur compani produc new drug becaus impact profit margin new drug less sever
19920723000000000_14	In addition foreign drug companies have started to terminate distribution tie ups as they establish their own networks in Japan reducing commissions for the former Japanese partners.	addit foreign drug compani start termin distribut tie establish network japan reduc commiss former japanes partner
19920723000000000_15	As companies increase R D and capital investment spending the need to establish a worldwide presence in order to recoup costs has increased sharply.	compani increas r capit invest spend need establish worldwid presenc order recoup cost ha increas sharpli
19920723000000000_16	Japanese companies also say that market share in Japan has hit a ceiling.	japanes compani also say market share japan ha hit ceil
19920723000000000_17	Profits have reached upward limits says Fujisawa Pharmaceutical Japan s third largest with sales of Y227bn.	profit reach upward limit say fujisawa pharmaceut japan third largest sale bn
19920723000000000_18	R D expenditure has doubled during the past 10 years while net sales increased by only 50 per cent during the same period.	r expenditur ha doubl dure past year net sale increas onli per cent dure period
19920723000000000_19	The percentage of R D expenses to net sales rose to 11.	percentag r expens net sale rose
19920723000000000_20	Because a typical drug takes 10 years and Y10bn to develop only those companies large enough to absorb costs will be able to survive in the long run.	becaus typic drug take year bn develop onli compani larg enough absorb cost abl surviv long run
19920723000000000_21	Companies without strong R D pipelines and new innovative products will drift sideways says Mr John Wilson analyst at James Capel in Tokyo.	compani without strong r pipelin new innov product drift sideway say mr john wilson analyst jame capel tokyo
19920723000000000_22	Yamanouchi Pharmaceutical one of the most aggressive in international expansion admits that it will take another 10 years before the company becomes truly global.	yamanouchi pharmaceut one aggress intern expans admit take anoth year befor compani becom truli global
19920723000000000_23	Fujisawa is also increasing production and marketing capacity in the US and Europe ahead of the launch of FK 506 an immune system suppressor used to prevent transplant patients rejecting new organs.	fujisawa also increas product market capac us europ ahead launch fk immun system suppressor use prevent transplant patient reject new organ
19920723000000000_24	Japanese drugs makers are currently boosting efforts to build comprehensive and independent operations in R D production and marketing.	japanes drug maker current boost effort build comprehens independ oper r product market
19920723000000000_25	However compared with the large scale mergers and acquisitions in the US and Europe the purchases and joint ventures have been modest in size.	howev compar larg scale merger acquisit us europ purchas joint ventur modest size
19920723000000000_26	Mr Thomas Hofstaetter executive managing director at Hoechst Japan says there is a lack of candidates for acquisitions by Japanese companies.	mr thoma hofstaett execut manag director hoechst japan say lack candid acquisit japanes compani
19920723000000000_27	Meanwhile the sharp decline in asset values in Japan bought on by the slump in the stock and property markets have made small and medium sized Japanese drugs companies ideal targets for global pharmaceutical groups looking to expand in Japan.	mean sharp declin asset valu japan bought slump stock properti market made small medium size japanes drug compani ideal target global pharmaceut group look expand japan
19920723000000000_28	The country s market holds substantial potential for further growth as the population ages rapidly and consumers become increasingly health conscious.	countri market hold substanti potenti grow th popul age rapidli consum becom increasingli health consciou
19920723000000000_29	Corporate financiers point out that the smaller companies unable to survive through the industry s consolidation due to the lack of financial and R D resources are receptive to cross border mergers and acquisitions.	corpor financi point smaller compani unabl surviv industri consolid due lack financi r resourc recept cross border merger acquisit
19920723000000000_30	Pfizer the US drugs and chemicals group announced plans to buy Koshin Medical a privately owned medical equipment distributor earlier this year.	pfizer us drug chemic group announc plan buy koshin medic privat medic equip distributor earlier thi year
19920723000000000_31	Last year Monsanto of the US acquired 12 per cent of Hokuriku Pharmaceuticals for Y14.	last year monsanto us acquir per cent hokuriku pharmaceut
19920723000000000_32	Mergers and acquisitions among Japanese companies including rescues of smaller companies are also expected to increase.	merger acquisit among japanes compani includ rescu smaller compani also expect increas
19920723000000000_33	But Mr John Wilson at James Capel predicts that alliances between industry leaders to create larger pharmaceuticals groups would be unlikely due to lingering negative attitudes towards M A among Japanese companies.	mr john wilson jame capel predict allianc industri leader creat larger pharmaceut group would unlik due linger neg attitud toward among japanes compani
19920723000000000_34	Prices continue to be a big issue Marjorie Shaffer examines developments in the US.	price continu big issu marjori shaffer examin develop us
19920723000000000_35	THE US pharmaceutical industry prospered mightily in the go go years of the 1980s.	us pharmaceut industri prosper mightili go go year
19920723000000000_36	Profit margins widened and revenue growth marched steadily and reliably upwards.	profit margin widen revenu grow th march steadili reliabl upward
19920723000000000_37	But no one expects a repeat performance in the 1990s amid continuing pressure from Washington patient advocacy groups and insurance companies to slow the rise in prescription drug prices.	one expect repeat perform mid continu pressur washington patient advocaci group insur compani slow rise prescript drug price
19920723000000000_38	Over the past decade the industry habitually raised the price of prescription drugs in the US at least twice or three times the rate of inflation.	past decad industri habitu rais price prescript drug us least twice three time rate inflat
19920723000000000_39	The steep price increases contributed to hefty double digit profit gains of 17 20 per cent.	steep price increas contribut hefti doubl digit profit gain per cent
19920723000000000_40	But because of the pressure to limit price increases most analysts agree that annual profit gains will slow to 13 15 per cent by 1995.	becaus pressur limit price increas analyst agre annual profit gain slow per cent
19920723000000000_41	Some analysts even predict that overall industry earnings growth could dip below 10 per cent.	analyst even predict overal industri earn grow th could dip per cent
19920723000000000_42	Whatever the numbers eventually turn out to be heavy criticism of US prescription drugs is forcing the industry to act with more restraint.	whatev number eventu turn heavi critic us prescript drug forc industri act restraint
19920723000000000_43	Pharmaceutical giant Merck said last year it would not raise prices more than the rate of inflation and other companies including Pfizer and Bristol Myers Squibb have followed suit.	pharmaceut giant merck said last year would rais price rate inflat compani includ pfizer bristol myer squibb follow suit
19920723000000000_44	I think there is less pricing flexibility than in the past said a spokesman for Warner Lambert a New Jersey based drug company which has announced that its price increases will be reasonable.	think less price flexibl past said spokesman warner lambert new jersey base drug compani ha announc price increas reason
19920723000000000_45	The pressure to stem the rise in drug prices is apparently taking a toll already in some areas.	pressur stem rise drug price appar take toll al readi area
19920723000000000_46	Earlier this year drug companies reported below par first quarter results leading to a sell off on Wall Street.	earlier thi year drug compani report par first quarter result lead sell wall street
19920723000000000_47	The first quarter is when the industry usually puts through its annual price raises.	first quarter industri usual put annual price rais
19920723000000000_48	This year price increases were halved to 5 6 per cent from the 10 12 per cent typical of the past five years.	thi year price increas halv per cent per cent typic past five year
19920723000000000_49	Analysts say continuing pricing constraints will hurt companies without strong product pipelines.	analyst say continu price constraint hurt compani without strong product pipelin
19920723000000000_50	Upjohn a drugs company based in Kalamazoo Michigan that many analysts say lacks a strong research and development pipeline has announced that it expects its second quarter net income to be flat.	upjohn drug compani base kalamazoo michigan mani analyst say lack strong research develop pipelin ha announc expect second quarter net incom flat
19920723000000000_51	It said it was offering voluntary retirement to about 10 per cent of its workforce to reduce costs.	said wa offer voluntari retir per cent workforc reduc cost
19920723000000000_52	Bristol Meyers Squibb surprised Wall Street last month when it released a disappointing second quarter earnings forecast.	bristol meyer squibb surpris wall street last month releas disappoint second quarter earn fore cast
19920723000000000_53	While price increases have apparently moderated Americans still pay some of the highest prices in the world for prescription drugs.	price increas appar moder american still pay highest price world prescript drug
19920723000000000_54	In most other countries prices are subsidised by governments that negotiate with drugs companies but drugs companies in the US have long set their own prices.	countri price subsidis govern negoti drug compani drug compani us long set price
19920723000000000_55	Elderly consumers bear the brunt of the costs according to a study by Purdue University s Pharmaceutical Economics Research Center in Layfayette Indiana.	elderli consum bear brunt cost accord studi purdu univers pharmaceut econom research center lay fayett indiana
19920723000000000_56	The Purdue study estimates that the elderly account for nearly 35 per cent of retail expenditures for prescription drugs in the US.	purdu studi estim elderli account nearli per cent retail expenditur prescript drug us
19920723000000000_57	The cost of prescription drugs can be an overwhelming burden for people on fixed incomes.	cost prescript drug whelm burden peopl fix incom
19920723000000000_58	Senator David Pryor chairs the Senate Special Committee on Ageing and is a critic of prescription drug prices.	senat david pryor chair senat special committe age critic prescript drug price
19920723000000000_59	Earlier this year the Senate defeated a bill proposed by Senator Pryor to control pharmaceutical prices but he intends to keep the pressure on.	earlier thi year senat defeat bill propos senat pryor control pharmaceut price intend keep pressur
19920723000000000_60	Some well publicised prices for newer drugs underscore the issue.	well publicis price newer drug underscor issu
19920723000000000_61	In May cancer experts criticised Johnson Johnson for setting too high a price for the drug Levamisole to treat colon cancer.	may cancer expert criticis johnson johnson set high price drug levamisol treat colon cancer
19920723000000000_62	The company set the price at Dollars 1 250 to Dollars 1 500 for a year s supply some 100 times higher than an older version of the drug used in veterinarian medicine.	compani set price dollar dollar year suppli time higher older version drug use veterinarian medicin
19920723000000000_63	Advocates for the mentally ill have attacked Swiss drug giant Sandoz for the price it has set for Clozapine used to treat schizophrenia.	advoc mental ill attack swiss drug giant sandoz price ha set clozapin use treat schizophrenia
19920723000000000_64	Dollars 7 500 for the drug itself plus a required weekly blood monitoring.	dollar drug plu requir weekli blood monitor
19920723000000000_65	And even before the experimental cancer drug Taxol is out of clinical trials advocates for breast cancer patients wonder if the price of the drug which may eventually reach Dollars 2 000 a gram will simply be out of reach of most women.	even befor experiment cancer drug taxol clinic trial advoc breast cancer patient wonder price drug may eventu reach dollar gram simpli reach women
19920723000000000_66	The pharmaceutical industry has long justified its prices by citing huge research and development costs.	pharmaceut industri ha long justifi price cite huge research develop cost
19920723000000000_67	According to the Pharmaceutical Manufacturers Association (PMA) the industry s trade group in Washington research costs will near Dollars 11bn in 1992 up from Dollars 9.	accord pharmaceut manufactur associ pma industri trade group washington research cost near dollar bn dollar
19920723000000000_68	The industry argues that it has to recoup its R D costs.	industri argu ha recoup r cost
19920723000000000_69	In the US it spends a little over 16 cents out of each sales dollar for R D compared to 4.	us spend littl cent sale dollar r compar
19920723000000000_70	5 cents to 5 cents for all other industries said Mr Jeff Trewhitt PMA spokesman.	cent cent industri said mr jeff trewhitt pma spokesman
19920723000000000_71	Of course in nations where there are price controls like southern Europe the prices are lower said Mr Trewhitt adding that in those countries with price controls there is little biomedical innovation.	cours nation price control like southern europ price lower said mr trewhitt ad countri price control littl biomed innov
19920723000000000_72	Between 1975 and 1989 47 major world class drugs originated in the US alone.	jor world class drug origin us alon
19920723000000000_73	This innovation has been fostered in a free market atmosphere.	thi innov ha foster free market atmospher
19920723000000000_74	Certainly the R D costs have to be covered said Mr Trewhitt.	certainli r cost cover said mr trewhitt
19920723000000000_75	Despite the industry s protests drug prices continue to be a big issue according to analysts.	despit industri protest drug price continu big issu accord analyst
19920723000000000_76	It will stay very difficult to increase prices three times whatever the consumer price index is said Mr Neil Sweig a drug analyst with Capital Institutional Services.	stay veri difficult increas price three time whatev consum price index said mr neil sweig drug analyst capit institut servic
19920723000000000_77	Indeed as the US pharmaceutical industry braces itself for a colder business climate analysts say the near future will be filled with lower growth rates and lower share prices.	inde us pharmaceut industri brace colder busi climat analyst say near futur fill lower grow th rate lower share price
19920723000000000_78	Emphasis shifts to elderly Alan Archer assesses threats to profitability.	emphasi shift elderli alan archer assess threat profit
19920723000000000_79	AT a time when most of the world s industry has been undergoing a restructuring phase brought about by the recession the pharmaceuticals industry worldwide (not accounting for the former communist bloc for which reliable sources are not yet available) has been putting forward its defensive qualities and has lived up to its description.	time world industri ha undergo restructur phase brought recess pharmaceut industri worldwid account former communist bloc reliabl sourc yet avail ha put forward defens qualiti ha live descript
19920723000000000_80	Industry executives are asking themselves with increasing nervousness how much longer the good times can last.	industri execut ask themselv increas nervous much longer good time last
19920723000000000_81	According to Mr Sam Isaly of Mehta and Isaly New York the world market grew 10 per cent with total sales of Dollars 165bn in 1991.	accord mr sam isali mehta isali new york world market grew per cent total sale dollar bn
19920723000000000_82	The industry s annual growth rate has slowed a little over recent years but continues to exceed the rate of growth of the world economy as a whole.	industri annual grow th rate ha slow littl recent year continu exceed rate grow th world economi whole
19920723000000000_83	The past few decades have proved to be a golden era for the pharmaceutical industry but despite the rise in sales the industry is still in a transition period highlighted by the amount of consolidation taking place in the past few years.	past decad prove golden era pharmaceut industri despit rise sale industri still transit period highlight amount consolid take place past year
19920723000000000_84	On the positive front many in the industry feel that the underlying demand for innovative drugs to meet and satisfy medical needs will be boosted by the shift of focus towards the elderly.	posit front mani industri feel underli demand innov drug meet sati fy medic need boost shift focu toward elderli
19920723000000000_85	This is a continuing campaign run by the UK pharmaceutical industry according to Mr Ben Hayes spokesman for the Association of the British Pharmaceutical Industry (ABPI).	thi continu campaign run uk pharmaceut industri accord mr ben hay spokesman associ british pharmaceut industri abpi
19920723000000000_86	Using the UK as an example drug expenditure per head in the over 65 age group is four times the level of the rest of the population.	use uk exampl drug expenditur per head age group four time level rest popul
19920723000000000_87	Companies which will benefit most from the changing demographic pattern will be those that provide for the chronic diseases of old age.	compani benefit chang demograph pattern provid chronic diseas old age
19920723000000000_88	arthritis coronary disease hypertension and central nervous system related illness.	arthriti coronari diseas hypertens central nervou system relat ill
19920723000000000_89	Many companies are investing heavily in this latter area particularly in research into Alzheimer s and Parkinson s disease.	mani compani invest heavili thi latter area particularli research alzheim parkinson diseas
19920723000000000_90	The company which comes out first with a product that treats these ailments would be guaranteed spectacular sales as Wellcome has had with its Aids treatment Retrovir (Zidovudine).	compani come first product treat ailment would guarante spectacular sale well come ha aid treatment retrovir zidovudin
19920723000000000_91	Another important issue is that of demographic changes and their impact on demand.	anoth import issu demograph chang impact demand
19920723000000000_92	The world population is growing rapidly by some 17 per cent a year with the poorest countries growing the fastest.	world popul grow rapidli per cent year poorest countri grow fastest
19920723000000000_93	The less developed regions of the world account for 76 per cent of the population and at present less than 15 per cent of pharmaceutical consumption.	less develop region world account per cent popul present less per cent pharmaceut consumpt
19920723000000000_94	But many industry observers believe that this will rapidly change over the next two decades.	mani industri observ believ thi rapidli chang next two decad
19920723000000000_95	It is thought that this demand will be satisfied by the launch of new products resulting from new technology such as molecular biology which is now producing a large quantity of new drug products based on the rational drug design.	thought thi demand satisfi launch new product result new technolog molecular biolog produc larg quantiti new drug product base ration drug design
19920723000000000_96	On the negative side there are many cries from the industry forecasting reduced profitability in the next decade.	neg side mani cri industri fore cast reduc profit next decad
19920723000000000_97	Pricing pressures from governments worldwide and also private buying organisations.	price pressur govern worldwid also privat buy organis
19920723000000000_98	Drugs are a tempting target for governments wishing to restrain soaring healthcare costs although they represent only about 10 per cent of health spending and can save money if used sensibly.	drug tempt target govern wish restrain soar health care cost although repres onli per cent health spend save money use sensibl
19920723000000000_99	The increasing trend in generic prescribing and generic substitution means that products will lose their market share rapidly after patent expiry.	increas trend gener prescrib gener substitut mean product lose market share rapidli patent expiri
19920723000000000_100	This will be further highlighted by the fact that tried and tested branded products such as Tagament Capoten and Tenormin will be included in the new generics being offered in the near future.	thi highlight fact tri test brand product tagament capoten tenormin includ new gener offer near futur
19920723000000000_101	Increasing regulatory requirements are delaying product launches and causing an erosion of patent life.	increas regulatori requir delay product launch caus eros patent life
19920723000000000_102	In many countries regulatory departments have a backlog of filings awaiting review.	mani countri regulatori depart backlog file await review
19920723000000000_103	According to the US Pharmaceutical Manufacturers Association the most recent estimate of cost involved in developing a new drug has risen from Dollars 125m in 1987 to Dollars 245m in 1991.	accord us pharmaceut manufactur associ recent estim cost involv develop new drug ha risen dollar dollar
19920723000000000_104	For several years many drug companies had no clear policy on what therapeutic product groups and geographical areas they wanted to trade in taking a somewhat haphazard approach.	sever year mani drug compani clear polici therapeut product group geograph area want trade take haphazard approach
19920723000000000_105	Pressure is building and only companies with a clear strategy on what areas they want to compete in will be successful.	pressur build onli compani clear strategi area want compet success ful
19920723000000000_106	Most companies have decided where they want to be by the year 2000 says Mr Robin Gilbert analyst at James Capel.	compani decid want year say mr robin gilbert analyst jame capel
19920723000000000_107	Certainly Merck and Glaxo have clearly defined their role but others like Upjohn Warner Lambert Pfizer and Syntex are not completely clear what their position is.	certainli merck glax clearli defin role like upjohn warner lambert pfizer syntex complet clear posit
19920723000000000_108	The 1990s have brought about the need for a much greater awareness of the drugs available and the world s drug market.	brought need much greater awar drug avail world drug market
19920723000000000_109	GPs now have a much better choice of medications for prescribing and are increasingly using computer data bases not only for information sourcing but also the ordering of pharmaceuticals.	gp much better choic medic prescrib increasingli use comput data base onli inform sourc also order pharmaceut
19920723000000000_110	The greater concern taken by the general public (action and lobby groups) and media to investigate wherever possible the cost benefits and safety of the drugs they are prescribed.	greater concern taken gener public action lobbi group media investig wherev possibl cost benefit safeti drug prescrib
19920723000000000_111	An increasing collaboration world wide by regulatory bodies.	increas collabor world wide regulatori bodi
19920723000000000_112	The globalisation of industry in the 1990s will be assisted by the standardisation of regulatory approval procedures for new drugs.	globalis industri assist standardis regulatori approv procedur new drug
19920723000000000_113	As European regulations are unified after 1992 they will gradually come together with those of the US Food and Drug Administration (FDA).	european regul unifi gradual come togeth us food drug administr fda
19920723000000000_114	The use by the FDA of European data for the investigation of Glaxo s filing of its new migraine drug Imigran (sumatriptan) is a very good example.	use fda european data investig glax file new migrain drug migran sumatriptan veri good exampl
19920723000000000_115	Launched in the UK in October 1991 the drug has been fast tracked in the US and approval by the FDA may be imminent.	launch uk octob drug ha fast track us approv fda may immin
19920723000000000_116	The growing knowledge by competing companies of each other s R D programmes and general strategies.	grow knowledg compet compani r programm gener strategi
19920723000000000_117	Professor Horst Meyer head of Bayer Pharmaceuticals thinks further concentration of the world s pharmaceutical industry is inevitable.	professor horst meyer head bayer pharmaceut think concentr world pharmaceut industri inevit
19920723000000000_118	The need for substantial investment in research and development required to discover block buster drugs with sales of more than Dollars 500m a year was beyond the means of all but the largest companies.	need substanti invest research develop requir discov block buster drug sale dollar year wa beyond mean largest compani
19920723000000000_119	Prof Meyer said the top 10 companies were spending 35 per cent of all money dedicated to pharmaceutical R D and the proportion was likely to increase.	prof meyer said top compani spend per cent money dedic pharmaceut r proport wa like increas
19920723000000000_120	In addition smaller companies were handicapped by their inability to market drugs in the three largest markets the US Europe and Japan.	addit smaller compani handicap inabl market drug three largest market us europ japan
19920723000000000_121	The top pharmaceutical groups were able to recover their ever larger investments by selling the drugs in all three areas added Prof Meyer.	top pharmaceut group abl recov ever larger invest sell drug three area ad prof meyer
19920723000000000_122	The author is the editor of Financial Times Pharmaceutical Business News.	author editor financi time pharmaceut busi news
19920723000000000_123	Shake up is on the way Drugs companies are concerned that they could be forced to negotiate not only the traditional hurdles of safety quality and efficacy but a new one that of cost benefit.	shake way drug compani concern could forc negoti onli tradit hurdl safeti qualiti efficaci new one cost benefit
19920723000000000_124	PHARMACEUTICAL companies have withstood the recession as though charmed.	pharmaceut compani withstood recess though charm
19920723000000000_125	Apparently inoculated against the slowdown in the world economy the sector has offered conspicuously impressive earnings growth.	appar inocul slow world economi sector ha offer conspicu impress earn grow th
19920723000000000_126	But parts of the pharmaceuticals business look sick and the prognosis for some groups is gloomy.	part pharmaceut busi look sick prognosi group gloomi
19920723000000000_127	Income growth looks set to slow while costs continue to escalate.	incom grow th look set slow cost continu escal
19920723000000000_128	Faced with the danger of falling returns the sector looks set for significant restructuring with the strong becoming stronger and the weak driven into mergers or even forced to exit.	face danger fall return sector look set signific restructur strong becom stronger weak driven merger even forc exit
19920723000000000_129	The main driving force behind the coming shake up is increasing state interference with drug prices.	main drive forc behind come shake increas state interfer drug price
19920723000000000_130	Governments everywhere are trying to control rapidly expanding healthcare budgets.	govern everi tri control rapidli expand health care budget
19920723000000000_131	Ageing populations and the growing cost of health technology have led to an alarming increase in healthcare expenditure.	age popul grow cost health technolog led alarm increas health care expenditur
19920723000000000_132	5 per cent of GNP to 12 per cent according to Mr Peter Lauper head of pharma economics at Ciba Geigy the Swiss group.	per cent gnp per cent accord mr peter lauper head pharma econom ciba geigi swiss group
19920723000000000_133	He estimates the figure will reach 15 per cent by the end of the decade.	estim figur reach per cent end decad
19920723000000000_134	For governments the agony has been compounded because the burden of such increases has fallen disproportionately on the state.	govern agoni ha compound becaus burden increas ha fallen disproportion state
19920723000000000_135	Over the past 20 years the proportion of healthcare spending paid for by the US federal and state authorities has risen from 22 per cent to 41 per cent.	past year proport health care spend paid us feder state author ha risen per cent per cent
19920723000000000_136	Governments scared by such figures but politically shy of tackling expenditure on hospitals and doctors see drugs expenditure as an attractive target for cost savings.	govern scare figur polit shi tackl expenditur hospit doctor see drug expenditur attract target cost save
19920723000000000_137	Most governments have attempted to achieve savings through aggressive pharmaceuticals price controls.	govern attempt achiev save aggress pharmaceut price control
19920723000000000_138	Last month the German government extended its reference pricing system setting limits for the reimbursement of certain drugs.	last month german govern extend refer price system set limit reimburs certain drug
19920723000000000_139	In Japan the Finance Ministry launched the latest in a series of price cuts last April.	japan financ ministri launch latest seri price cut last april
19920723000000000_140	In the US political pressure from politicians has drawn blood.	us polit pressur politician ha drawn blood
19920723000000000_141	Last month Mr Gerald Mossinghoff president of the US Pharmaceutical Manufacturers Association said drugs companies supplying a third of the US market had promised voluntarily to keep price increases at or below the rate of inflation.	last month mr gerald mossinghoff presid us pharmaceut manufactur associ said drug compani suppli third us market promis voluntarili keep price increas rate inflat
19920723000000000_142	As price controls start to bite so growth in the world pharmaceuticals market will decelerate.	price control start bite grow th world pharmaceut market deceler
19920723000000000_143	Wellcome the British group estimates that between 1985 and 1990 the world drugs market increased on average by 13 per cent a year.	well come british group estim world drug market increas averag per cent year
19920723000000000_144	For the five years after 1995 that figure could fall to only 5 per cent it believes.	five year figur could fall onli per cent believ
19920723000000000_145	The other force driving change is the rapidly rising cost of research and development.	forc drive chang rapidli rise cost research develop
19920723000000000_146	In the US R D expenditure was Dollars 11bn in 1992 up from Dollars 9.	us r expenditur wa dollar bn dollar
19920723000000000_147	Dr Armin Kessler president of the European Federation of Pharmaceutical Industries Associations has warned that even the existing level of expenditure is unsustainable.	dr armin kessler presid european feder pharmaceut industri associ ha warn even exist level expenditur unsustain
19920723000000000_148	It is in this context of rising costs and slowing growth that pharmaceuticals groups and the drugs divisions of almost all the big chemicals companies are trying to expand.	thi context rise cost slow grow th pharmaceut group drug divis almost big chemic compani tri expand
19920723000000000_149	But the industry cannot accommodate them all warns Mr David Alcraft director of healthcare and pharmaceuticals at PA Consulting Group.	industri cannot accommod warn mr david alcraft director health care pharmaceut pa consult group
19920723000000000_150	In the UK for example there were 28 per cent more drugs on the market in 1990 than in 1980 according to Mr Martyn Postle a consultant at Coopers Lybrand.	uk exampl per cent drug market accord mr martyn postl consult cooper lybrand
19920723000000000_151	With slowing revenue growth and increasing costs the industry s return on capital is bound to fall warns Mr Postle.	slow revenu grow th increas cost industri return capit bound fall warn mr postl
19920723000000000_152	Those companies that have previously been able to offset a lack of new products by increasing prices will prove most vulnerable.	compani previous abl offset lack new product increas price prove vulner
19920723000000000_153	Analysts believe US companies such as Warner Lambert and Upjohn have been highly dependent on price increases for revenue growth.	analyst believ us compani warner lambert upjohn highli depend price increas revenu grow th
19920723000000000_154	First they must create innovative products that can command premium prices.	first must creat innov product command premium price
19920723000000000_155	Then they must have the necessary marketing networks to exploit them fully.	must necessari market network exploit fulli
19920723000000000_156	Discovering new chemical entities is fairly simple.	discov new chemic entiti fairli simpl
19920723000000000_157	The difficult part is identifying which ones are likely to provide competitive advantage through greater safety or efficacy.	difficult part identifi one like provid competit advantag greater safeti efficaci
19920723000000000_158	You have to learn to manage the pipeline accelerating development of selected compounds so you can reach the market more quickly while at the same time remaining ethical in other words not cutting corners.	learn manag pipelin acceler develop select compound reach market quickli time remain ethic word cut corner
19920723000000000_159	In the battle to demonstrate the extent to which a drug is innovative pharmaceuticals groups are adding a new weapon to their armoury.	battl demonstr extent drug innov pharmaceut group ad new weapon armouri
19920723000000000_160	In order to guarantee premium prices for innovative products the drugs groups are looking to demonstrate the cost benefit of new compounds.	order guarante premium price innov product drug group look demonstr cost benefit new compound
19920723000000000_161	Previously you just had to demonstrate the drug s quality efficacy and safety.	previous demonstr drug qualiti efficaci safeti
19920723000000000_162	Now you have to show it is cost effective says Mr Lauper.	show cost effect say mr lauper
19920723000000000_163	SmithKline Beecham s Tagamet and Glaxo s Zantac both allow stomach ulcers to be treated at home rather than using expensive potentially dangerous surgery.	smith kline beecham tagamet glax zantac allow stomach ulcer treat home rather use expens potenti danger surgeri
19920723000000000_164	However there is concern that drugs companies could be forced to negotiate not only the traditional hurdles of safety quality and efficacy but a new fourth that of cost benefit.	howev concern drug compani could forc negoti onli tradit hurdl safeti qualiti efficaci new fourth cost benefit
19920723000000000_165	The danger is that regulatory authorities currently only concerned with the safety quality and efficiency of drugs will in future only licence medicines that also demonstrate they can save costs elsewhere.	danger regulatori author current onli concern safeti qualiti effici drug futur onli licenc medicin also demonstr save cost el se
19920723000000000_166	Drugs groups will need access to worldwide marketing forces so they can maximise sales during the short period when the drug s patents remain valid says Mr Postle.	drug group need access worldwid market forc maximis sale dure short period drug patent remain valid say mr postl
19920723000000000_167	Several groups have been been able to increase their revenues significantly by setting up joint marketing agreements.	sever group abl increas revenu significantli set joint market agreement
19920723000000000_168	Wellcome for example has agreements to market Zovirax its anti viral medicine with Hoechst in Germany Sigma Tau in Italy and Sumitomo in Japan.	well come exampl ha agreement market zovirax anti viral medicin hoechst germani sigma tau itali sumitomo japan
19920723000000000_169	Some small companies should be able to survive by creating niches either in research using new technologies or in marketing in specific therapeutic or geographical areas says Mr Alcraft.	small compani abl surviv creat nich either research use new technolog market specif therapeut geograph area say mr alcraft
19920723000000000_170	Without sufficient critical mass in research and development they will have few compounds and little experience in negotiating the necessary regulatory hurdles.	without suffici critic mass research develop compound littl experi negoti necessari regulatori hurdl
19920723000000000_171	In addition they will have increasing difficulty attracting good researchers.	addit increas difficulti attract good research
19920723000000000_172	The problem for the medium sized players is that emotionally it is difficult to admit you aren t going to be the next giant.	problem medium size player emot difficult admit go next giant
19920723000000000_173	The option of being a niche operator is open but it s a tricky decision to make.	option nich oper open tricki decis make
19920723000000000_174	One solution for smaller organisations is to set up joint ventures to share the costs of marketing and to increase revenues that will offset massive expenditure on research and development.	one solut smaller organis set joint ventur share cost market increas revenu offset massiv expenditur research develop
19920723000000000_175	The main synergies appear to be that marketing reach is extended and that cost savings are achieved by rationalising headquarters costs.	main synergi appear market reach extend cost save achiev rationalis headquart cost
19920723000000000_176	Many pharmaceuticals companies are parts of larger chemicals groups.	mani pharmaceut compani part larger chemic group
19920723000000000_177	In the short term most main boards will be unwilling to give up their high performing pharmaceuticals divisions.	short term main board unwil give high perform pharmaceut divis
19920723000000000_178	But in the long term pharmaceuticals groups must gain critical mass find niche areas of specialisation or wither.	long term pharmaceut group must gain critic mass find nich area specialis wither
19920723000000000_179	PHARMACEUTICAL laboratories come in many shapes and sizes.	pharmaceut laboratori come mani shape size
19920723000000000_180	Grandest of all is the Pounds 500m research centre now under construction for Glaxo in Stevenage 30 miles north of London.	grandest pound research centr construct glax stevenag mile north london
19920723000000000_181	The Glaxo labs said to be largest building project in the UK after the Channel Tunnel will house 1 400 researchers when they open in 1994.	glax lab said largest build project uk channel tunnel hous research open
19920723000000000_182	Having so many scientists working together on one site gives them all access to the best possible range of expensive up to date equipment.	mani scientist work togeth one site give access best possibl rang expens date equip
19920723000000000_183	There is a danger however that bureaucracy will smother the imaginative approach that is essential for developing innovative drugs.	danger howev bureaucraci smother imagin approach essenti develop innov drug
19920723000000000_184	Glaxo will try to overcome this by clever research management to make the scientists feel they are working in small units.	glax tri overcom thi clever research manag make scientist feel work small unit
19920723000000000_185	The opposite school of thought that research flourishes best in genuinely small groups is illustrated by Scotia Pharmaceuticals an emerging UK company which specialises in drugs based on essential fatty acids.	opposit school thought research flourish best genuin small group illustr scotia pharmaceut emerg uk compani specialis drug base essenti fatti acid
19920723000000000_186	Yet it carries out research and development on six widely separated sites.	yet carri research develop six wide separ site
19920723000000000_187	at Callanish on the Isle of Lewis in the Outer Hebrides Dundee on the east coast of Scotland Carlisle in north west England Writtle in Essex Guildford in Surrey and Nova Scotia in Canada.	callanish isl lewi outer hebrid dunde east coast scotland carlisl north west england writtl essex guildford surrey nova scotia canada
19920723000000000_188	Dr Iain Law who is in charge of R D at Callanish surely the most remote pharmaceutical laboratory in Europe says he keeps in good touch with the other facilities through visits from colleagues and through the weekly notes written by all Scotia R D managers and circulated around the company.	dr iain law charg r callanish sure remot pharmaceut laboratori europ say keep good touch facil visit colleagu weekli note written scotia r manag circul around compani
19920723000000000_189	All pharmaceutical labs whatever their size and location face a common challenge.	pharmaceut lab whatev size locat face common challeng
19920723000000000_190	how to restrain the soaring costs of R D and at the same time speed up the discovery and development of new drugs.	restrain soar cost r time speed discoveri develop new drug
19920723000000000_191	According to data collected by the Centre for Medicines Research in the UK worldwide spending on pharmaceutical R D increased by an average of 16 per cent a year during the 1980s.	accord data collect centr medicin research uk worldwid spend pharmaceut r increas averag per cent year dure
19920723000000000_192	Almost half of the industry s R D expenditure is in Europe 36 per cent in the US and 15 per cent in Japan.	almost half industri r expenditur europ per cent us per cent japan
19920723000000000_193	Unfortunately the rapid rise in R D spending has not produced a corresponding increase in the flow of new drugs onto the market.	unfortun rapid rise r spend ha produc correspond increas flow new drug onto market
19920723000000000_194	The number of medicines launched during the early 1980s averaged about 60 per year.	number medicin launch dure earli averag per year
19920723000000000_195	During the three years 1989 91 it was close to 40 a year.	dure three year wa close year
19920723000000000_196	The number of new drugs originating in Europe has fallen over the decade from 30 40 a year to 10 20 a year.	number new drug origin europ ha fallen decad year year
19920723000000000_197	) The total time taken to develop each new drug has increased steadily since the 1960s.	total time taken develop new drug ha increas steadili sinc
19920723000000000_198	The clinical phase testing the drug on human patients doubled during the 1980s to reach an average of seven years.	clinic phase test drug human patient doubl dure reach averag seven year
19920723000000000_199	Trials are taking longer because regulatory authorities are requiring more and more clinical data while doctors and their patients are becoming more reluctant to take part.	trial take longer becaus regulatori author requir clinic data doctor patient becom reluct take part
19920723000000000_200	Companies are having to spend more time and money to recruit the hundreds or even thousands of people they require to test each drug.	compani spend time money recruit hundr even thou peopl requir test drug
19920723000000000_201	lobbying the authorities to reduce the regulatory burden and operating its R D effort more efficiently.	lobbi author reduc regulatori burden oper r effort effici
19920723000000000_202	One way to ease the regulatory burden is to harmonise requirements around the world so that companies do not have to repeat tests unnecessarily to satisfy authorities in different countries.	one way eas regulatori burden harmonis requir around world compani repeat test unnecessarili sati fy author differ countri
19920723000000000_203	This is already happening within Europe through the EC.	thi al readi happen within europ ec
19920723000000000_204	On a global level the first international conference on harmonisation in Brussels last November was an important step toward bringing the US Japan and Europe into line.	global level first intern confer harmonis brussel last novemb wa import step toward bring us japan europ line
19920723000000000_205	It was agreed then for example that routine 12 month toxicity tests on animals should be abandoned in favour of six month studies.	wa agre exampl routin month toxic test anim abandon favour six month studi
19920723000000000_206	But much more needs to be done particularly to harmonise clinical requirements.	much need done particularli harmonis clinic requir
19920723000000000_207	Complete standardisation is unattainable because medical practice and social conditions vary so much around the world.	complet standardis unattain becaus medic practic social condit vari much around world
19920723000000000_208	The ultimate objective is to retain only those differences that can be justified by rational criteria.	ultim object retain onli differ justifi ration criteria
19920723000000000_209	At the same time companies are trying to improve the productivity of their researchers particularly in the pre clinical phase which they can control more closely than clinical trials.	time compani tri improv product research particularli pre clinic phase control close clinic trial
19920723000000000_210	They are investing heavily in new technology ranging from computerised chemical databases to molecular modelling graphics and automatic gene sequencing machines to help the scientists select and adapt compounds more rapidly for drug development.	invest heavili new technolog rang computeris chemic databas molecular model graphic automat gene sequenc machin help scientist select adapt compound rapidli drug develop
19920723000000000_211	Besides introducing new technology the industry is changing the way it manages R D.	besid introduc new technolog industri chang way manag r
19920723000000000_212	We have redesigned our approach to get the fastest possible answer to the question.	redesign approach get fastest possibl answer question
19920723000000000_213	says Dr Tom McKillop technical director.	say dr tom mckillop technic director
19920723000000000_214	ICI is now consistently achieving its target of administering candidate drugs to human volunteers within 14 months of their first synthesis a great improvement on the company s previous average performance of 30 months.	ici consist achiev target administ candid drug human volunt within month first synthesi great improv compani previou averag perform month
19920723000000000_215	At the same time ICI is being much more ruthless in abandoning compounds that do not live up to their initial promise.	time ici much ruthless abandon compound live initi promis
19920723000000000_216	Dr McKillop says the new regime is quite different to ICI s traditional approach which assumed that every drug was going to succeed.	dr mckillop say new regim quit differ ici tradit approach assum everi drug wa go succeed
19920729000000000_1	British Bio technology loss doubles to Pounds 11.	british bio technolog loss doubl pound
19920729000000000_2	BRITISH Bio technology the recently floated pharmaceuticals group yesterday reported losses before tax for the year ended April 30 almost doubled from Pounds 6.	british bio technolog recent float pharmaceut group yesterday report loss befor tax year end april almost doubl pound
19920729000000000_3	Mr Keith McCullagh chief executive said the results were in line with expectations.	mr keith mccullagh chief execut said result line expect
19920729000000000_4	Product research and development expenditure was likely to increase from about Pounds 11.	product research develop expenditur wa like increas pound
19920729000000000_5	This would lead to losses about 50 per cent higher for the current year.	thi would lead loss per cent higher current year
19920729000000000_6	Net cash outflow was Pounds 12m (Pounds 10m) partly because of increased spending.	net cash flow wa pound pound partli becaus increas spend
19920729000000000_7	Mr McCullagh said this followed a decision to push through more research to the development stage allowing the company to generate more substantial revenues at a later date.	mr mccullagh said thi follow decis push research develop stage allow compani gener substanti revenu later date
19920729000000000_8	The balance sheet remained strong with cash reserves of more than Pounds 37m at the year end he said.	balanc sheet remain strong cash reserv pound year end said
19920729000000000_9	This had been increased to Pounds 60m following the flotation and would allow the group to extend its clinical trial programme.	thi increas pound follow flotat would allow group extend clinic trial programm
19920729000000000_10	Mr McCullagh said the group s strategy was to sell the marketing rights for medicines that would be prescribed by general practitioners but keep the UK and possibly European rights for products to be sold into hospitals.	mr mccullagh said group strategi wa sell market right medicin would prescrib gener practition keep uk possibl european right product sold hospit
19920729000000000_11	These drugs required smaller less expensive sales forces.	drug requir smaller less expens sale forc
19920729000000000_12	British Bio technology would be looking to sign a co development and marketing deal late this year or early next year with a significant pharmaceuticals company for its Aids vaccine.	british bio technolog would look sign co develop market deal late thi year earli next year signific pharmaceut compani aid vaccin
19920729000000000_13	The drug has completed phase I safety trials on healthy volunteers and the group is hoping to establish its efficacy with further trials.	drug ha complet phase safeti trial healthi volunt group hope establish efficaci trial
19920731000000000_1	Pharmaceuticals division entering flat period after decade of success.	pharmaceut divis enter flat period decad success
19920731000000000_2	IF ICI Bioscience were demerged this year it would account for 31 per cent of the group s sales and 70 per cent of its profits and research spending.	ici bioscienc demerg thi year would account per cent group sale per cent profit research spend
19920731000000000_3	ICI Bio will take the fast growing science based businesses that have propped up ICI s fortunes during the recession of the last two years.	ici bio take fast grow scienc base busi prop ici fortun dure recess last two year
19920731000000000_4	The international company closest in shape to ICI Bio is Ciba Geigy of Switzerland which is also dominated by a large and profitable pharmaceutical business and a large and less profitable agrochemical business with a scattering of smaller specialist chemical activities.	intern compani closest shape ici bio ciba geigi switzerland also domin larg profit pharmaceut busi larg less profit agrochem busi scatter smaller specialist chemic activ
19920731000000000_5	Monsanto of the US and Sandoz of Switzerland are other international chemical groups with a biological orientation similar to ICI Bio.	monsanto us sandoz switzerland intern chemic group biolog orient similar ici bio
19920731000000000_6	The pharmaceutical division was ICI s most successful operation in the last decade.	pharmaceut divis wa ici success ful oper last decad
19920731000000000_7	It has not only shared in the general prosperity of the international drugs industry but also contributed some best sellers of its own particularly to treat heart disease and cancer.	ha onli share gener prosper intern drug industri also contribut best seller particularli treat heart diseas cancer
19920731000000000_8	However most analysts believe the current rapid growth of ICI Pharmaceuticals is over.	howev analyst believ current rapid grow th ici pharmaceut
19920731000000000_9	Indeed the half yearly results announced yesterday show that drug sales and profits are up only marginally on 1991.	inde half yearli result announc yesterday show drug sale profit onli margin
19920731000000000_10	The best that Mr Ronnie Hampel ICI chief operating officer could say was.	best mr ronni hampel ici chief oper offic could say wa
19920731000000000_11	We continue to expect pharmaceuticals to perform over the whole year at a level approaching that of last year.	continu expect pharmaceut perform whole year level approach last year
19920731000000000_12	Pharmaceutical sales are suffering from the expiry last year of US patent protection on Tenormin ICI s best selling heart drug.	pharmaceut sale suffer expiri last year us patent protect tenormin ici best sell heart drug
19920731000000000_13	Already 30 per cent of Tenormin prescriptions have been replaced by its cheaper generic version atenolol.	al readi per cent tenormin prescript replac cheaper gener version atenolol
19920731000000000_14	ICI did at least expect to lose Tenormin revenues.	ici least expect lose tenormin revenu
19920731000000000_15	This year s unexpected blow was the withdrawal because of side effects of Temafloxacin the antibiotic which the company licensed from Abbott of the US in order to fill a gap in its product line.	thi year unexpect blow wa drawal becaus side effect tema floxacin antibiot compani licens abbott us order fill gap product line
19920731000000000_16	On the positive side sales of ICI s three newest drugs Zestril (heart) Zoladex (cancer) and Diprivan (anaesthetic) are all up by more than a third this year.	posit side sale ici three ne west drug zestril heart zoladex cancer diprivan anaesthet third thi year
19920731000000000_17	And Dr Tom McKillop technical director of ICI Pharmaceuticals says the company has a very strong portfolio of drugs at various stages of development with about 10 in clinical trials.	dr tom mckillop technic director ici pharmaceut say compani ha veri strong portfolio drug variou stage develop clinic trial
19920731000000000_18	These could give ICI Pharmaceuticals a new burst of growth in the late 1990s after a relatively flat period.	could give ici pharmaceut new burst grow th late rel flat period
19920731000000000_19	However successful the new drugs are ICI Bio may find it difficult to keep the pharmaceuticals business running independently as a medium sized player in an increasingly competitive global industry.	howev success ful new drug ici bio may find difficult keep pharmaceut busi run independ medium size player increasingli competit global industri
19920731000000000_20	ICI is only number 17 in the world league of drug companies in terms of sales.	ici onli number world leagu drug compani term sale
19920731000000000_21	Analysts predict it will have to link up with a competitor through merger acquisition or a comprehensive global alliance in order to maintain strength in research development and marketing.	analyst predict link competitor merger acquisit comprehens global allianc order maintain strength research develop market
19920731000000000_22	Last year there was speculation about an ICI Wellcome combination which would make strategic sense and both the recent Wellcome share sale and proposed demerger of ICI Bio would make this easier.	last year wa specul ici well come combin would make strateg sens recent well come share sale propos demerg ici bio would make thi easier
19920731000000000_23	Although restructuring is on the agenda for the international pharmaceutical business it is a more urgent priority for the agrochemicals industry in which ICI is the world s second largest player after Ciba Geigy.	although restructur agenda intern pharmaceut busi urgent prioriti agrochem industri ici world second largest player ciba geigi
19920731000000000_24	Curbs on agricultural production especially in Europe are reducing sales of farm chemicals and leading to overcapacity.	curb agricultur product especi europ reduc sale farm chemic lead overcapac
19920731000000000_25	ICI Agrochemicals has a strong scientific and marketing base but its prospects do not look bright.	ici agrochem ha strong scientif market base prospect look bright
19920731000000000_26	ICI Seeds is still a much smaller business than agrochemicals but it has better growth prospects.	ici seed still much smaller busi agrochem ha better grow th prospect
19920731000000000_27	The company is developing a range of genetically engineered seeds for crops ranging from non squashy tomatoes to herbicide resistant corn.	compani develop rang genet engin seed crop rang non squashi tomato herbicid resist corn
19920731000000000_28	Other promising ICI Bio businesses include Quorn the fungal food and Biopol a biodegradable plastic made by bacteria.	promis ici bio busi includ quorn fungal food biopol biodegrad plastic made bacteria
19920902000000000_1	FT 02 SEP 92 SmithKline plans R D shake up.	ft sep smith kline plan r shake
19920902000000000_2	Group to cut jobs invest in new facilities and end research into gastro intestinal drugs.	group cut job invest new facil end research gastro intestin drug
19920902000000000_3	SMITHKLINE Beecham the Anglo US pharmaceutical group is to to make far reaching changes in research and development.	smi thk line beecham anglo us pharmaceut group make far reach chang research develop
19920902000000000_4	They involve 150 redundancies among UK research staff a Pounds 200m investment in new R D facilities and most surprisingly withdrawal from long term research in gastro intestinal drugs the field that provided its best selling product the ulcer medicine Tagamet.	involv redund among uk research staff pound invest new r facil surprisingli drawal long term research gastro intestin drug field provid best sell product ulcer medicin tagamet
19920902000000000_5	The strategic realignment of R D is the final phase of cost cutting and rationalisation that followed the merger between Beecham of the UK and SmithKline Beckman of the US in 1989.	strateg realign r final phase cost cut rationalis follow merger beecham uk smith kline beckman us
19920902000000000_6	Savings in manufacturing marketing and administration have already cut the group s workforce by about 2 000 and helped raise pre tax profits 18 per cent a year.	save manufactur market administr al readi cut group workforc help rais pre tax profit per cent year
19920902000000000_7	Resources must be focused on drug discovery with the highest potential for return said Dr George Poste R D chairman.	resourc must focus drug discoveri highest potenti return said dr georg post r chairman
19920902000000000_8	As a result SB has decided to discontinue several research programmes.	result sb ha decid discontinu sever research programm
19920902000000000_9	The most striking casualty is gastro intestinal drug discovery which led to Tagamet with sales exceeding Dollars 1bn (Pounds 500m) in each of the past six years and more recently to Kytril the anti nausea drug launched last year as a competitor to Glaxo s Zofran.	strike casualti gastro intestin drug discoveri led tagamet sale exceed dollar bn pound past six year recent kytril anti nausea drug launch last year competitor glax zofran
19920902000000000_10	We feel that basic research in this area has proceeded more slowly than in others and it s more difficult to identify rational candidates for drug discovery said Dr Poste.	feel basic research thi area ha proceed slowli difficult identifi ration candid drug discoveri said dr post
19920902000000000_11	But he emphasised that development work on SB s existing gastro intestinal compounds would continue.	emphasis develop work sb exist gastro intestin compound would continu
19920902000000000_12	The realignment will leave SB with drug discovery programmes in five areas.	realign leav sb drug discoveri programm five area
19920902000000000_13	UK R D sites will be cut from eight to six.	uk r site cut eight six
19920902000000000_14	SB will close its medical offices in Reigate Surrey and the small research facility at its antibiotics factory in Worthing Sussex.	sb close medic offic reigat surrey small research facil antibiot factori worth sussex
19920902000000000_15	The 150 redundancies including scientists technicians and office staff will be spread across the eight sites.	redund includ scientist technician offic staff spread across eight site
19920902000000000_16	The Pounds 200m investment in new buildings and equipment over the next four years will concentrate on Brockham Park and Great Burgh in Surrey and Mundells in Hertfordshire.	pound invest new build equip next four year concentr brockham park great burgh surrey mundel hertfordshir
19920902000000000_17	SB will continue to divide its R D effort equally between the UK and US.	sb continu divid r effort equal uk us
19920902000000000_18	Dr Poste said SB planned to devote about 15 per cent of pharmaceutical sales to R D.	dr post said sb plan devot per cent pharmaceut sale r
19920922000000000_1	Molecules muscle in A look at a faster method of getting drugs to market.	molecul muscl look faster method get drug market
19920922000000000_2	A visit to a biotechnology or pharmaceutical company these days may yield some surprises to the casual observer.	visit biotechnolog pharmaceut compani day may yield surpris casual observ
19920922000000000_3	The labs complete with test tubes and scientists in goggles and white coats are still there.	lab complet test tube scientist goggl white coat still
19920922000000000_4	Increasingly prominent though are computer rooms where researchers sit in the dark looking at coloured pictures on the screen and designing the drugs of the future.	increasingli promin though comput room research sit dark look colour pictur screen design drug futur
19920922000000000_5	These new molecular design methods will become increasingly significant for the industry and in 10 to 30 years will account for many of the new drugs on the market said Jaqueline Siegel an industry analyst at Hambrecht Quist in New York.	new molecular design method becom increasingli signific industri year account mani new drug market said jaquelin siegel industri analyst hambrecht quist new york
19920922000000000_6	The new method sometimes referred to as second generation biotech is really a convergence of biotechnology with more conventional molecular design.	new method sometim refer second gener biotech realli converg biotechnolog convent molecular design
19920922000000000_7	The biotech industry s traditional products are proteins for which a useful application has been discovered.	biotech industri tradit product protein use ful applic ha discov
19920922000000000_8	But the problem with using proteins as drugs is that they are too big to get through biological barriers in the body.	problem use protein drug big get biolog barrier bodi
19920922000000000_9	They are simply too large explains Joshua Boger chief executive officer of Boston based Vertex Pharmaceuticals.	simpli larg explain joshua boger chief execut offic boston base vertex pharmaceut
19920922000000000_10	Their size means they must be injected straight into the blood.	size mean must inject straight blood
19920922000000000_11	Insulin considered the first biotech product and one of the smallest proteins in existence has a molecular weight of 7 000 compared with aspirin which has a weight of 150.	insulin consid first biotech product one smallest protein exist ha molecular weight compar aspirin ha weight
19920922000000000_12	This is a particular problem because the greatest medical challenge to scientists is fighting diseases like cancer and Aids.	thi particular problem becaus greatest medic challeng scientist fight diseas like cancer aid
19920922000000000_13	Biotech products are too big to be taken orally and if you want to treat chronic diseases which require continuous administration you really need an oral product Boger said.	biotech product big taken oral want treat chronic diseas requir continu administr realli need oral product boger said
19920922000000000_14	Scientists agree that the industry s familiarity with protein structure is invaluable in the search for useful drugs.	scientist agre industri familiar protein structur invalu search use ful drug
19920922000000000_15	But the new second generation techniques require a change in philosophy in the industry.	new second gener techniqu requir chang philosophi industri
19920922000000000_16	Under the new methodology the protein is no longer thought of as a possible product.	new methodolog protein longer thought possibl product
19920922000000000_17	What we realised is that many chronic diseases are caused by reactions of a single protein within the body said John Maraganore head of biological research at Boston based Biogen.	realis mani chronic diseas caus reaction singl protein within bodi said john maraganor head biolog research boston base biogen
19920922000000000_18	So if we can design molecules that bind to the protein to somehow affect the reaction we may have a useful drug.	design molecul bind protein somehow affect reaction may use ful drug
19920922000000000_19	Vertex is using the new method to work out a cure for the Aids causing HIV virus.	vertex use new method work cure aid caus hiv viru
19920922000000000_20	The company has discovered an empty space in the protein where a chemical process causes the virus to become active.	compani ha discov empti space protein chemic process caus viru becom activ
19920922000000000_21	The hope is that by plugging up that space the molecule would simply lay dormant in the body.	hope plug space molecul would simpli lay dormant bodi
19920922000000000_22	The product which will probably come on market first is one developed by a traditional pharmaceutical group Merck to prevent glaucoma.	product probabl come market first one develop tradit pharmaceut group merck prevent glaucoma
19920922000000000_23	In late clinical trials the product may be on pharmacy shelves as early as 1994.	late clinic trial product may pharmaci shelv earli
19920922000000000_24	Squibb and Hoffmann La Roche are also using second generation molecular design techniques to come up with new drugs.	squibb hoffmann la roch also use second gener molecular design techniqu come new drug
19920922000000000_25	(Second generation) is a powerful approach which is being heavily utilised in the industry said Peter Lomedico senior director of molecular biology at Hoffmann La Roche.	second gener power approach heavili utilis industri said peter lomedico senior director molecular biolog hoffmann la roch
19920922000000000_26	Traditional pharmaceutical companies are approaching the new technique from a different direction than biotechnology firms.	tradit pharmaceut compani approach new techniqu differ direct biotechnolog firm
19920922000000000_27	Unlike biotechnology companies pharmaceutical groups were always in the business of looking for small molecules.	unlik biotechnolog compani pharmaceut group alway busi look small molecul
19920922000000000_28	The problem was that there was little method to the madness.	problem wa wa littl method mad
19920922000000000_29	Old fashioned research methods call for years of random testing said Boger who worked for many years in the pharmaceutical industry.	old fashion research method call year random test said boger work mani year pharmaceut industri
19920922000000000_30	They often use soil samples because they contain so many different compounds.	often use soil sampl becaus contain mani differ compound
19920922000000000_31	Traditional drug discovery takes an average of seven years.	tradit drug discoveri take averag seven year
19920922000000000_32	And the average cost of traditional drug development is a hefty Dollars 220m (Pounds 124m) per product.	averag cost tradit drug develop hefti dollar pound per product
19920922000000000_33	It s trial and error with too much error said Boger.	trial error much error said boger
19920922000000000_34	The aim of second generation biotech is to get drugs on to the market faster.	aim second gener biotech get drug market faster
19920922000000000_35	The new techniques are a lot better than the traditional grind and find approach said Siegel.	new techniqu lot better tradit grind find approach said siegel
19920922000000000_36	Another problem with traditional drug development is that it creates a product which often has side effects.	anoth problem tradit drug develop creat product often ha side effect
19920922000000000_37	The compound may cleave to the protein you want but it may bind to other proteins as well said Boger.	compound may cleav protein want may bind protein well said boger
19920922000000000_38	With new molecular design methods we try to get as specific as possible trying to come up with a molecule that binds to just one specific protein.	new molecular design method tri get specif possibl tri come molecul bind one specif protein
19920922000000000_39	Whatever direction they are coming from both biotechnology and pharmaceutical companies are now using similar methods in the new molecular design approach.	whatev direct come biotechnolog pharmaceut compani use similar method new molecular design approach
19920922000000000_40	The latest techniques take advantage of a process called X ray crystallography which enables researchers to take a three dimensional picture of a protein.	latest techniqu take advantag process call x ray crystallographi enabl research take three dimension pictur protein
19920922000000000_41	The protein is then entered on to a computer screen where scientists design drugs they believe will react with the target molecule.	protein enter comput screen scientist design drug believ react target molecul
19920922000000000_42	This method is sometimes referred to as structured rational drug design.	thi method sometim refer structur ration drug design
19920922000000000_43	It s becoming increasingly like a recipe explained Maraganore.	becom increasingli like recip explain maraganor
19920922000000000_44	If you want to make the compound longer to fit on to the protein better you add on some amino acids shorter and you take a few beads off.	want make compound longer fit protein better add mino acid shorter take bead
19920922000000000_45	What you come up with is not something found in nature which would be a traditional biotech product but a unique designed drug which binds to a specific protein.	come someth found natur would tradit biotech product uniqu design drug bind specif protein
19920922000000000_46	Structured rational drug design uses both the protein expertise of the biotechnology firms and the molecular design methods of the pharmaceutical groups.	structur ration drug design use protein expertis biotechnolog firm molecular design method pharmaceut group
19920922000000000_47	For that reason many companies find that joint projects are the best road to take.	reason mani compani find joint project best road take
19920922000000000_48	It s the development of this new technique which uses the expertise of both industries which is inspiring a lot of the partnerships now forming between biotechnology and pharmaceutical groups said Siegel.	develop thi new techniqu use expertis industri inspir lot partnership form biotechnolog pharmaceut group said siegel
19920922000000000_49	The latest method of drug research is just beginning to take hold in the industry and no products developed through the technique are yet available on the market.	latest method drug research begin take hold industri product develop techniqu yet avail market
19920922000000000_50	This is the permanent trend of the industry said Lomedico of Hoffmann La Roche.	thi perman trend industri said lomedico hoffmann la roch
19921027000000000_1	Price constraints threaten to undermine the sales and earnings of leading drugs companies.	price constraint threaten undermin sale earn lead drug compani
19921027000000000_2	The prospect of a victory for Governor Bill Clinton in the US presidential election has hit US pharmaceuticals stocks.	prospect victori governor bill clinton us presidenti elect ha hit us pharmaceut stock
19921027000000000_3	Since the Democratic convention in July the shares which were the market s favourites last year have fallen by more than 10 per cent on average.	sinc democrat convent juli share market favourit last year fallen per cent averag
19921027000000000_4	The sharp decline has been prompted by fears that a Clinton administration might introduce controls on drug prices following the lead of other countries.	sharp declin ha prompt fear clinton administr might introduc control drug price follow lead countri
19921027000000000_5	Ministries of health in nearly all the largest markets are planning measures to slow the growth of drugs spending through price cuts or freezes.	ministri health nearli largest market plan measur slow grow th drug spend price cut freez
19921027000000000_6	Such pressure threatens to undermine sales and earnings growth leading eventually to a restructuring of the world s pharmaceuticals industry.	pressur threaten undermin sale earn grow th lead eventu restructur world pharmaceut industri
19921027000000000_7	In August for the first time Germany s Krankenkassen the health insurance organisations which provide cover for everyone in work slashed the amount they were willing to pay for drugs cutting prices on average by 5 per cent.	august first time germani krankenkassen health insur organis provid cover everyon work slash amount pay drug cut price averag per cent
19921027000000000_8	The reductions followed by a two year price freeze are part of a package that observers believe could slice drugs groups profits in Germany the world s third largest market for pharmaceuticals by a quarter.	reduct follow two year price freez part packag observ believ could slice drug group profit germani world third largest market pharmaceut quarter
19921027000000000_9	In Italy the world s fourth largest market the treasury which sets drugs prices has refused to allow any further increases.	itali world fourth largest market treasuri set drug price ha refus allow ani increas
19921027000000000_10	Meanwhile in Japan the world s second largest market the ministry of health has cut drugs prices by 8 per cent on average this year.	mean japan world second largest market ministri health ha cut drug price per cent averag thi year
19921027000000000_11	The prices of some medicines have been reduced nine times in the past 14 years.	price medicin reduc nine time past year
19921027000000000_12	But it is in the US the world s biggest market for pharmaceuticals and one of the last with Denmark in which drug prices are not set by the government where the implications of price curbs could be most serious.	us world biggest market pharmaceut one last denmark drug price set govern implic price curb could seriou
19921027000000000_13	Companies are already voluntarily limiting their prices in the hope of avoiding legislation but their efforts may be too late to prevent it.	compani al readi voluntarili limit price hope avoid legisl effort may late prevent
19921027000000000_14	The reason for worldwide pressure on prices is that healthcare budgets in almost every developed country are out of control.	reason worldwid pressur price health care budget almost everi develop countri control
19921027000000000_15	A combination of rising demand for care from ageing populations and increasingly expensive medical technology has sent health spending spiralling.	combin rise demand care age popul increasingli expens medic technolog ha sent health spend spiral
19921027000000000_16	Germany spent about 9 per cent of gross national product on healthcare in 1989 compared with 6 per cent in 1970.	germani spent per cent gross nation product health care compar per cent
19921027000000000_17	Last month the German health ministry warned that the Krankenkassen could register a deficit in western Germany alone of DM10bn (Pounds 4bn) this year because the cost of healthcare would outstrip contributions.	last month german health ministri warn krankenkassen could regist deficit western germani alon dm bn pound bn thi year becaus cost health care would outstrip contribut
19921027000000000_18	In the US healthcare expenditure has risen from 7 per cent of GNP in 1970 to 12 per cent in 1990.	us health care expenditur ha risen per cent gnp per cent
19921027000000000_19	Over the same period the proportion of the costs met by federal and state authorities has increased from 22 per cent to 41 per cent.	period proport cost met feder state author ha increas per cent per cent
19921027000000000_20	The rest is paid by individuals and private health insurers.	rest paid individu privat health insur
19921027000000000_21	Governments faced with such rising healthcare expenditure have preferred to target the prices and volumes of drugs prescribed rather than trim spending on politically sensitive areas such as hospitals and doctors.	govern face rise health care expenditur prefer target price volum drug prescrib rather trim spend polit sensit area hospit doctor
19921027000000000_22	The dilemma is particularly acute in the US where American congressmen threatened the industry with legislation following the publication in August of a report by the US General Accounting Office the investigative arm of Congress.	dilemma particularli acut us american congressmen threaten industri legisl follow public august report us gener account offic investig arm congress
19921027000000000_23	The report showed that the price of some drugs (see accompanying chart) had increased by more than 200 per cent over the past six years compared with an overall rise in the consumer price index of 26.	report show price drug see accompani chart increas per cent past six year compar overal rise consum price index
19921027000000000_24	Congressman Pete Stark Californian Democrat and chairman of the House Ways and Means health subcommittee said the report demonstrated there was no justification for the steep price increases in prescription drugs.	congressman pete stark californian democrat chairman hous way mean health subcommitte said report demonstr wa justif steep price increas prescript drug
19921027000000000_25	The drugs companies are using their monopoly status to make a killing on very sick people he said after the report s publication.	drug compani use monopoli statu make kill veri sick peopl said report public
19921027000000000_26	Mr Paul Freiman chairman of the US Pharmaceutical Manufacturers Association says the war of words over prices is partly the reason why relations between the government and the American pharmaceuticals sector is at its lowest point for 30 years.	mr paul freiman chairman us pharmaceut manufactur associ say war word price partli reason whi relat govern american pharmaceut sector lowest point year
19921027000000000_27	The response from global drugs groups has been defensive.	respons global drug group ha defens
19921027000000000_28	They argue that by setting their sights on prices governments are aiming at the wrong target.	argu set sight price govern aim wrong target
19921027000000000_29	Expanding healthcare budgets are not a drug driven phenomenon.	expand health care budget drug driven phenomenon
19921027000000000_30	In the UK the proportion of health expenditure represented by drugs has only risen from 9 per cent in 1960 to 10 per cent in 1990 says Mr Jim Attridge international business operations manager at ICI s pharmaceuticals division.	uk proport health expenditur repres drug ha onli risen per cent per cent say mr jim attridg intern busi oper manag ici pharmaceut divis
19921027000000000_31	Expenditure on drugs accounted for 14 per cent of total US healthcare costs in 1960 according to Mr Peter Lauper head of pharma economics at Ciba Geigy in Switzerland.	expenditur drug account per cent total us health care cost accord mr peter lauper head pharma econom ciba geigi switzerland
19921027000000000_32	By last year the proportion was down to 7 per cent although overall spending on drugs was up.	last year proport wa per cent although overal spend drug wa
19921027000000000_33	Over the same period much of the rise in healthcare spending was generated by the cost of running hospitals and doctors surgeries.	period much rise health care spend wa gener cost run hospit doctor surgeri
19921027000000000_34	Mr Lauper says expenditure on hospital staff and other costs represented 34 per cent of healthcare spending in the US in 1960 and had reached 45 per cent in 1990.	mr lauper say expenditur hospit staff cost repres per cent health care spend us reach per cent
19921027000000000_35	Nevertheless drugs companies admit their case is not helped by their traditionally high profit margins and returns on capital.	nevertheless drug compani admit case help tradit high profit margin return capit
19921027000000000_36	At Glaxo worldwide pre tax profit margins were 31.	glax worldwid pre tax profit margin
19921027000000000_37	4 per cent last year while those of SmithKline Beecham the Anglo American healthcare and consumer products company were 25.	per cent last year smith kline beecham anglo american health care consum product compani
19921027000000000_38	Merck the US giant and the world s largest drugs group had margins last year of 36.	merck us giant world largest drug group margin last year
19921027000000000_39	During the fatter years of the late 1980s such pre tax margins attracted little attention.	dure fatter year late pre tax margin attract littl attent
19921027000000000_40	But while other industries earnings have plunged during the current recession those of the pharmaceuticals groups have been conspicuous by their strength.	industri earn plung dure current recess pharmaceut group conspicu strength
19921027000000000_41	The industry defends its profits by arguing it needs to invest in research and development.	industri defend profit argu need invest research develop
19921027000000000_42	American groups for example now spend about Dollars 11bn a year researching and bringing new drugs to market compared with Dollars 4.	american group exampl spend dollar bn year research bring new drug market compar dollar
19921027000000000_43	Many diseases still have no cure ranging from Aids to Alzheimer s.	mani diseas still cure rang aid alzheim
19921027000000000_44	Given adequate resources the industry claims it can find them.	given adequ resourc industri claim find
19921027000000000_45	More than 90 per cent of medicine discoveries are developed by the drugs industry according to the US pharmaceutical manufacturers association.	per cent medicin discoveri develop drug industri accord us pharmaceut manufactur associ
19921027000000000_46	American companies discovered 47 of the top 97 selling drugs launched between 1975 and 1889.	american compani discov top sell drug launch
19921027000000000_47	Countries with lower prices and profit margins such as France do not develop best selling medicines because they do not earn enough to plough into R D the US industry alleges.	countri lower price profit margin franc develop best sell medicin becaus earn enough plough r us industri alleg
19921027000000000_48	One snag with this argument is that the industry s high margins are calculated after the costs of R D have been deducted.	one snag thi argument industri high margin calcul cost r deduct
19921027000000000_49	In other words the substantial profits achieved by most of the industry are banked after companies have met their R D expenses.	word substanti profit achiev industri bank compani met r expens
19921027000000000_50	If they did not spend as much on R D their profits would be greater.	spend much r profit would greater
19921027000000000_51	American politicians have so far been unimpressed by voluntary undertakings by the industry to control its prices.	american politician far unimpress voluntari undertak industri control price
19921027000000000_52	Merck Upjohn Hoechst Roussel Bristol Myers Squibb ICI and Pfizer have all introduced measures holding down some or all of their prices.	merck upjohn hoechst roussel bristol myer squibb ici pfizer introduc measur hold price
19921027000000000_53	So far companies supplying a third of the US market have promised to keep price rises in line with the consumer price index according to the industry association.	far compani suppli third us market promis keep price rise line consum price index accord industri associ
19921027000000000_54	In spite of such undertakings global pressure on pricing is unlikely to disappear.	spite undertak global pressur price unlik disappear
19921027000000000_55	The ensuing structural change according to Mr Viren Mehta partner at Mehta and Isalay the New York healthcare investment group is producing a bifurcation of the industry between the haves and the have nots.	ensu structur chang accord mr viren mehta partner mehta isalay new york health care invest group produc bifurc industri
19921027000000000_56	The haves according to Mr Mehta are those companies with development departments which have the expertise and scale necessary to bring drugs to market quickly in the US Europe and Japan.	accord mr mehta compani develop depart expertis scale necessari bring drug market quickli us europ japan
19921027000000000_57	They also have strong marketing skills to exploit the new medicines to the full.	also strong market skill exploit new medicin full
19921027000000000_58	Among them he lists Merck and Pfizer of the US and Glaxo of the UK.	among list merck pfizer us glax uk
19921027000000000_59	These weaker groups which used to generate profit growth through price increases have been particularly hard hit by the recent pricing constraints.	weaker group use gener profit grow th price increas particularli hard hit recent price constraint
19921027000000000_60	In the third quarter of this year for example the US group Bristol Myers Squibb reported pre tax profits growth of 5 per cent while Upjohn s increase was only 1.	third quarter thi year exampl us group bristol myer squibb report pre tax profit grow th per cent upjohn increas wa onli
19921027000000000_61	In contrast Merck one of the haves increased earnings by 17 per cent.	contrast merck one increas earn per cent
19921027000000000_62	The polarisation of the industry could be followed by consolidation among the have nots.	polaris industri could follow consolid among
19921027000000000_63	Mr Martyn Postle a pharmaceuticals industry consultant at Coopers Lybrand the management consultancy group says.	mr martyn postl pharmaceut industri consult cooper lybrand manag consult group say
19921027000000000_64	In 1989 the top 25 companies had about 50 per cent of world pharmaceuticals sales.	top compani per cent world pharmaceut sale
19921027000000000_65	By the end of the decade the top 15 groups will control half of the market.	end decad top group control half market
19921027000000000_66	Economies of scale among the leading M D groups would allow them to reduce the proportion of turnover spent on marketing and R D.	economi scale among lead group would allow reduc proport turnov spent market r
19921027000000000_67	Mr Paul Krikler industry analyst at Goldman Sachs the stockbroker says leading companies could reduce their sales and general administration costs to about 25 per cent of turnover Glaxo currently spends about 40 per cent of turnover on sales and administration.	mr paul krikler industri analyst goldman sach stockbrok say lead compani could reduc sale gener administr cost per cent turnov glax current spend per cent turnov sale administr
19921027000000000_68	Further costs could be saved through the rationalisation of pharmaceuticals manufacturing an area of significant over capacity.	cost could save rationalis pharmaceut manufactur area signific capac
19921027000000000_69	Drugs groups have duplicated manufacturing plants particularly in European countries where they have used the promise of local investment to negotiate higher drugs prices from governments.	drug group duplic manufactur plant particularli european countri use promis local invest negoti higher drug price govern
19921027000000000_70	Glaxo has manufacturing capacity in 42 sites in 31 countries.	glax ha manufactur capac site countri
19921027000000000_71	The cost cutting has already started.	cost cut ha al readi start
19921027000000000_72	Last week Eli Lilly said it was spending Dollars 519.	last week eli lilli said wa spend dollar
19921027000000000_73	Syntex a US group also announced a restructuring plan during the same week.	syntex us group also announc restructur plan dure week
19921027000000000_74	Through such cost containment some of the larger groups may become stronger global competitors.	cost contain larger group may becom stronger global competitor
19921027000000000_75	But for the weaker companies the trend towards government imposed price constraints in the world s main markets threatens their survival.	weaker compani trend toward govern impos price constraint world main market threaten surviv
19921027000000000_76	PRESSURE ON PRICES Percentage wholesale price rises over six years Tenormin (Hypertension) ICI 85.	pressur e price percentag wholesal price rise six year tenormin hypertens ici
19921027000000000_77	2 Du Pont Merck) CONSUMER PRICE INDICES All items 26.	du pont merck consum price indic item
19921117000000000_1	A tighter lid on the pillbox Drug companies are toughening their approach to research and development.	tighter lid pillbox drug compani toughen approach research develop
19921117000000000_2	THE drugs industry is adopting an increasingly ruthless attitude to research and development spending which grew fourfold over the past decade to reach an estimated Dollars 25bn (Pounds 16.	drug industri adopt increasingli ruthless attitud research develop spend grew fourfold past decad reach estim dollar bn pound
19921117000000000_3	Companies are working to reduce the interval between drug discovery and marketing averaging about 10 years and at the same time to control the soaring costs of R D.	compani work reduc interv drug discoveri market averag year time control soar cost r
19921117000000000_4	A striking example of the hard decisions being made was this autumn s announcement by SmithKline Beecham the Anglo US group of 150 redundancies among its UK R D staff.	strike exampl hard decis made wa thi autumn announc smith kline beecham anglo us group redund among uk r staff
19921117000000000_5	Equally shocking to people inside and outside the company was its withdrawal from long term research into gastro intestinal drugs the field that led to its best selling product the ulcer medicine Tagamet.	equal shock peopl insid outsid compani wa drawal long term research gastro intestin drug field led best sell product ulcer medicin tagamet
19921117000000000_6	But George Poste SB s new chairman of pharmaceutical R D said that in today s climate resources must be focused on drug discovery with the highest potential for return.	georg post sb new chairman pharmaceut r said today climat resourc must focus drug discoveri highest potenti return
19921117000000000_7	It was not worth continuing to search for new gastro intestinal drugs because there were better targets in other fields.	wa worth continu search new gastro intestin drug becaus better target field
19921117000000000_8	Poste also stated SB s intention to hold R D budgets to about 15 per cent of pharmaceutical sales.	post also state sb intent hold r budget per cent pharmaceut sale
19921117000000000_9	That is similar to the R D commitment of most international drug companies based in Europe and the US.	similar r commit intern drug compani base europ us
19921117000000000_10	Roche of Switzerland stands out for its large R D spending equivalent to 26 per cent of prescription drug sales.	roch switzerland stand larg r spend equival per cent prescript drug sale
19921117000000000_11	As the table shows Roche more or less matches the two giants of the industry Glaxo of the UK and Merck of the US in its total spending on R D about Dollars 1bn in 1991.	tabl show roch less match two giant industri glax uk merck us total spend r dollar bn
19921117000000000_12	But research expenses are exceptionally high in Switzerland so Roche does not employ such a large R D workforce.	research expens except high switzerland roch doe employ larg r workforc
19921117000000000_13	At the other extreme companies based in the UK where scientific salaries are notoriously low can afford to employ more people for each Dollars 1m spent on R D.	extrem compani base uk scientif salari notori low afford employ peopl dollar spent r
19921117000000000_14	To force the pace of development companies are setting an increasingly tight timetable for each stage of R D accompanied by tough criteria which every project must satisfy if it is to move on to the next stage.	forc pace develop compani set increasingli tight timet stage r accompani tough criteria everi project must sati fy move next stage
19921117000000000_15	For example ICI Pharmaceuticals in the UK now consistently achieves its target of administering candidate drugs to human volunteers within 14 months of their first synthesis says Tom McKillop technical director.	exampl ici pharmaceut uk consist achiev target administ candid drug human volunt within month first synthesi say tom mckillop technic director
19921117000000000_16	This stage used to take an average of 30 months.	thi stage use take averag month
19921117000000000_17	At the same time ICI has become more determined to abandon drugs that do not live up to their initial promise.	time ici ha becom determin abandon drug live initi promis
19921117000000000_18	The new approach is quite different to the company s traditional attitude which assumed that every drug was going to succeed McKillop says.	new approach quit differ compani tradit attitud assum everi drug wa go succeed mckillop say
19921117000000000_19	Strong management is required to kill a promising research project in the face of lobbying from scientists who have devoted years of work to it and who still believe it would lead to a blockbuster drug if only the company would let them continue a little longer.	strong manag requir kill promis research project face lobbi scientist devot year work still believ would lead blockbust drug onli compani would let continu littl longer
19921117000000000_20	As Max Gurtner head of corporate communications at Roche puts it managing the development pipeline is really tough because you re dealing with people who feel they live or die with their project.	max gurtner head corpor commun roch put manag develop pipelin realli tough becaus deal peopl feel live die project
19921117000000000_21	A comprehensive survey of R D management in the international pharmaceutical industry published this year by the UK based Centre for Medicines Research shows that about half the companies have a target maximum time to take a new drug from discovery to first market.	comprehens survey r manag intern pharmaceut industri publish thi year uk base centr medicin research show half compani target maximum time take new drug discoveri first market
19921117000000000_22	This averages eight to nine years for US and European companies and 12 years for Japanese companies.	thi averag eight nine year us european compani year japanes compani
19921117000000000_23	Detailed analysis of 114 research projects by PA Consulting of the UK suggests that the two largest pharmaceutical companies succeed in getting their drugs to market faster than their competitors.	detail analysi research project pa consult uk suggest two largest pharmaceut compani succeed get drug market faster competitor
19921117000000000_24	the average time to market for eight other international companies was 10.	averag time market eight intern compani wa
19921117000000000_25	Their speed is partly the result of clear sighted management.	speed partli result clear sight manag
19921117000000000_26	You have to pick the winners set your priorities and prevent anything else distracting you or cluttering up the system said Richard Sykes Glaxo research director.	pick winner set prioriti prevent anyth els distract clutter system said richard syke glax research director
19921117000000000_27	But size may be an advantage in itself because the giants have more drugs in development at any one time and therefore more flexibility to concentrate on the most promising candidates.	size may advantag becaus giant drug develop ani one time therefor flexibl concentr promis candid
19921117000000000_28	An example is the way Glaxo switched chemical research resources this year into developing a promising Aids drug 3TC.	exampl way glax switch chemic research resourc thi year develop promis aid drug tc
19921117000000000_29	nothing is being allowed to stand in its way said Grahaem Brown who is in charge of the development programme.	noth allow stand way said grahaem brown charg develop programm
19921117000000000_30	The giants can also afford to take more risks than smaller companies through parallel development moving on to the next phase of a project before completing the current one.	giant also afford take risk smaller compani parallel develop move next phase project befor complet current one
19921117000000000_31	Pharmaceutical companies in Japan tend to proceed more cautiously preferring to carry out R D step by step rather than in parallel as Stuart Walker director of the Centre for Medicines Research points out.	pharmaceut compani japan tend proceed cautious prefer carri r step step rather parallel stuart walker director centr medicin research point
19921117000000000_32	As a result Japanese drugs take even longer to reach the market than western ones but fewer of them are dropped during the development process.	result japanes drug take even longer reach market western one fewer drop dure develop process
19921117000000000_33	Japanese drug companies do not yet spend as much on R D as their European and US counterparts with R D budgets typically amounting to only 10 to 12 per cent of sales.	japanes drug compani yet spend much r european us counterpart r budget typic amount onli per cent sale
19921117000000000_34	They are going to have to increase that spend to come into line with the rest of the world if they want to become major global players Walker says.	go increas spend come line rest world want becom jor global player walker say
19921117000000000_35	Once drug companies have put the right management in place researchers can call on an enormous range of new technologies to help them.	onc drug compani put right manag place research call enorm rang new technolog help
19921117000000000_36	Computers are now used in every aspect of pharmaceutical R D from graphics systems for designing new molecules to information systems for keeping track of the immense volumes of patient data amassed during clinical trials.	comput use everi aspect pharmaceut r graphic system design new molecul inform system keep track immens volum patient data amass dure clinic trial
19921117000000000_37	An example from the start of the drug discovery process is Glaxo s Core 2000 a collection of 2 000 compounds chosen by computer and chemical analysis to give a representative sample of the 10m molecules known to science.	exampl start drug discoveri process glax core collect compound chosen comput chemic analysi give repres sampl molecul known scienc
19921117000000000_38	The idea was to come up with the most diverse possible selection of molecular structures.	idea wa come divers possibl select molecular structur
19921117000000000_39	Glaxo researchers who want to develop a medicine against a particular target can start by screening the Core 2000 chemicals to discover which has the biological activity they want.	glax research want develop medicin particular target start screen core chemic discov ha biolog activ want
19921117000000000_40	This should give a lead compound which can be improved with the help of molecular graphics computers to produce one or more candidate drugs.	thi give lead compound improv help molecular graphic comput produc one candid drug
19921117000000000_41	There may be even more opportunity to use information technology later in the R D process to accelerate the clinical trials which usually take up more than half of the total time taken to get a drug to market.	may even opportun use inform technolog later r process acceler clinic trial usual take half total time taken get drug market
19921117000000000_42	Merck s Clin Net project shows how a company can benefit from a computer network linking its headquarters to clinical centres around the world.	merck clin net project show compani benefit comput network link headquart clinic centr around world
19921117000000000_43	Clin Net installed over the last four years allows managers to follow the progress of thousands of patients far more effectively than the unwieldy mixture of mail telephone calls and faxes used previously.	clin net instal last four year allow manag follow progress thou patient far effect unwieldi mixtur mail telephon call fax use previous
19921117000000000_44	For example the network enabled Merck to analyse early clinical results from Proscar its new prostate drug as they came in and to make a quick judgment that it was worth waiting for 12 month data before submitting a licensing application because these would provide more persuasive evidence of the medicine s efficacy than the six month data.	exampl network enabl merck analys earli clinic result proscar new prostat drug came make quick judgment wa worth wait month data befor submit licens applic becaus would provid persuas evid medicin efficaci six month data
19921117000000000_45	The progress of science particularly in genetics and molecular biology has given the pharmaceutical industry more possible avenues of research than ever before.	progress scienc particularli genet molecular biolog ha given pharmaceut industri possibl avenu research ever befor
19921117000000000_46	In one sense this is a golden age of drug development.	one sens thi golden age drug develop
19921117000000000_47	But pharmaceutical manufacturers already devote a higher proportion of their revenues to R D than other high technology industries such as electronics and aerospace.	pharmaceut manufactur al readi devot higher proport revenu r high technolog industri electron aerospac
19921117000000000_48	They face a likely squeeze on profits over the next few years as governments tighten price controls.	face like squeez profit next year govern tighten price control
19921117000000000_49	So rising R D spending for long a source of pride for drug companies could soon become an embarrassment.	rise r spend long sourc pride drug compani could soon becom embarrass
19921117000000000_50	WORLD S TOP PHARMACEUTICAL RESEARCH COMPANIES R D R D R D as manpower expenditure of sales 1990 1991 1991 (pounds m) Glaxo 5 700 540 14 Merck 5 300 510 12 SmithKline Beecham 4 800 370 15 Hoechst 4 500 430 16 Ciba Geigy 4 300 380 17 Bristol Myers Squibb 4 000 490 15 Roche 4 000 530 26 Eli Lilly 3 600 360 16 Sanofi Winthrop 3 600 280 20 Wellcome 3 600 230 19 Boehringer Ingelheim 3 500 250 20 Rhone Poulenc Rorer 3 400 250 13 ICI 3 300 220 14 Sandoz 3 300 380 16 Source.	world top pharmaceut research compani r r r manpow expenditur sale pound glax merck smith kline beecham hoechst ciba geigi bristol myer squibb roch eli lilli sanofi winthrop well come boehring ingel im rhone poulenc rorer ici sandoz sourc
19921214000000000_1	PFIZER one of the fastest growing US drugs groups is to increase its annual research and development spending to more than Dollars 1bn next year.	pfizer one fastest grow us drug group increas annual research develop spend dollar bn next year
19921214000000000_2	Mr Henry McKinnel chief financial officer said the aim was to increase the percentage of group sales from pharmaceuticals.	mr henri mckinnel chief financi offic said aim wa increas percentag group sale pharmaceut
19921214000000000_3	During the first nine months of this year drugs generated 62 per cent of its Dollars 5.	dure first nine month thi year drug gener per cent dollar
19921214000000000_4	28bn sales compared with 54 per cent last year.	bn sale compar per cent last year
19921214000000000_5	Mr McKinnel said the group would limit price rises on US prescription drugs to between 2 per cent and 3 per cent in the coming year.	mr mckinnel said group would limit price rise us prescript drug per cent per cent come year
19921214000000000_6	The announcement follows growing political pressure from Congress to limit price increases.	announc follow grow polit pressur congress limit price increas
19921214000000000_7	A number of other groups including Merck the largest US drugs company have undertaken not to raise prices or at least limit them to the rate of inflation.	number group includ merck largest us drug compani undertaken rais price least limit rate inflat
19921214000000000_8	The promise to increase investment in research and development by up to 20 per cent next year follows an 18 per cent rise to Dollars 756.	promis increas invest research develop per cent next year follow per cent rise dollar
19921214000000000_9	The investment is designed to help the group counter the expiry of patents.	invest design help group counter expiri patent
19921215000000000_1	Patent improvement Robert Rice explains how changes to EC regulations will affect the Community s pharmaceutical industry.	patent improv robert rice explain chang ec regul affect commun pharmaceut industri
19921215000000000_2	It looks like being a happy new year for Europe s pharmaceutical industry.	look like happi new year europ pharmaceut industri
19921215000000000_3	on January 2 after years of wrangling and intensive lobbying the European Community will adopt a regulation granting up to five years extra patent protection for drugs.	januari year wrangl intens lobbi european commun adopt regul grant five year extra patent protect drug
19921215000000000_4	The extension of the effective period of marketing exclusivity for drugs through a system of supplementary protection certificates (SPCs) is designed to give pharmaceutical companies a fair return on the growing cost of researching and developing new drugs and to prevent research work moving from the EC to the US or Japan where drugs already enjoy extended patent protection.	extens effect period market exclus drug system supplementari protect certif spc design give pharmaceut compani fair return grow cost research develop new drug prevent research work move ec us japan drug al readi enjoy extend patent protect
19921215000000000_5	As with all legislation born of political compromise however the European SPC system is far from straightforward.	legisl born polit compromis howev european spc system far straight forward
19921215000000000_6	The extent to which different EC states can alter the effect of the regulation by the way they implement it threatens a bureaucratic and administrative nightmare.	extent differ ec state alter effect regul way implement threaten bureaucrat administr night mare
19921215000000000_7	Generic producers and companies making patented drugs under licence face a period of uncertainty.	gener produc compani make patent drug licenc face period uncertainti
19921215000000000_8	For a long time there has been widespread concern that necessary safety testing for new drugs imposes a heavy penalty on pharmaceutical inventions compared with other sectors of technology.	long time ha wide pread concern necessari safeti test new drug impos heavi penalti pharmaceut invent compar sector technolog
19921215000000000_9	Patents in Europe generally last a maximum of 20 years from the application date.	patent europ gener last maximum year applic date
19921215000000000_10	But according to Ms Patricia Harris an intellectual property lawyer with City solicitors Lovell White Durrant the development period for new drugs from discovery to marketing authorisation lasts an average of 12 years.	accord ms patricia harri intellectu properti lawyer citi solicitor lovel white durrant develop period new drug discoveri market authoris last averag year
19921215000000000_11	In complex areas of research into diseases currently regarded as incurable such as Alzheimer s motor neurone disease and multiple sclerosis the development time may be even longer.	complex area research diseas current regard incur alzheim motor neuron diseas multipl sclerosi develop time may even longer
19921215000000000_12	This means that by the time they have obtained approval to market the drug companies have little of the patent term left in which to use their monopoly rights to recoup the increasingly heavy costs of research and development she says.	thi mean time obtain approv market drug compani littl patent term left use monopoli right recoup increasingli heavi cost research develop say
19921215000000000_13	Although there has been little evidence of research migrating to the US or Japan where patent protection is longer or of it being abandoned European governments accepted that it would be foolhardy to wait for signs of decline in the EC pharmaceutical industry before taking action.	although ha littl evid research migrat us japan patent protect longer abandon european govern accept would fool hardi wait sign declin ec pharmaceut industri befor take action
19921215000000000_14	Consumer organisations however warned that extended patent protection could push up the overall drugs bill for public health services across Europe by restricting the market for generic products.	consum organis howev warn extend patent protect could push overal drug bill public health servic across europ restrict market gener product
19921215000000000_15	But governments recognised that far from pushing up the overall drugs bill extended protection could be used to drive pharmaceutical prices down says Mr Martin Paltnoi a pharmaceuticals marketing consultant.	govern recognis far push overal drug bill extend protect could use drive pharmaceut price say mr martin paltnoi pharmaceut market consult
19921215000000000_16	This is because once a reasonable period of marketing exclusivity is guaranteed the rationale for allowing drug companies to charge high prices to recoup development costs over an uncertain and short period of patent cover no longer exists.	thi becaus onc reason period market exclus guarante rational allow drug compani charg high price recoup develop cost uncertain short period patent cover longer exist
19921215000000000_17	It will be available for the length of a drug s development period minus five years and for a maximum of five years.	avail length drug develop period minu five year maximum five year
19921215000000000_18	The development period is defined as the time between filing the patent in the EC country in which the SPC is sought and the date that it is first authorised for use in the EC as a whole.	develop period defin time file patent ec countri spc sought date first authoris use ec whole
19921215000000000_19	Ms Harris says this means that if the development period is five years or less no supplementary protection will be available.	ms harri say thi mean develop period five year less supplementari protect avail
19921215000000000_20	If the development period is between five and 10 years an SPC of up to five years will be available and for development periods of between 10 and 20 years a full five year SPC will apply.	develop period five year spc five year avail develop period year full five year spc appli
19921215000000000_21	A separate application will have to be made in the patent office of each member state in which supplementary protection is required.	separ applic made patent offic member state supplementari protect requir
19921215000000000_22	Applications will have to be filed within six months of the drug being authorised for use in the relevant country.	applic file within six month drug authoris use relev countri
19921215000000000_23	For drugs already patented and authorised in the relevant member state on January 2 1993 transitional provisions will apply and any applications for an SPC must be filed by July 2 1993.	drug al readi patent authoris relev member state januari transit provis appli ani applic spc must file juli
19921215000000000_24	Under the transitional provisions for SPCs a product must generally have been first authorised for use in the EC after January 1 1985.	transit provis spc product must gener first authoris use ec januari
19921215000000000_25	However Belgium Italy Germany and Denmark have adopted different dates while the transitional provisions will not apply at all in Greece Portugal and Spain where the regulation will not come into force until 1998.	howev belgium itali germani denmark adopt differ date transit provis appli greec portug spain regul come forc
19921215000000000_26	To complicate matters further the Spanish government has started proceedings in the European Court to have the regulation set aside.	complic matter spanish govern ha start proceed european court regul set asid
19921215000000000_27	The changes mean an administrative headache for the national patent agencies Mr Paltnoi believes as they struggle to find out when and where in the EC a drug was first authorised for use in order to calculate the length of an SPC.	chang mean administr headach nation patent agenc mr paltnoi believ struggl find ec drug wa first authoris use order calcul length spc
19921215000000000_28	Without a pooling of international data accurate verification of first authorisation may prove impossible in many cases he warns.	without pool intern data accur verif first authoris may prove imposs mani case warn
19921215000000000_29	Ms Harris warns of an uncertain period for companies producing patented drugs under licence.	ms harri warn uncertain period compani produc patent drug licenc
19921215000000000_30	Licences are usually expressed to last for the duration of the patent.	licenc usual express last durat patent
19921215000000000_31	But an SPC does not extend the patent it simply grants additional protection.	spc doe extend patent simpli grant addit protect
19921215000000000_32	Licensees who want a continued exclusive licence to produce and market a drug under an SPC will have to renegotiate their licence agreements.	license want continu exclus licenc produc market drug spc renegoti licenc agreement
19921215000000000_33	The SPCs will go some way towards meeting the industry s requirements for an adequate period of patent protection in Europe says Ms Harris.	spc go way toward meet industri requir adequ period patent protect europ say ms harri
19921215000000000_34	It will also be watched with interest by other industries such as agrochemicals which also experience problems in recouping R D costs because of the length of time it takes to obtain marketing authorisations.	also watch interest industri agrochem also experi problem recoup r cost becaus length time take obtain market authoris
19930422000000000_1	FT 22 APR 93 Survey of Pharmaceuticals Research and Development (8).	ft apr survey pharmaceut research develop
19930422000000000_2	Selection process is critical How winners and losers are decided.	select process critic winner loser decid
19930422000000000_3	DEVELOPMENT is a crucial component in the future fortunes of pharmaceuticals groups.	develop crucial compon futur fortun pharmaceut group
19930422000000000_4	Most have access either internally or externally to exciting research.	access either intern extern excit research
19930422000000000_5	But the way companies select new chemical entities and the way they develop them decides the sector s winners and losers.	way compani select new chemic entiti way develop decid sector winner loser
19930422000000000_6	Differentiation comes from the way you select research and how you use it in a creative and flexible way explains Dr Rolf Krebs chairman of Boehringer Ingelheim.	differenti come way select research use creativ flexibl way explain dr rolf kreb chairman boehring ingel im
19930422000000000_7	Selecting compounds is far from easy yet according to Dr Richard Sykes Glaxo s chief executive and director of R D this is where the critical decisions are made.	select compound far easi yet accord dr richard syke glax chief execut director r thi critic decis made
19930422000000000_8	The drug must have the potential to be an important medicine significant advantages in terms of safety and efficacy or both says Dr Sykes.	drug must potenti import medicin signific advantag term safeti efficaci say dr syke
19930422000000000_9	Most R D directors agree that any compounds must be innovative if they are to be successful.	r director agre ani compound must innov success ful
19930422000000000_10	If the industry does not generate enough innovative products it will end up fighting cheap generics with me too products says Dr Krebs.	industri doe gener enough innov product end fight cheap gener product say dr kreb
19930422000000000_11	Defining let alone generating innovative products is not easy however.	defin let alon gener innov product easi howev
19930422000000000_12	The problem is you don t know what s going on elsewhere says Dr George Poste R D chairman at SmithKline Beecham.	problem know go el se say dr georg post r chairman smith kline beecham
19930422000000000_13	Take Tagamet our anti ulcer product with sales of more than Dollars 1bn a year.	take tagamet anti ulcer product sale dollar bn year
19930422000000000_14	New chemical entities are like black boxes says Dr Poste.	new chemic entiti like black box say dr post
19930422000000000_15	You might be behind three other companies but the opposition s second and third compounds could fall by the wayside he explains.	might behind three compani opposit second third compound could fall waysid explain
19930422000000000_16	Only generic compounds set out to be me too drugs says Dr Poste.	onli gener compound set drug say dr post
19930422000000000_17	Me too has wrongly become a pejorative term says Dr Leon Rosenberg president Bristol Myers Squibb Pharmaceutical Research Institute.	ha wrongli becom pejor term say dr leon rosenberg presid bristol myer squibb pharmaceut research institut
19930422000000000_18	Giant steps are only made once in a decade or even every 20 years.	giant step onli made onc decad even everi year
19930422000000000_19	The world s two top selling drugs Zantac and Vasotec were me too compounds but with dosing or safety improvements.	world two top sell drug zantac vasotec compound dose safeti improv
19930422000000000_20	Dr Poste agrees pointing out that 25 of the 32 compounds given a me too classification by the US Food and Drug Administration in the 1980s actually offered improved safety tolerability or quality of life or had better dosing than earlier medicines.	dr post agre point compound given classif us food drug administr actual offer improv safeti toler qualiti life better dose earlier medicin
19930422000000000_21	Such molecules take longer to develop than me toos and there is a heightened danger of them being cut for reasons of safety and efficacy.	molecul take longer develop heighten danger cut reason safeti efficaci
19930422000000000_22	Dr Max Wilhelm at Ciba says a development portfolio must be balanced with follow up products in case some fail.	dr max wilhelm ciba say develop portfolio must balanc follow product case fail
19930422000000000_23	There must also be a good mixture of safe bets and high risk high reward products.	must also good mixtur safe bet high risk high reward product
19930422000000000_24	He will only develop products that will reach annual sales of more than SFr500m.	onli develop product reach annual sale
19930422000000000_25	Sometimes not being innovative can be justified says Dr Wilhelm.	sometim innov justifi say dr wilhelm
19930422000000000_26	He explains his recent decision to launch Lotensin an ace inhibitor for hypertension even though the market is saturated and there is even price competition in the US.	explain hi recent decis launch lotensin ace inhibitor hypertens even though market satur even price competit us
19930422000000000_27	He argues that by developing the drug it gave the company access to experts and opinion formers.	argu develop drug gave compani access expert opinion former
19930422000000000_28	Without Lotensin Ciba s credibility in the cardiovascular market would have been undermined.	without lotensin ciba credibl cardiovascular market would undermin
19930422000000000_29	It kept us in the market place and in the scientific community and it ll make some money says Dr Wilhelm.	kept us market place scientif commun make money say dr wilhelm
19930422000000000_30	Dr Frank Joachim Morich director of pharmaceuticals R D at Bayer says he is pleased his company fails to figure among the top 50 groups listed in order of the number of compounds in development.	dr frank joachim morich director pharmaceut r bayer say pleas hi compani fail figur among top group list order number compound develop
19930422000000000_31	He says there is no relationship between the number of compounds in development and innovation.	say relationship number compound develop innov
19930422000000000_32	Dr Jurgen Drews president of international R D at Roche has also become increasingly tough.	dr jurgen drew presid intern r roch ha also becom increasingli tough
19930422000000000_33	We have become very vigorous in refusing to develop agents that do not have an innovative profile.	becom veri vigor refus develop agent innov profil
19930422000000000_34	We have cut the number of compounds in development by 15 to 20 per cent over the past 12 to 16 months.	cut number compound develop per cent past month
19930422000000000_35	Dr Drews says an increasingly large proportion of molecules proposed by research are now rejected.	dr drew say increasingli larg proport molecul propos research reject
19930422000000000_36	He reckons 10 years ago only 10 per cent of compounds entering clinical development made it to the market.	reckon year ago onli per cent compound enter clinic develop made market
19930422000000000_37	Now that barriers are higher the proportion reaching the market is at about 30 per cent.	barrier higher proport reach market per cent
19930422000000000_38	There are fewer of them they are of higher quality and there is less attrition he says.	fewer higher qualiti less attrit say
19930422000000000_39	An added complication to the development process is the need to conduct it internationally.	ad complic develop process need conduct intern
19930422000000000_40	In spite of efforts to harmonise regulations authorities in the US Japan and Europe still often require different clinical trials.	spite effort harmonis regul author us japan europ still often requir differ clinic trial
19930422000000000_41	Given the costs of bringing a drug to market pharmaceuticals groups must develop their medicines in all three regions covering more than 80 per cent of the world market.	given cost bring drug market pharmaceut group must develop medicin three region cover per cent world market
19930422000000000_42	While some are beginning to license out products for co development others are turning to contract research organisations such as Bessalaar and Pharmaco of the US and Munich based Harrison Clinical Research to conduct clinical trials.	begin licens product co develop turn contract research organis bessalaar pharmaco us munich base harrison clinic research conduct clinic trial
19930422000000000_43	Given the increasing demands of regulatory groups most groups are looking to cut down on the numbers of studies and the complexity of studies they conduct.	given increas demand regulatori group group look cut number studi complex studi conduct
19930422000000000_44	It s seductive when conducting trials to add in supplementary questions that aren t really necessary and that create enormous quantities of data that can t be analysed says Dr Stephen Hill medical director of Roche Products Roche s UK subsidiary.	seduct conduct trial add supplementari question realli necessari creat enorm quantiti data analys say dr stephen hill medic director roch product roch uk subsidiari
19930422000000000_45	R D directors must also be brutal in cutting projects says Dr Sykes at Glaxo.	r director must also brutal cut project say dr syke glax
19930422000000000_46	If a company is ahead of you and your drug is not as good then you need to act.	compani ahead drug good need act
19930422000000000_47	There s nothing wrong with cutting projects the decisions have to be made.	noth wrong cut project decis made
19930422000000000_48	Finally the end product should be a good read says Dr Drews.	final end product good read say dr drew
19930422000000000_49	The new drug application must be attractive and the dossier must have entertainment value.	new drug applic must attract dossier must entertain valu
19930422000000000_50	It will then be read faster because the investigator becomes involved in a positive way he claims.	read faster becaus investig becom involv posit way claim
19930422000000000_51	FT 22 APR 93 Survey of Pharmaceuticals Research and Development (7).	ft apr survey pharmaceut research develop
19930422000000000_52	When time can cost a fortune Speed is essential when bringing drugs to market.	time cost fortun speed essenti bring drug market
19930422000000000_53	REDUCING the time it takes to bring a drug to market has become the pharmaceutical industry s overriding objective.	reduc time take bring drug market ha becom pharmaceut industri overrid object
19930422000000000_54	The most urgent and immediate issue concerning the industry has been that of time to market says Dr Jurgen Drews president of international R D at Roche.	urgent immedi issu concern industri ha time market say dr jurgen drew presid intern r roch
19930422000000000_55	There are two mains reasons for shorter development time.	two main reason shorter develop time
19930422000000000_56	First you want to help the unmet medical needs of the public you are trying to serve says Dr Leon Rosenberg president Bristol Myers Squibb Pharmaceutical Research Institute.	first want help unmet medic need public tri serv say dr leon rosenberg presid bristol myer squibb pharmaceut research institut
19930422000000000_57	The second reason is the limited period that a drug is protected by its patents.	second reason limit period drug protect patent
19930422000000000_58	Anything you can do to pick up time means millions of dollars in sales he says.	anyth pick time mean million dollar sale say
19930422000000000_59	The rule of thumb for drug development is that every day a drug is held back from the market costs the drug company Dollars 1m explains Mr David Matheson senior vice president at Boston Consulting Group.	rule thumb drug develop everi day drug held back market cost drug compani dollar explain mr david matheson senior vice presid boston consult group
19930422000000000_60	Dr Willi Stammberger head of development at Hoechst estimates that one month s delay in launching an important new product results in a cumulative sales loss of DM30m (Dollars 18.	dr willi stammberg head develop hoechst estim one month delay launch import new product result cumul sale loss dm dollar
19930422000000000_61	It adds costs to the development bill and it reduces revenues at the end of the product s patent life.	add cost develop bill reduc revenu end product patent life
19930422000000000_62	Speed to market also offers competitive advantage.	speed market also offer competit advantag
19930422000000000_63	Dr George Poste chairman of R D at SmithKline Beecham points out that no matter how good a compound is speed is essential.	dr georg post chairman r smith kline beecham point matter good compound speed essenti
19930422000000000_64	There is no point being five years behind a competitor s product.	point five year behind competitor product
19930422000000000_65	It s fair to say that speed to market was the primary reason for success during the 1980s says Mr Bob Easton president of The Wilkerson group the New York based consultants.	fair say speed market wa primari reason success dure say mr bob easton presid wilkerson group new york base consult
19930422000000000_66	It s no coincidence that the two fastest companies Glaxo and Merck are also the world s biggest pharmaceuticals groups.	coincid two fastest compani glax merck also world biggest pharmaceut group
19930422000000000_67	But while most groups agree on the need to accelerate drug development the performance of many groups continues to be disappointing.	group agre need acceler drug develop perform mani group continu disappoint
19930422000000000_68	There s still tremendous variability in performance between different companies says Mr Matheson The fastest at conducting phase two and phase three studies are three times quicker than the slowest.	still tremend variabl perform differ compani say mr matheson fastest conduct phase two phase three studi three time quicker slowest
19930422000000000_69	Some are taking eight years and some as little as two and a half years.	take eight year littl two half year
19930422000000000_70	Many research and development directors justify the length of time they take to develop drugs by pointing out it is far more difficult to prove safety and efficacy in some therapeutic areas and indications than others.	mani research develop director justifi length time take develop drug point far difficult prove safeti efficaci therapeut area indic
19930422000000000_71	For example it becomes clear within a couple of weeks whether or not an antibiotic works whereas a central nervous system product can take years.	exampl becom clear within coupl week whether antibiot work wherea central nervou system product take year
19930422000000000_72	Take the 5HT3s says Dr Richard Sykes chief executive and head of R D at Glaxo.	take ht say dr richard syke chief execut head r glax
19930422000000000_73	Zofran for emesis was easy you either feel sick or you don t.	zofran emesi wa easi either feel sick
19930422000000000_74	But for anxiety depression ordementia it s much more subjective whether or not it works.	anxieti depress ordementia much subject whether work
19930422000000000_75	Many R D directors claim there s a problem of comparing apples and oranges.	mani r director claim problem compar appl orang
19930422000000000_76	They are slower because their portfolio has more difficult drugs in it says Mr Matheson at Boston Consulting Group.	slower becaus portfolio ha difficult drug say mr matheson boston consult group
19930422000000000_77	There are huge differences in performance within therapeutic areas according to Mr George Farrington head of pharmaceuticals at The Wilkerson Group.	huge differ perform within therapeut area accord mr georg farrington head pharmaceut wilkerson group
19930422000000000_78	In antibiotics for example the best companies can develop medicines in 60 months compared with 250 months for the worst.	antibiot exampl best compani develop medicin month compar month worst
19930422000000000_79	One of the key areas that drug groups can improve is the management of their portfolios.	one key area drug group improv manag portfolio
19930422000000000_80	You have to match resources to the portfolio available being ruthless about which drugs they take into development says Dr Tom McKillop research and technology director at Zeneca.	match resourc portfolio avail ruthless drug take develop say dr tom mckillop research technolog director zeneca
19930422000000000_81	You can t run 12 compounds simultaneously and then decide which one to bet on.	run compound simultan decid one bet
19930422000000000_82	Many companies try to run too many candidates through their pipeline which slows down the development of all of them.	mani compani tri run mani candid pipelin slow develop
19930422000000000_83	Dr Rosenberg at Bristol Myers Squibb agrees that resources are always finite.	dr rosenberg bristol myer squibb agre resourc alway finit
19930422000000000_84	Each compound at a late stage of development needs the best clinical trials that we can offer he says.	compound late stage develop need best clinic trial offer say
19930422000000000_85	At Schering Prof Gunter Stock board director in charge of R D says a master plan is agreed at the start of the project.	schere prof gunter stock board director charg r say master plan agre start project
19930422000000000_86	A key compound in accelerated development must not be held up by lack of resources.	key compound acceler develop must held lack resourc
19930422000000000_87	The correct mix of products within the portfolio is also essential says Mr Matheson.	correct mix product within portfolio also essenti say mr matheson
19930422000000000_88	Groups must have a balance between familiar and new areas.	group must balanc familiar new area
19930422000000000_89	If the area is familiar the company will know the regulators and understand the required end points for the clinical studies.	area familiar compani know regul understand requir end point clinic studi
19930422000000000_90	For new therapeutic areas the development scientists are leaping the fences for the first time.	new therapeut area develop scientist leap fenc first time
19930422000000000_91	There must also be a balance of risk within the portfolio especially in phase one trials where the likelihood of a compound dropping out is higher.	must also balanc risk within portfolio especi phase one trial likelihood compound drop higher
19930422000000000_92	A balance between obtaining the necessary data for registration but not making the dossier too complicated.	balanc obtain necessari data registr make dossier complic
19930422000000000_93	Integrating a team of pharma economists into clinical development process so the cost effectiveness of a drug can be incorporated in the regulatory dossier.	integr team pharma economist clinic develop process cost effect drug incorpor regulatori dossier
19930422000000000_94	They must ensure adequate supplies of the compound are ready for clinical trials.	must ensur adequ suppli compound readi clinic trial
19930422000000000_95	Many groups take the risk of manufacturing large quantities before the end of pre clinical development.	mani group take risk manufactur larg quantiti befor end pre clinic develop
19930422000000000_96	Starting the pivotal study usually the longest and largest as soon as possible while ensuring the design is right.	start pivot studi usual longest largest soon possibl ensur design right
19930422000000000_97	Managing the dozens of investigators around the world necessary for the trials.	manag dozen investig around world necessari trial
19930422000000000_98	It is not clear to the average scientist on the bench how much money you re losing by delaying a project.	clear averag scientist bench much money lose delay project
19930422000000000_99	Coping effectively with the paper mountain that builds up from the clinical trials.	cope effect paper mountain build clinic trial
19930422000000000_100	However Dr Drews at Roche warns that rushing a product to market is not a panacea.	howev dr drew roch warn ru hing product market panacea
19930422000000000_101	Bringing products to market in any quality as quickly as possible only makes sense if you have something worthwhile.	bring product market ani qualiti quickli possibl onli make sens someth worth
19930422000000000_102	There is no point developing something at the speed of light if it is trivial.	point develop someth speed light trivial
19930422000000000_103	FT 22 APR 93 Survey of Pharmaceuticals Research and Development (5).	ft apr survey pharmaceut research develop
19930422000000000_104	Working together to create new products Research and development and marketing departments need to focus resources.	work togeth creat new product research develop market depart need focu resourc
19930422000000000_105	AS research and development costs increase the need to focus resources becomes ever greater.	research develop cost increas need focu resourc becom ever greater
19930422000000000_106	R D departments must join the marketing department in matching scientific expertise with market opportunities said Dr Trevor Jones Wellcome s director of research development and medical UK.	r depart must join market depart match scientif expertis market opportun said dr trevor jone well come director research develop medic uk
19930422000000000_107	Market pressure on the world s pharmaceutical companies to find effective new drugs is increasing.	market pressur world pharmaceut compani find effect new drug increas
19930422000000000_108	According to the US Pharmaceutical Manufacturers Association the US industry is spending some Dollars 12.	accord us pharmaceut manufactur associ us industri spend dollar
19930422000000000_109	To achieve a 15 per cent return on investment which is the minimum a company might expect given the risks a 10 per cent per annum compound growth in sales (currently Dollars 231bn) is demanded when there is downward price pressure.	achiev per cent return invest minimum compani might expect given risk per cent per annum compound grow th sale current dollar bn demand downward price pressur
19930422000000000_110	Companies most likely to be long term winners in an increasingly aggressive and competitive R D environment are those with effective R D management which can make full use of the new technologies to discover new compounds and utilise the skills of the marketing department from early stages of the conception of an idea.	compani like long term winner increasingli aggress competit r environ effect r manag make full use new technolog discov new compound utilis skill market depart earli stage concept idea
19930422000000000_111	One such company is Wellcome which believes the success of a pharmaceutical company depends fundamentally on the quality of its R D and marketing activities and the interaction and synergy between them.	one compani well come believ success pharmaceut compani depend fundament qualiti r market activ interact synergi
19930422000000000_112	The three phases involved in the development of a product according to Dr Jones require good commercial input and this becomes more quantified and more important as each phase progresses.	three phase involv develop product accord dr jone requir good commerci input thi becom quantifi import phase progress
19930422000000000_113	A good example of where marketing and R D can work together is on 5 lipoxygenase inhibitors said Dr Jones.	good exampl market r work togeth lipoxygenas inhibitor said dr jone
19930422000000000_114	The lipoxygenase pathway is generally responsible for inflammatory disorders and is known to be involved in inflammation whether it is inflammatory bowel asthma allergic rhinitis psoriasis and arthritis.	lipoxygenas pathway gener respons inflammatori disord known involv inflamm whether inflammatori bowel asthm allerg rhiniti psoriasi arthriti
19930422000000000_115	Dr Jones questions where the focus is on such products These are all inflammatory conditions so if a drug works here at an early stage I want the marketing department to focus my attention on which of these areas is likely to be the one to go for because otherwise it is shotgun therapy.	dr jone question focu product inflammatori condit drug work earli stage want market depart focu attent area like one go becaus otherwis shotgun therapi
19930422000000000_116	That is where I need someone to work with and agree together the focus beyond the the discovery in the first phase he said.	need someon work agre togeth focu beyond discoveri first phase said
19930422000000000_117	If it s asthma because it s a big pathway my first task is to go to volunteers to see if it works.	asthm becaus big pathway first task go volunt see work
19930422000000000_118	That s when I need the marketing department to give me a design and business case because I am going to start spending the Pounds 50m Pounds 100m.	need market depart give design busi case becaus go start spend pound pound
19930422000000000_119	The goals have changed considerably in the past five to 10 years said Dr Jones.	goal chang consider past five year said dr jone
19930422000000000_120	If a drug is not going to make Wellcome more than Pounds 50m by year three we are not going to do it.	drug go make well come pound year three go
19930422000000000_121	Dr Rolf Krebs chairman of Boehringer Ingelheim and former head of Bayer R D said.	dr rolf kreb chairman boehring ingel im former head bayer r said
19930422000000000_122	Boehringer Ingelheim has no problem in choosing compounds.	boehring ingel im ha problem choos compound
19930422000000000_123	We are currently in the process of setting up and testing a properly functioning development process.	current process set test properli function develop process
19930422000000000_124	People formerly feared to go into small markets.	peopl formerli fear go small market
19930422000000000_125	It makes you look at marketing and development in a different way.	make look market develop differ way
19930422000000000_126	Dr Krebs points out that the total cost of Dollars 200m includes the failures divided by the successful.	dr kreb point total cost dollar includ failur divid success ful
19930422000000000_127	You have to realise that if competing in a highly competitive market you need a high therapeutic standard and need far more marketing.	realis compet highli competit market need high therapeut standard need far market
19930422000000000_128	It takes three to nine years to establish a drug.	take three nine year establish drug
19930422000000000_129	If you have a lower therapeutic standard but a completely new product you need less marketing.	lower therapeut standard complet new product need less market
19930422000000000_130	That may well allow you to be more profitable in niche markets.	may well allow profit nich market
19930422000000000_131	The changes in technologies opens up niche markets for new drugs and this may be acceptable in the future.	chang technolog open nich market new drug thi may accept futur
19930422000000000_132	If you have indications with high therapeutic benefit you can get higher prices and lower promotional costs.	indic high therapeut benefit get higher price lower promot cost
19930422000000000_133	Boehringer Ingelheim in the future will look at the medical properties of the compound and then decide what areas they are interested in it may have a wide range of compounds.	boehring ingel im futur look medic properti compound decid area interest may wide rang compound
19930422000000000_134	I ve told the marketing people this could happen.	told market peopl thi could happen
19930422000000000_135	They have to re organise themselves because marketing is no longer a stable function said Dr Krebs.	organis themselv becaus market longer stabl function said dr kreb
19930422000000000_136	The view taken at Ciba Geigy is that they will work only in areas where there is an unmet medical need where there is room for improvement and where there is internal know how.	view taken ciba geigi work onli area unmet medic need room improv intern know
19930422000000000_137	Dr Max Wilhelm and Pierre Douaze head of pharmaceuticals at Ciba said.	dr max wilhelm pierr douaz head pharmaceut ciba said
19930422000000000_138	We have a target of SFr300m by five years for any drug if not we question the development.	target fr five year ani drug question develop
19930422000000000_139	They said the figure in the US is about Dollars 250m otherwise they will license out products especially if it is a product aimed at general practitioners that would stretch marketing resources.	said figur us dollar otherwis licens product especi product aim gener practition would stretch market resourc
19930422000000000_140	At Astra the therapeutic areas were not chosen said Dr Claes Wilhelmsson executive vice president of R D.	astra therapeut area chosen said dr clae wilhelmsson execut vice presid r
19930422000000000_141	Three years ago the company was not in cancer but isinto it now.	three year ago compani wa cancer isinto
19930422000000000_142	Immuno suppressors have taken it from the respiratory field to cancer.	immuno suppressor taken respiratori field cancer
19930422000000000_143	We look for medicines where there are therapeutic needs and try to develop completely new ideas rather than me too compounds.	look medicin therapeut need tri develop complet new idea rather compound
19930422000000000_144	For example we haven t developed an ace inhibitor we licensed one in from Hoechst he said.	exampl develop ace inhibitor licens one hoechst said
19930422000000000_145	Alan Archer is editor of Financial Times Pharmaceutical Business News.	alan archer editor financi time pharmaceut busi news
19930923000000000_1	Glaxo the world s biggest spender of pharmaceuticals research and development is reorganising its R D.	glax world biggest spender pharmaceut research develop reorganis r
19930923000000000_2	The company which spent Pounds 739 on R D last financial year and intends to spend Pounds 850m this year has split the position of R D director.	compani spent pound r last financi year intend spend pound thi year ha split posit r director
19930923000000000_3	Sir Mark Richmond 62 chairman of the UK s Science and Engineering Research Council is to become director of the research division for a period of two years.	sir mark richmond chairman uk scienc engin research council becom director research divis period two year
19930923000000000_4	The SERC is the largest of Britain s government funded research councils.	serc largest britain govern fund research council
19930923000000000_5	it distributes more than Pounds 500m a year in grants to university scientists and engineers.	distribut pound year grant univers scientist engin
19930923000000000_6	Goran Ando currently research and development director becomes director of group development and product strategy.	goran ando current research develop director becom director group develop product strategi
19930923000000000_7	Both Ando and Sir Mark will report to Richard Sykes chief executive and board director responsible for R D.	ando sir mark report richard syke chief execut board director respons r
19930923000000000_8	Sykes says the rapidly expanding knowledge base especially in the understanding of the genetic basis of disease and the microbiology of cells means that pharmaceutical companies would increasingly have to have access to information from both universities and biotechnology groups.	syke say rapidli expand knowledg base especi understand genet basi diseas microbiolog cell mean pharmaceut compani would increasingli access inform univers biotechnolog group
19930923000000000_9	Having access research is really critical to the future of the company and you need very good people to do it.	access research realli critic futur compani need veri good peopl
19930923000000000_10	Sir Mark has exceptional scientific skills from his experience of molecular genetics at Edinburgh University and microbial biology at Bristol University.	sir mark ha except scientif skill hi experi molecular genet edinburgh univers microbi biolog bristol univers
19930923000000000_11	He also has organisational skills from running the SERC and being vice chancellor of Manchester University the largest outside London.	also ha organis skill run serc vice chancellor manchest univers largest outsid london
19930923000000000_12	Sir Mark will be responsible for research as Glaxo s research organisation moves into its new headquarters in Stevenage.	sir mark respons research glax research organis move new headquart stevenag
19930923000000000_13	Sykes says Ando s position was also highly critical.	syke say ando posit wa also highli critic
19930923000000000_14	He would be responsible for developing safe effective medicines that represented significant advances in therapy.	would respons develop safe effect medicin repres signific advanc therapi
19930923000000000_15	As head of product strategy he would ensure that the important links between product development and marketing were tightened.	head product strategi would ensur import link product develop market tighten
19931029000000000_1	FT 29 OCT 93 SmithKline to move 1 000 research staff.	ft oct smith kline move research staff
19931029000000000_2	SMITHKLINE Beecham the second biggest drug company in Britain is to spend more than Pounds 200m consolidating its research and development centres.	smi thk line beecham second biggest drug compani britain spend pound consolid research develop centr
19931029000000000_3	The company said yesterday that no jobs would be lost but 1 000 people would be asked to relocate.	compani said yesterday job would lost peopl would ask reloc
19931029000000000_4	SmithKline is buying the 40 acre site of BP s maritime centre in Harlow Essex which is next to one of its existing research centres.	smith kline buy acr site bp maritim centr harlow essex next one exist research centr
19931029000000000_5	This will enable it to stop research at four of its seven centres at Brockham Park Great Burgh and Reigate in Surrey and at Worthing in Sussex.	thi enabl stop research four seven centr brockham park great burgh reigat surrey worth sussex
19931029000000000_6	The research headquarters will move from Great Burgh to Harlow.	research headquart move great burgh harlow
19931029000000000_7	There will be significant cost savings through reduction in operating costs by maintaining fewer sites.	signific cost save reduct oper cost maintain fewer site
19931029000000000_8	5m miles a year between sites and that more people on a single site would improve interactions and efficiency.	mile year site peopl singl site would improv interact effici
19931029000000000_9	The acquisition also provides enough land to eventually consolidate all UK pharmaceutical R D in one location if desired.	acquisit also provid enough land eventu consolid uk pharmaceut r one locat desir
19931029000000000_10	The Pounds 200m capital cost of the scheme and the costs of relocation have already been accounted for by the company in provisions for the restructuring of its research side.	pound capit cost scheme cost reloc al readi account compani provis restructur research side
19931029000000000_11	SmithKline s plan comes when the drug sector is under increasing pressure to cut prices from governments anxious to reduce health spending.	smith kline plan come drug sector increas pressur cut price govern anxiou reduc health spend
19931029000000000_12	The company conceded that some might be offered redundancy but that the object is not to reduce numbers.	compani conced might offer redund object reduc number
19931029000000000_13	The Reigate centre will close next year when the lease runs out.	reigat centr close next year leas run
19931029000000000_14	Most non research staff will have moved by the third quarter of next year.	non research staff move third quarter next year
19931029000000000_15	Harlow Tonbridge in Kent and Welwyn Garden City Hertfordshire.	harlow tonbridg kent welwyn garden citi hertfordshir
19940128000000000_1	Like many big pharmaceutical groups Sandoz of Switzerland has lived the nightmare of discovering a drug in a new category and then seeing another company bring a competitor compound to market first.	like mani big pharmaceut group sandoz switzerland ha live night mare discov drug new categori see anoth compani bring competitor compound market first
19940128000000000_2	That is one reason why it has split its development department away from its research activity.	one reason whi ha split develop depart away research activ
19940128000000000_3	Britain s Glaxo announced a similar move last year.	britain glax announc similar move last year
19940128000000000_4	Once you decide to develop a product you have to go full out.	onc decid develop product go full
19940128000000000_5	There is no room for half measures says Urs Barlocher chief executive of Sandoz.	room half measur say ur barloch chief execut sandoz
19940128000000000_6	The other reason for the change comes from the research side where the rapid advance of biochemistry is changing the nature of research management.	reason chang come research side rapid advanc biochemistri chang natur research manag
19940128000000000_7	In the past pharmaceutical research was chemical based and proceeded at a relatively gentle pace.	past pharmaceut research wa chemic base proceed rel gentl pace
19940128000000000_8	Now with the rise of biochemistry it has become more fast moving.	rise biochemistri ha becom fast move
19940128000000000_9	Pharmaceutical companies have recognised that the speed of advances in biotechnology makes it impossible to keep their in house laboratories up to speed on all fronts.	pharmaceut compani recognis speed advanc biotechnolog make imposs keep hous laboratori speed front
19940128000000000_10	Consequently they have tended to set up co operation arrangements with independent biotechnology laboratories and start up companies.	consequ tend set co oper arrang independ biotechnolog laboratori start compani
19940128000000000_11	Sandoz now has more than 30 such arrangements consuming a tenth of its SFr1.	sandoz ha arrang consum tenth fr
19940128000000000_12	2bn (Pounds 540m) R D budget and Barlocher is convinced the number will rise.	bn pound r budget barloch convinc number rise
19940128000000000_13	We do not yet have a good feel for the right balance but the trend is increasing he says.	yet good feel right balanc trend increas say
19940128000000000_14	He points out that it has always been difficult to find researchers with management skills and now the requirements are much greater.	point ha alway difficult find research manag skill requir much greater
19940128000000000_15	You need someone who knows what is happening in basic research where we can find leads for new compounds.	need someon know happen basic research find lead new compound
19940128000000000_16	He has to be able to decide quickly which co operation deals we should enter and which ones we should keep.	ha abl decid quickli co oper deal enter one keep
19940128000000000_17	Assuming such a person can be found he argues that it is now too much to ask him to look after development as well.	assum person found argu much k look develop well
19940128000000000_18	In any event he believes that the management of development which involves testing a discovery to the point where it can be put on the market demands different skills from research management.	ani event believ manag develop involv test discoveri point put market demand differ skill research manag
19940128000000000_19	It should be run in a way very similar to a production centre.	run way veri similar product centr
19940128000000000_20	Sandoz has had a notoriously slow development department in the past.	sandoz ha notori slow develop depart past
19940128000000000_21	A few years ago it brought in the management consultants McKinsey to try to speed the process and last year it set up a project team approach.	year ago brought manag consult mckinsey tri speed process last year set project team approach
19940128000000000_22	We still feel we are not among the very best Barlocher admits but we are now confident that we can catch up.	still feel among veri best barloch admit confid catch
19940128000000000_23	We want to give full responsibility to the heads of different sections and reduce the matrix to a minimum.	want give full respons head differ section reduc matrix minimum
19940128000000000_24	Development is by far the most expensive part of the R D process especially the clinical studies.	develop far expens part r process especi clinic studi
19940128000000000_25	Thus the group believes it must concentrate its research efforts on finding what it calls number one compounds those that are clearly ahead of the competition.	thu group believ must concentr research effort find call number one compound clearli ahead competit
19940128000000000_26	Even if you have a fast development department it will become more and more difficult to catch up Barlocher says.	even fast develop depart becom difficult catch barloch say
19940208000000000_1	Delays cut at the stroke of a pen How computing with a stylus could shorten trial periods for pharmaceutical companies.	delay cut stroke pen comput stylu could shorten trial period pharmaceut compani
19940208000000000_2	Delays in getting a blockbuster compound to market give rivals time to launch price cutting imitations.	delay get blockbust compound market give rival time launch price cut imit
19940208000000000_3	Each day s hold up can cost a drug company Dollars 1m (Pounds 600 000) in lost revenues.	day hold cost drug compani dollar pound lost revenu
19940208000000000_4	As a result the race is on to bring in the latest computer technology to cut approval times.	result race bring latest comput technolog cut approv time
19940208000000000_5	Clinical trials in particular have been targeted by the big pharmaceutical companies.	clinic trial particular target big pharmaceut compani
19940208000000000_6	While many big drug companies are investing in personal computers or facsimile machines Rhone Poulenc Rorer in the US has gone one step further.	mani big drug compani invest person comput facsimil machin rhone poulenc rorer us ha gone one step
19940208000000000_7	It is conducting trials with pen computers electronic tablets reminiscent of a Victorian school slate with a stylus or pen used for writing on the screen.	conduct trial pen comput electron tablet reminisc victorian school slate stylu pen use write screen
19940208000000000_8	The software is usually displayed as forms with boxes that can be ticked or filled in.	softwar usual display form box tick fill
19940208000000000_9	Eventually pen based machines could obviate the mountains of paperwork associated with drug trials.	eventu pen base machin could obviat mountain paperwork associ drug trial
19940208000000000_10	These case record forms completed in triplicate can be up to 2cm thick for just one patient.	case record form complet triplic cm thick one patient
19940208000000000_11	A typical trial would involve three phases with an average of 200 patients per trial.	typic trial would involv three phase averag patient per trial
19940208000000000_12	Rhone Poulenc Rorer part of Rhone Poulenc of France is using pen computers in a trial of antibiotics which began last December.	rhone poulenc rorer part rhone poulenc franc use pen comput trial antibiot began last decemb
19940208000000000_13	Of the 30 to 40 sites involved eight will be using the pen computers to duplicate the paper system.	site involv eight use pen comput duplic paper system
19940208000000000_14	The aim says Greg Fromell associate director of clinical research in the US is to assess how much quicker the electronic system could be.	aim say greg fromel associ director clinic research us assess much quicker electron system could
19940208000000000_15	Fromell sees two big areas of time saving.	fromel see two big area time save
19940208000000000_16	First data entry transferring the paper based test results on to the computer is always a bottleneck.	first data entri transfer paper base test result comput alway bottleneck
19940208000000000_17	Data often have to be typed two or three times introducing errors and delays.	data often type two three time introduc error delay
19940208000000000_18	With the pen computer information is entered on the screen and can be transferred directly to the main database.	pen comput inform enter screen transfer directli main databas
19940208000000000_19	Second researchers lose months correcting basic errors in paper data.	second research lose month correct basic error paper data
19940208000000000_20	The software selected by Rhone Poulenc Rorer from the German company Padcom helps eliminate these.	softwar select rhone poulenc rorer german compani padcom help elimin
19940208000000000_21	If a number is required in response to a specific question the software will not allow the doctor to enter a letter or a tick.	number requir respons specif question softwar allow doctor enter letter tick
19940208000000000_22	The software can check the birth date of the patient to ensure that he or she is of the appropriate age to take part in the study or query information which appears to be outside the likely boundaries unlike a paper questionnaire.	softwar check birth date patient ensur appropri age take part studi queri inform appear outsid like boundari unlik paper questionnair
19940208000000000_23	Although Fromell believes that the breakthrough has been in the creation of computers that take handwritten information from companies such as Grid NCR Tandy and IBM of the US and NEC and Toshiba in Japan he argues that it is not the hardware that will provide the competitive edge in drug trials but the software.	although fromel believ breakthrough ha creation comput take handwritten inform compani grid ncr tandi ibm us nec toshiba japan argu hardwar provid competit edg drug trial softwar
19940208000000000_24	At Casella the Hoechst subsidiary in Frankfurt clinical project manager Dieter R.	casella hoechst subsidiari frank furt clinic project manag dieter r
19940208000000000_25	Dannhorn believes it is critical to have software which can guide doctors many of whom will be inexperienced in the use of computers through the form.	dannhorn believ critic softwar guid doctor mani inexperienc use comput form
19940208000000000_26	I need doctors who are happy with the system otherwise I am not going to get any patients for the trials.	need doctor happi system otherwis go get ani patient trial
19940208000000000_27	Casella has already conducted a short clinical trial with pen computers on 16 patients and is now planning clinical trials of an anti fungal product involving 240 patients in 10 centres with each patient questioned three times.	casella ha al readi conduct short clinic trial pen comput patient plan clinic trial anti fungal product involv patient centr patient question three time
19940208000000000_28	Each doctor involved will receive a diskette to be completed on each patient visit.	doctor involv receiv diskett complet patient visit
19940208000000000_29	For the Rhone Poulenc Rorer trial diskettes will also be used to record patient information.	rhone poulenc rorer trial diskett also use record patient inform
19940208000000000_30	They will be posted to the central office where the data will be entered on the database.	post central offic data enter databas
19940208000000000_31	In future the data could be sent automatically over a phone line.	futur data could sent automat phone line
19940208000000000_32	While drugs companies believe it is too early to predict potential savings Padcom s director of marketing Peter Munzel calculates that for a typical Phase II trial where the drug is tested for efficacy for the first time the savings could be more than 40 per cent.	drug compani believ earli predict potenti save padcom director market peter munzel calcul typic phase ii trial drug test efficaci first time save could per cent
19940208000000000_33	If 10 centres and 200 patients were involved over a 12 month period with each patient visiting the doctor six times Munzel calculates a saving of more than Dollars 205 000 out of a total study cost of Dollars 511 440 in reducing the number of queries and the need for retyping.	centr patient involv month period patient visit doctor six time munzel calcul save dollar total studi cost dollar reduc number queri need retyp
19940208000000000_34	He argues that if pen computers were used throughout the drugs approval procedure they could cut a month off each study.	argu pen comput use throughout drug approv procedur could cut month studi
19940208000000000_35	With an average of 30 studies per drug that could cut months or even years off the eight to 12 years it usually takes to get a drug approved giving companies an extra two or three years of sales of a compound before competitors flooded the market.	averag studi per drug could cut month even year eight year usual take get drug approv give compani extra two three year sale compound befor competitor flood market
19940208000000000_36	The challenge is to make major improvements in a whole host of areas says Mark Delfino a manager specialising in information technology with the Boston Consulting Group in Chicago.	challeng make jor improv whole host area say mark delfino manag specialis inform technolog boston consult group chicago
19940208000000000_37	A pen based system per se is only a more friendly interface and an easier way of getting data.	pen base system per se onli friendli interfac easier way get data
19940208000000000_38	Once the data comes in you still need a set of processes to handle it quickly.	onc data come still need set process handl quickli
19940208000000000_39	Although pen computers save time in data entry Dannhorn calculates that unfamiliarity with writing case study books for pen PCs means that it takes him up to five times as long to write one for a pen computer as it does for a paper based trial.	although pen comput save time data entri dannhorn calcul unfamiliar write case studi book pen pc mean take five time long write one pen comput doe paper base trial
19940208000000000_40	Drugs companies could be drawn into writing much of their own software with the need to set up expensive centres of technical expertise adds Delfino.	drug compani could drawn write much softwar need set expens centr technic expertis add delfino
19940208000000000_41	He reckons it costs between Dollars 5 000 and Dollars 20 000 per site to equip trial sites with machines.	reckon cost dollar dollar per site equip trial site machin
19940208000000000_42	Today s pen computers are often relatively heavy and have a short battery life.	today pen comput often rel heavi short batteri life
19940208000000000_43	So far there is no de facto operating system some companies favour that developed by the Silicon Valley start up Go.	far de facto oper system compani favour develop silicon valley start go
19940208000000000_44	While some pharmaceutical companies have been quick to adopt pen computing others have strong reservations.	pharmaceut compani quick adopt pen comput strong reserv
19940208000000000_45	One concern is that handwriting recognition technology is still relatively primitive.	one concern handwrit recognit technolog still rel primit
19940208000000000_46	doctors have notoriously bad handwriting says Stephen Hill UK medical director for Roche the Swiss pharmaceuticals company.	doctor notori bad handwrit say stephen hill uk medic director roch swiss pharmaceut compani
19940208000000000_47	He fears that data could be inaccurately recorded particularly in international trials conducted in English where English is not the first language of the doctors involved.	fear data could inaccur record particularli intern trial conduct english english first languag doctor involv
19940208000000000_48	One of the biggest problems is to make sure that the information we collect matches the information on the patient s records continues Hill.	one biggest problem make sure inform collect match inform patient record continu hill
19940208000000000_49	If the data are entered directly by PC from the doctor s surgery to the company s main database without intermediary checking mistakes could slip through.	data enter directli pc doctor surgeri compani main databas without intermediari check mistak could slip
19940208000000000_50	Regulatory issues are also hampering the widespread take up of such systems.	regulatori issu also hamper wide pread take system
19940208000000000_51	At Pfizer s UK operation in Sandwich Kent for example researchers are still waiting for a pronouncement from the US Food and Drug Administration about the use of electronic signatures.	pfizer uk oper sandwich kent exampl research still wait pronounc us food drug administr use electron signatur
19940208000000000_52	With paper trials the investigating doctor has to sign all the trial results to validate them but there are no guidelines about electronic signatures.	paper trial investig doctor ha sign trial result valid guidelin electron signatur
19940208000000000_53	Although the information from the Casella trial will be recorded on screen German law requires that the results of the trials be printed out and signed by the doctor if the trial is to be valid.	although inform casella trial record screen german law requir result trial print sign doctor trial valid
19940208000000000_54	At Glaxo in the UK researchers are experimenting with pen based computers but believe it will be another two to three years before they can rely on them utterly.	glax uk research experi pen base comput believ anoth two three year befor reli utterli
19940208000000000_55	By then says a spokesman for Glaxo voice recognition technology where doctors simply talk to their machines could have made similar advances and might become the dominant technology.	say spokesman glax voic recognit technolog doctor simpli talk machin could made similar advanc might becom domin technolog
19940323000000000_1	Thorough preparation can cut costs If the manufacturer of a product can save a year in its development that could be equivalent to the final year s sales.	thorough prepar cut cost manufactur product save year develop could equival final year sale
19940323000000000_2	For a leading compound that could be Dollars 400m Clinical Trials.	lead compound could dollar clinic trial
19940323000000000_3	Few industries operate under such stringent regulatory controls as the pharmaceutical industry.	industri oper stringent regulatori control pharmaceut industri
19940323000000000_4	The complexity and volume of the regulations indicate a high cost area one of which is clinical trials which are expensive and time consuming.	complex volum regul indic high cost area one clinic trial expens time consum
19940323000000000_5	The three phases of clinical research are the longest and most costly stages in the development of a new drug.	three phase clinic research longest costli stage develop new drug
19940323000000000_6	They take an average of four to six years although depending on the type of drug they may in an extreme case require 10 years.	take averag four six year although depend type drug may extrem case requir year
19940323000000000_7	A single advance in efficiency can be both commercially and scientifically beneficial.	singl advanc effici commerci scientif benefici
19940323000000000_8	Considerable data is assembled from the trials which is subjected to detailed statistical evaluation and medical interpretation.	consider data assembl trial subject detail statist evalu medic interpret
19940323000000000_9	Effective information technology (IT) management can be a competitive aid in cutting high costs and helping to streamline the product development and approval process.	effect inform technolog manag competit aid cut high cost help streamlin product develop approv process
19940323000000000_10	Companies cannot take short cuts with clinical trials but with well planned IT the risk of errors in documentation and testing can be greatly reduced.	compani cannot take short cut clinic trial well plan risk error document test greatli reduc
19940323000000000_11	Today an increasing number of the world s leading pharmaceutical companies are looking to contract research organisations (CROs) to run part or in some cases the whole package of clinical trials.	today increas number world lead pharmaceut compani look contract research organis cro run part case whole packag clinic trial
19940323000000000_12	Dr John Mills international vice president of Besselaar one of the largest CROs worldwide said there is a dramatic increase in the amount of contracting out of clinical trials.	dr john mill intern vice presid besselaar one largest cro worldwid said dramat increas amount contract clinic trial
19940323000000000_13	In the past couple of years we have had twice the number of proposals says Dr Mills.	past coupl year twice number propos say dr mill
19940323000000000_14	Some companies request part service while others are requesting the full works he adds.	compani request part servic request full work add
19940323000000000_15	A measure of how much clinical trials cost is highlighted by Prof.	measur much clinic trial cost highlight prof
19940323000000000_16	Richard Peto of the clinical trial service unit Radcliffe Infirmary Oxford who is carrying out a significant trial on 20 000 people for the effectiveness of a cholesterol lowering drug.	richard peto clinic trial servic unit radcliff infirmari oxford carri signific trial peopl effect cholesterol lower drug
19940323000000000_17	The trial costing some Pounds 20m is being equally sponsored by Roche Merck and the MRC.	trial cost pound equal sponsor roch merck mrc
19940323000000000_18	According to a spokesman at the US Pharmaceutical Manufacturers Association some clinical trials in the US are now costing Dollars 35 000 per patient over a six month period.	accord spokesman us pharmaceut manufactur associ clinic trial us cost dollar per patient six month period
19940323000000000_19	In 1989 the US Congress created the Agency for Health Care Policy and Research (AHCPR) to comb through vast databases of records accumulated by hospitals insurers and government health programmes since the late 1980s.	us congress creat agenc health care polici research ahcpr comb vast databas record accumul hospit insur govern health programm sinc late
19940323000000000_20	After spending nearly Dollars 200m on this type of research AHCPR cannot point to a single case in which its database studies have changed clinical practice comments Prof Peto.	spend nearli dollar thi type research ahcpr cannot point singl case databas studi chang clinic practic comment prof peto
19940323000000000_21	Many companies in the industry are hoping the International Conference on Harmonisation (ICH) process will save a lot of time and money on clinical trials.	mani compani industri hope intern confer harmonis ich process save lot time money clinic trial
19940323000000000_22	There is a desire by the Japanese regulatory agency to harmonise its requirements with those of Europe and America.	desir japanes regulatori agenc harmonis requir europ america
19940323000000000_23	Dr Trevor Jones research and development director at Wellcome says.	dr trevor jone research develop director well come say
19940323000000000_24	Until now we have had to repeat all of the stability data storage shelf life and so on.	repeat stabil data storag shelf life
19940323000000000_25	The difficulty is the clinical side and it is still the case that we have to repeat a lot of clinical work in Japan.	difficulti clinic side still case repeat lot clinic work japan
19940323000000000_26	We now have 65 mostly clinical related scientists in Japan to carry out the necessary Phase III trials he adds.	mostli clinic relat scientist japan carri necessari phase iii trial add
19940323000000000_27	Dr Jones says Wellcome has reorganised R D to meet global changes.	dr jone say well come ha reorganis r meet global chang
19940323000000000_28	A new group set up in Wellcome called Euroclin as a prelude to Worldclin.	new group set well come call euroclin prelud worldclin
19940323000000000_29	It has 200 staff spread geographically across Europe.	ha staff spread geograph across europ
19940323000000000_30	There is a large group in France with other groups in Italy and Germany with basic acquisition of data this has been done without incentives such as tax relief but there are three very important advantages.	larg group franc group itali germani basic acquisit data thi ha done without incent tax relief three veri import advantag
19940323000000000_31	Dr Pierre Simon research and development director of Sanofi observes that you have to set high standards to get compounds into full development.	dr pierr simon research develop director sanofi observ set high standard get compound full develop
19940323000000000_32	We look at strength oral activity duration of action the toxicology and genotoxicity.	look strength oral activ durat action toxicolog genotox
19940323000000000_33	We also make sure that the molecule is metabolised in man.	also make sure molecul metabolis man
19940323000000000_34	The drug has to clear the bar even if its set high says Dr Simon.	drug ha clear bar even set high say dr simon
19940323000000000_35	When you have to organise a trial like we have for the anti thrombotic Clopidogrel this is a real challenge he adds.	organis trial like anti thrombot clopidogrel thi real challeng add
19940323000000000_36	We need a two year study with 500 centres and 15 000 patients.	need two year studi centr patient
19940323000000000_37	So far we have enrolled 9 000 patients far faster than we thought and we ve saved about six months.	far enrol patient far faster thought save six month
19940323000000000_38	jAnother company that keeps a tight rein on its clinical trials preparation is Fujisawa where Dr Hitoshi Oyasu managing director research and development division comments.	j anoth compani keep tight rein clinic trial prepar fujisawa dr hitoshi oyasu manag director research develop divis comment
19940323000000000_39	We don t like cutting out compounds from our product pipeline but clinical trials are costly.	like cut compound product pipelin clinic trial costli
19940323000000000_40	We look at the pre clinical data and if there is no clinical advantages it gets killed.	look pre clinic data clinic advantag get kill
19940323000000000_41	We cut a promising oral anti histamine only last year he adds.	cut promis oral anti histamin onli last year add
19940323000000000_42	The company believes that the ICH will make a difference to future clinical trials one day but progress seems to be difficult at the moment.	compani believ ich make differ futur clinic trial one day progress seem difficult moment
19940323000000000_43	We are trying to reduce the numbers of clinicians and centres we use for our trials.	tri reduc number clinician centr use trial
19940323000000000_44	We want to focus on those investigators who are more reliable and deliver the data on time.	want focu investig reliabl deliv data time
19940323000000000_45	In the past some Japanese groups have used the clinical trials as part of their marketing strategy in some cases there was only one patient per hospital.	past japanes group use clinic trial part market strategi case wa onli one patient per hospit
19940323000000000_46	Dr William Scott senior vice president exploratory and drug discovery Bristol Myers Squibb says.	dr william scott senior vice presid exploratori drug discoveri bristol myer squibb say
19940323000000000_47	If you can save one year in development that s equivalent to the final year s sales.	save one year develop equival final year sale
19940323000000000_48	For a big compound that could be Dollars 400m comments to Dr Scott.	big compound could dollar comment dr scott
19940323000000000_49	So even if its costs more up front saving time can be worth hundreds of millions of dollars.	even cost front save time worth hundr million dollar
19940323000000000_50	The problem is that the hurdles are getting higher all the time he adds.	problem hurdl get higher time add
19940323000000000_51	The regulatory process is becoming increasingly complex and demanding just take the fact that you now have to do trials using active control compounds so you can compare the new molecule against the old ones.	regulatori process becom increasingli complex demand take fact trial use activ control compound compar new molecul old one
19940323000000000_52	And the fact that regulatory authorities are asking for clinical end points rather than just surrogate markers.	fact regulatori author ask clinic end point rather surrog marker
19940323000000000_53	Admittedly one counter trend is in the area of life threatening diseases when there s no available therapy.	admittedli one counter trend area life threaten diseas avail therapi
19940323000000000_54	There you can get accelerated approval using surrogate markers.	get acceler approv use surrog marker
19940323000000000_55	BMS did this with DDI which we gave to 27 000 patients and with D4T which we gave to 9 600 patients Taxol was also given accelerated approval.	bm thi ddi gave patient gave patient taxol wa also given acceler approv
19940323000000000_56	The writer Alan Archer is editor of the FT newsletter Pharmaceutical Business News.	writer alan archer editor ft newslett pharmaceut busi news
19940323000000000_57	A more selective approach Case study Schering Plough Research Institute.	select approach case studi schere plough research institut
19940323000000000_58	For US pharmaceutical companies the impending healthcare reforms promise an era of increased cost containment and pricing controls.	us pharmaceut compani impend health care reform promis era increas cost contain price control
19940323000000000_59	According to Dr Robert Spiegel senior vice president clinical research at Schering Plough Research Institute the market for new drugs will never subside we believe that there will always be a market and a very profitable market for drug companies that can develop novel products that satisfy an unmet need in an important therapeutic area he says.	accord dr robert spiegel senior vice presid clinic research schere plough research institut market new drug never subsid believ alway market veri profit market drug compani develop novel product sati fy unmet need import therapeut area say
19940323000000000_60	In 1993 Schering Plough spent USDollars 578m on research and development an investment which it expects to increase to over Dollars 600m this year.	schere plough spent usdollar research develop invest expect increas dollar thi year
19940323000000000_61	Despite its continued commitment to R D funding Schering Plough admits that the more cost driven market has triggered a change of approach.	despit continu commit r fund schere plough admit cost driven market ha trigger chang approach
19940323000000000_62	There is a new world now that is forcing us even more to adapt our research and development process says Dr Spiegel.	new world forc us even adapt research develop process say dr spiegel
19940323000000000_63	At Schering Plough most of this adaptation has been evolutionary.	schere plough thi adapt ha evolutionari
19940323000000000_64	About three years ago the company set up a Pharmaceutical Economic Unit designed to assess the economic cost and quality of life benefit of potential new drugs at the earliest possible stage.	three year ago compani set pharmaceut econom unit design assess econom cost qualiti life benefit potenti new drug earliest possibl stage
19940323000000000_65	Evaluation of exactly what Schering Plough expects to bring to the market when a product is fully developed is now a prominent part of its core R D process says Dr Spiegel.	evalu exactli schere plough expect bring market product fulli develop promin part core r process say dr spiegel
19940323000000000_66	Combined with this more selective approach to R D is the knowledge that on the way to discovering breakthrough products drug companies are inevitably exposed to greater risks.	combin thi select approach r knowledg way discov breakthrough product drug compani inevit expos greater risk
19940323000000000_67	This means manufacturers have to be increasingly daring when deciding which compounds to back.	thi mean manufactur increasingli dare decid compound back
19940323000000000_68	If you re only going after Alzheimer s drugs the winner of that in the pharmaceutical industry will have a nice pot of gold at the end of the process but there will be a lot more losers along the way.	onli go alzheim drug winner pharmaceut industri nice pot gold end process lot loser along way
19940323000000000_69	Willingness to conduct research in more high risk areas then is no guarantee of commercial success.	willing conduct research high risk area guarante commerci success
19940323000000000_70	As Raul Cesan president Schering Laboratories suggests.	raul cesan presid schere laboratori suggest
19940323000000000_71	We all want to develop something that is unique yet we may end up with something that is a marginal improvement.	want develop someth uniqu yet may end someth margin improv
19940323000000000_72	Development of compounds that may offer only a slightly better safety profile over products already on the market is a luxury which research based drug companies can no longer afford.	develop compound may offer onli slightli better safeti profil product al readi market luxuri research base drug compani longer afford
19940323000000000_73	In certain cases that marginal improvement gives to the system exactly what politicians and government officials want.	certain case margin improv give system exactli politician govern offici want
19940323000000000_74	They lower the price because once you have two or three or four of those (products) prices collapse immediately argues Raul Cesan.	lower price becaus onc two three four product price collaps immedi argu raul cesan
19940323000000000_75	Research at Schering Plough covers six main therapeutic areas.	research schere plough cover six main therapeut area
19940323000000000_76	According to Dr Spiegel the secret of the company s R D success lies in its balance of discovery areas.	accord dr spiegel secret compani r success lie balanc discoveri area
19940323000000000_77	It supports both research into quite comfortable scientific fields and high risk areas of great potential yield.	support research quit comfort scientif field high risk area great potenti yield
19940323000000000_78	There are times when you re in brand new areas where the regulatory environment and clinical development environment is also unknown.	time brand new area regulatori environ clinic develop environ also unknown
19940323000000000_79	But if you re in those areas that have high potential success it s worth taking that risk too.	area high potenti success worth take risk
19940323000000000_80	However incentives to take such risks could soon disappear if the pricing controls proposed under healthcare reform are approved the proposal to severely review the ultimate pricing of a drug even if it s a breakthrough product gives a disincentive to how much risk money you would put up for those types of activities warns Dr Spiegel.	howev incent take risk could soon disappear price control propos health care reform approv propos sever review ultim price drug even breakthrough product give disincent much risk money would put type activ warn dr spiegel
19940323000000000_81	In any case he believes that current market forces are taking care of price controls within the drug industry.	ani case believ current market forc take care price control within drug industri
19940323000000000_82	In its 1993 annual report published last week Schering Plough announced that between 1991 and 1993 it held average US net prescription drug price increases to below the rate of increase in the consumer price index (CPI) and in 1994 expects price rises again to be at or below the increase in CPI.	annual report publish last week schere plough announc held averag us net prescript drug price increas rate increas consum price index cpi expect price rise increas cpi
19940323000000000_83	Prices have been moderating dramatically comments Raul Cesan.	price moder dramat comment raul cesan
19940323000000000_84	While individual companies may be suffering a loss of appetite for R D risk taking the US drug industry as a whole is maintaining its commitment to R D through teamwork.	individu compani may suffer loss appetit r risk take us drug industri whole maintain commit r teamwork
19940323000000000_85	Joint ventures and alliances between university research departments smaller biotechnology companies or established pharmaceutical companies show that by pooling their resources drug companies can continue the search for innovative products.	joint ventur allianc univers research depart smaller biotechnolog compani establish pharmaceut compani show pool resourc drug compani continu search innov product
19940323000000000_86	In future Dr Spiegel predicts there will be more incentive to form alliances in the research area to spread your bets and that s certainly a concept that we embrace.	futur dr spiegel predict incent form allianc research area spread bet certainli concept embrac
19940323000000000_87	In its annual report Schering Plough says that about 25 per cent of its research dollars were targeted for biotechnology.	annual report schere plough say per cent research dollar target biotechnolog
19940323000000000_88	Another form of alliance has seen US drug companies tap into the market of managed care.	anoth form allianc ha seen us drug compani tap market manag care
19940323000000000_89	Last year Merck Co acquired health maintenance organisation Medco Containment Services for Dollars 6bn in a move widely regarded as an attempt to protect market share.	last year merck co acquir health mainten organis medco contain servic dollar bn move wide regard attempt protect market share
19940323000000000_90	Effectively the acquisition changed Merck s mission from being a research based pharmaceutical company to a major player in the healthcare market.	effect acquisit chang merck mission research base pharmaceut compani jor player health care market
19940323000000000_91	Such redefinition of company business strategy is not anticipated by Schering Plough.	redefinit compani busi strategi anticip schere plough
19940323000000000_92	To ensure long term survival beyond healthcare reform the company believes continued investment in its R D pipeline is essential.	ensur long term surviv beyond health care reform compani believ continu invest r pipelin essenti
19940323000000000_93	You have to find the very successful drugs eventually otherwise you cannot survive.	find veri success ful drug eventu otherwis cannot surviv
19940323000000000_94	Research moves to sharper focus Therapeutic categories.	research move sharper focu therapeut categori
19940323000000000_95	As growth of the world s pharmaceuticals market continues to decelerate so research and development managers are being forced to be more focused in the way they direct their companies R D efforts.	grow th world pharmaceut market continu deceler research develop manag forc focus way direct compani r effort
19940323000000000_96	I think R D spending will slow down says Dr Roy Vagelos chairman and chief executive of Merck.	think r spend slow say dr roy vagelo chairman chief execut merck
19940323000000000_97	Over the last 15 years R D has grown at about 14 per cent a year.	last year r ha grown per cent year
19940323000000000_98	Most groups are responding to the new environment by reducing the number of therapeutic categories they explore.	group respond new environ reduc number therapeut categori explor
19940323000000000_99	Admittedly a few giant groups can continue to cover most areas.	admittedli giant group continu cover area
19940323000000000_100	Dr Edward Scolnick president of Merck Research Laboratories says.	dr edward scolnick presid merck research laboratori say
19940323000000000_101	Other companies without the benefit of an R D budget of more than Dollars 1bn a year and 1 800 people working in discovery are being forced to concentrate their efforts.	compani without benefit r budget dollar bn year peopl work discoveri forc concentr effort
19940323000000000_102	You have to be at the leading edge of the areas you re researching and you have to be focused says Mr Lodewijk de Vink president and chief operating officer of Warner Lambert.	lead edg area research focus say mr lode wijk de vink presid chief oper offic warner lambert
19940323000000000_103	You ll soon be talking about burn out rate for those pharmaceuticals companies still looking at all areas.	soon talk burn rate pharmaceut compani still look area
19940323000000000_104	Choosing which therapeutic areas to investigate is far from easy the hardest decision you have to make is which areas to explore says Dr William Scott senior vice president exploratory drug discovery research at Bristol Myers Squibb.	choos therapeut area investig far easi hardest decis make area explor say dr william scott senior vice presid exploratori drug discoveri research bristol myer squibb
19940323000000000_105	It s like a kid going into a candy store with a credit card.	like kid go candi store credit card
19940323000000000_106	Many R D directors continue to duck the difficult decisions.	mani r director continu duck difficult decis
19940323000000000_107	Although they claim they are more focused than before the areas they continue to explore cover most human diseases.	although claim focus befor area continu explor cover human diseas
19940323000000000_108	An R D director whose researchers are looking at inflammatory diseases can cover diseases as diverse as asthma rheumatoid arthritis and inflammatory bowel syndrome.	r director whose research look inflammatori diseas cover diseas divers asthm rheumatoid arthriti inflammatori bowel syndrom
19940323000000000_109	When choosing which areas to cover there are a large number of criteria adopted by companies.	choos area cover larg number criteria adopt compani
19940323000000000_110	The most important are probably medical need and biological science according to Dr Scolnick biologically you have to understand the basic physiology what the disease mechanisms are.	import probabl medic need biolog scienc accord dr scolnick biolog understand basic physiolog diseas mechan
19940323000000000_111	We find projects with the right combination of scientific understanding and medical need and then we set to work.	find project right combin scientif understand medic need set work
19940323000000000_112	Dr Takao Tanakaya executive director drug discovery division at Fujisawa agrees.	dr takao tanakaya execut director drug discoveri divis fujisawa agre
19940323000000000_113	Although Alzheimer s looks interesting because there s a huge potential market we ve steered clear of dementia because we don t understand what s going on.	although alzheim look interest becaus huge potenti market steer clear dementia becaus understand go
19940323000000000_114	That means it s difficult to develop anything really innovative.	mean difficult develop anyth realli innov
19940323000000000_115	Some companies also try to match unmet needs with the their expertise.	compani also tri match unmet need expertis
19940323000000000_116	At Schering Plough management will only work in areas that match the company s strengths where the group has sufficient critical mass to make a difference according to Dr Robert Spiegel senior vice president clinical research.	schere plough manag onli work area match compani strength group ha suffici critic mass make differ accord dr robert spiegel senior vice presid clinic research
19940323000000000_117	The demand for new treatments for diseases in the elderly such as osteoporosis and Alzheimer s has attracted many companies.	demand new treatment diseas elderli osteoporosi alzheim ha attract mani compani
19940323000000000_118	Dr Teruhisa Noguchi executive vice president for R D at Yamanouchi explains.	dr teruhisa noguchi execut vice presid r yamanouchi explain
19940323000000000_119	We ve decided to concentrate on cardiovascular gastro intestinal and central nervous system diseases as well as endocrinology diabetes and bone disorders.	decid concentr cardiovascular gastro intestin central nervou system diseas well endocrinolog diabet bone disord
19940323000000000_120	They re all linked to the ageing population which is a real problem in Japan.	link age popul real problem japan
19940323000000000_121	But there are dangers in focusing only on untreated and unexplored areas.	danger focus onli untreat unexplor area
19940323000000000_122	Some groups see the need to balance the risks between different therapeutic categories.	group see need balanc risk differ therapeut categori
19940323000000000_123	There are some discovery areas where we are quite comfortable that if we invest the money and have the patience products will come out.	discoveri area quit comfort invest money patienc product come
19940323000000000_124	But there are others that are high risk areas that are scientifically exciting and could be of great potential yield if you hit it right.	high risk area scientif excit could great potenti yield hit right
19940323000000000_125	The problem is that the new areas are really difficult says Dr Spiegel.	problem new area realli difficult say dr spiegel
19940323000000000_126	In brand new fields the regulatory and clinical environments are unknown.	brand new field regulatori clinic environ unknown
19940323000000000_127	until Parke Davis had Cognex approved nobody knew what sort of efficacy the FDA wanted.	park davi cognex approv nobodi knew sort efficaci fda want
19940323000000000_128	A number of companies have cut the number of therapeutic areas in a meaningful way.	number compani cut number therapeut area mean ful way
19940323000000000_129	SmithKline Beecham s exit from gastro intestinal disease more than 12 months ago it was an area that virtually created its predecessor SmithKline French was probably the most dramatic.	smith kline beecham exit gastro intestin diseas month ago wa area virtual creat predecessor smith kline french wa probabl dramat
19940323000000000_130	However Wellcome has also moved out of tropical diseases and Dr Trevor Jones director of research development and medical says the group will stop developing new anaesthetics once it has completed its present generation of products.	howev well come ha also move tropic diseas dr trevor jone director research develop medic say group stop develop new anaesthet onc ha complet present gener product
19940323000000000_131	Dr Pierre Simon R D director at Elf Sanofi explains his company s decision to concentrate on only three areas.	dr pierr simon r director elf sanofi explain hi compani decis concentr onli three area
19940323000000000_132	Seven years ago Sanofi was present in all areas of research.	seven year ago sanofi wa present area research
19940323000000000_133	I told the chairman it was stupid you can t do all that effectively because development is becoming more and more sophisticated and expensive.	told chairman wa stupid effect becaus develop becom sophist expens
19940323000000000_134	Dr Leon Rosenberg president Bristol Myers Squibb Pharmaceutical Research Institute says.	dr leon rosenberg presid bristol myer squibb pharmaceut research institut say
19940323000000000_135	We won t scale back on cardiovascular or oncology and we have a very major position in dermatology.	scale back cardiovascular oncolog veri jor posit dermatolog
19940323000000000_136	We ll also stake our future on immunological areas but in central nervous system diseases and diagnostics we cannot lead.	also stake futur immunolog area central nervou system diseas diagnost cannot lead
19940323000000000_137	Now that there s a bright light shining down on everything we do we have to concentrate on those areas where we are leaders and have greatest strengths.	bright light shine everi thing concentr area leader greatest strength
19940323000000000_138	Once the therapeutic areas have been chosen the R D directors next difficulty is to decide which of the many compounds competing for limited developed resources should be selected.	onc therapeut area chosen r director next difficulti decid mani compound compet limit develop resourc select
19940323000000000_139	For the last while we have only pursued those new therapies that will produce a clear medical benefit.	last onli pursu new therapi produc clear medic benefit
19940323000000000_140	We will only develop those with a distinct advantage says Dr Paul Herrling head of research at Sandoz.	onli develop distinct advantag say dr paul herrl head research sandoz
19940323000000000_141	There s much more scrutiny than there used to be about the quality of the drugs in development agrees Dr Robert Spiegel senior vice president clinical research at Schering Plough.	much scrutini use qualiti drug develop agre dr robert spiegel senior vice presid clinic research schere plough
19940323000000000_142	You have to look at what the market will bear for a product which is only a minor improvement.	look market bear product onli minor improv
19940323000000000_143	The medicines have to add value otherwise we re not prepared to spend time and money on them says Sir Richard Sykes chief executive of Glaxo.	medicin add valu otherwis prepar spend time money say sir richard syke chief execut glax
19940323000000000_144	You have to have uniqueness in discovery otherwise you end up selling generic drugs.	uniqu discoveri otherwis end sell gener drug
19940323000000000_145	Dr Simon adds that he recently cut some beta blockers and H2 antagonists from his pipeline even though they were safe and effective they made no sense because they were little better than existing therapies.	dr simon add recent cut beta blocker h antagonist hi pipelin even though safe effect made sens becaus littl better exist therapi
19940323000000000_146	Similarly Rhone Poulenc Rorer last year cut a safe and effective 5HT 3 antagonist similar to Glaxo s highly successful Zofran because it was no better than existing compounds according to Mr Robert Cawthorn chief executive.	similarli rhone poulenc rorer last year cut safe effect ht antagonist similar glax highli success ful zofran becaus wa better exist compound accord mr robert cawthorn chief execut
19940323000000000_147	Some groups abandon even promising and innovative projects however.	group abandon even promis innov project howev
19940323000000000_148	When you are using biochemical screening you come up with interesting compounds that do not fit exactly in the areas where you want to work.	use biochem screen come interest compound fit exactli area want work
19940323000000000_149	We came up with a good asthma drug but we had no intention of getting into asthma.	came good asthm drug intent get asthm
19940323000000000_150	You have to have good clinical trials to show it s good and then sell out quickly.	good clinic trial show good sell quickli
19940323000000000_151	Most R D directors agree it is far easier to develop good quality drugs than poor ones.	r director agre far easier develop good qualiti drug poor one
19940323000000000_152	Dr Masaji Ohno managing director of R D at Eisai agrees.	dr masaji ohno manag director r eisai agre
19940323000000000_153	Our chairman Mr Yuji Naito asks us to find compounds that are so good they develop themselves.	chairman mr yuji naito ask us find compound good develop themselv
19940323000000000_154	You have to set high standards to get compounds into development.	set high standard get compound develop
19940323000000000_155	We look at strength oral activity duration of action the toxicology and genotoxicity.	look strength oral activ durat action toxicolog genotox
19940323000000000_156	We also make sure the molecule can be metabolised in man.	also make sure molecul metabolis man
19940323000000000_157	The drug has to clear the bar even if it s set high.	drug ha clear bar even set high
19940323000000000_158	Production costs are also an important issue according to Dr Herrling.	product cost also import issu accord dr herrl
19940323000000000_159	You have to look at how complicated the molecule is and how many steps it takes to synthesise.	look complic molecul mani step take synthesis
19940323000000000_160	The cost and complexity of manufacture is becoming much more important he says.	cost complex manufactur becom much import say
19940323000000000_161	Dr Stephen Carter senior vice president worldwide clinical research and development at Bristol Myers Squibb agrees.	dr stephen carter senior vice presid worldwid clinic research develop bristol myer squibb agre
19940323000000000_162	If it s going to takes 15 chemical steps to produce a compound I might need 20 chemists full time working for a year to generate enough for a clinical trial.	go take chemic step produc compound might need chemist full time work year gener enough clinic trial
19940323000000000_163	The potential market of a drug is also clearly important.	potenti market drug also clearli import
19940323000000000_164	Dr Noguchi at Yamanouchi says his company has set a target of minimum annual sales of Y2bn about Dollars 200m for drugs to move into development.	dr noguchi yamanouchi say hi compani ha set target minimum annual sale bn dollar drug move develop
19940323000000000_165	One consequence of the new cost conscious environment is that decisions about the future of molecules are made much earlier than before.	one consequ new cost consciou environ decis futur molecul made much earlier befor
19940323000000000_166	Just recently we discontinued a couple of compounds which in earlier times we would have continued to see what happened to them.	recent discontinu coupl compound earlier time would continu see happen
19940323000000000_167	Today we just don t have the luxury of doing that says Dr Spiegel at Schering Plough.	today luxuri say dr spiegel schere plough
19940323000000000_168	However although most companies pay lip service to the over riding drive towards innovation most R D directors admit they need to balance their portfolios for risk.	howev although compani pay lip servic ride drive toward innov r director admit need balanc portfolio risk
19940323000000000_169	In Japan these low risk low reward compounds are called survival drugs according to Dr Masaji Ohno managing director of R D at Eisai.	japan low risk low reward compound call surviv drug accord dr masaji ohno manag director r eisai
19940323000000000_170	Let s be honest about this agrees Dr Carter at Bristol Myers Squibb.	let honest thi agre dr carter bristol myer squibb
19940323000000000_171	If you just go for high risk high reward blockbusters you re just going for home runs.	go high risk high reward blockbust go home run
19940323000000000_172	You need to balance across the franchises and across the risk.	need balanc across franchis across risk
19940323000000000_173	A Dollars 100m product in an old franchise is more valuable than a Dollars 150m product in a new area.	dollar product old franchis valuabl dollar product new area
19940323000000000_174	However Dr Spiegel admits that when you set out to find something exciting you sometimes only come up with a drug offering marginal improvements.	howev dr spiegel admit set find someth excit sometim onli come drug offer margin improv
19940323000000000_175	An important area little stressed by R D directors publicly is that of line extensions.	import area littl stress r director publicli line extens
19940323000000000_176	We call the process evergreening says Dr John Niblack president Pfizer central research.	call process evergreen say dr john niblack presid pfizer central research
19940323000000000_177	Dr Carter at Bristol Myers Squibb agrees.	dr carter bristol myer squibb agre
19940323000000000_178	Line extensions help quality of life and generate increased exclusivity for the company.	line extens help qualiti life gener increas exclus compani
19940323000000000_179	Besides developing line extensions is easier than developing new compounds because the safety is already proven you just have to show efficacy.	besid develop line extens easier develop new compound becaus safeti al readi proven show efficaci
